Registration of Securities by a Small-Business Issuer — Form SB-2
Filing Table of Contents
Document/Exhibit Description Pages Size
1: SB-2 Registration of Securities by a Small-Business 85 455K
Issuer
2: EX-3.1 Amended and Restated Articles of Incorporation 25 105K
3: EX-5 Legal Opinion of Reinhart, Boerner, Van Deuren 2± 8K
4: EX-10.40 Form of Change of Control Agreement 11 71K
5: EX-23 Conesnt of McGladrey & Pullen, LLP 1 6K
SB-2 — Registration of Securities by a Small-Business Issuer
Document Table of Contents
As filed with the Securities and Exchange Commission on ___________, 1999
Registration No. ________
-------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM SB-2
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
-------------------------
THE FEMALE HEALTH COMPANY
(NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)
-------------------------
[Enlarge/Download Table]
WISCONSIN 3069 39-1144397
(STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION) CLASSIFICATION CODE NUMBER)
O.B. PARRISH, CHAIRMAM
875 NORTH MICHIGAN AVENUE OF THE BOARD AND CHIEF
SUITE 3660 EXECUTIVE OFFICER
CHICAGO, ILLINOIS 60611 875 NORTH MICHIGAN AVENUE
(312) 280-1119 SUITE 3660
(ADDRESS AND TELEPHONE NUMBER CHICAGO, ILLINOIS 60611
OF PRINCIPAL EXECUTIVE OFFICES AND (312) 280-1119
PRINCIPAL PLACE OF BUSINESS) (NAME, ADDRESS AND TELEPHONE
NUMBER OF AGENT FOR SERVICE)
COPIES TO:
JAMES M. BEDORE, ESQ.
REINHART, BOERNER, VAN DEUREN
NORRIS & RIESELBACH, S.C.
1000 NORTH WATER STREET, SUITE 2100
MILWAUKEE, WI 53202
(414) 298-1000
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC: AS SOON AS PRACTICABLE AFTER
THE EFFECTIVE DATE OF THIS REGISTRATION STATEMENT.
IF ANY OF THE SECURITIES BEING REGISTERED ON THIS FORM ARE TO BE OFFERED ON A
DELAYED OR CONTINUOUS BASIS PURSUANT TO RULE 415 UNDER THE SECURITIES ACT OF
1933, CHECK THE FOLLOWING BOX. |X|
IF THIS FORM IS FILED TO REGISTER ADDITIONAL SECURITIES FOR AN OFFERING PURSUANT
TO RULE 462(B) UNDER THE SECURITIES ACT, CHECK THE FOLLOWING BOX AND LIST THE
SECURITIES ACT REGISTRATION STATEMENT NUMBER OF THE EARLIER EFFECTIVE
REGISTRATION STATEMENT FOR THE SAME OFFERING. |_|
IF THIS FORM IS A POST-EFFECTIVE AMENDMENT FILED PURSUANT TO RULE 462(C) UNDER
THE SECURITIES ACT, CHECK THE FOLLOWING BOX AND LIST THE SECURITIES ACT
REGISTRATION STATEMENT NUMBER OF THE EARLIER EFFECTIVE REGISTRATION STATEMENT
FOR THE SAME OFFERING. |_|
IF DELIVERY OF THE PROSPECTUS IS EXPECTED TO BE MADE PURSUANT TO RULE 434,
PLEASE CHECK THE FOLLOWING BOX. |_|
CALCULATION OF REGISTRATION FEE
[Enlarge/Download Table]
================================================================================================================
TITLE OF EACH PROPOSED PROPOSED
CLASS OF MAXIMUM MAXIMUM
SECURITIES AMOUNT OFFERING AGGREGATE AMOUNT OF
TO BE TO BE PRICE OFFERING REGISTRATION
REGISTERED REGISTERED(1) PER SHARE(2) PRICE FEE
----------------------------------------------------------------------------------------------------------------
COMMON STOCK, PAR VALUE $.01 1,500,000 $1.00 $1,500,000 $417
PER SHARE ISSUABLE UPON
CONVERSION OF CONVERTIBLE
DEBENTURES
----------------------------------------------------------------------------------------------------------------
COMMON STOCK, PAR VALUE $.01 2,587,500 $1.00 $2,587,500 $719
PER SHARE, ISSUABLE UPON
EXERCISE OF WARRANTS
----------------------------------------------------------------------------------------------------------------
COMMON STOCK, PAR VALUE $.01 841,671 $1.00 $841,671 $234
PER SHARE TO BE SOLD BY
CERTAIN SELLING STOCKHOLDERS
================================================================================================================
(1) IN THE EVENT OF A STOCK SPLIT, STOCK DIVIDEND OR SIMILAR TRANSACTION
INVOLVING THE REGISTRANT'S COMMON STOCK, IN ORDER TO PREVENT DILUTION, THE
NUMBER OF SHARES REGISTERED SHALL AUTOMATICALLY BE INCREASED TO COVER THE
ADDITIONAL SHARES IN ACCORDANCE WITH RULE 416(A) UNDER THE SECURITIES ACT.
(2) ESTIMATED SOLELY FOR PURPOSES OF CALCULATING THE REGISTRATION FEE PURSUANT
TO RULE 457(C) UNDER THE SECURITIES ACT, ON THE BASIS OF THE AVERAGE OF THE BID
AND ASKED PRICES OF THE REGISTRANT'S COMMON STOCK ON OCTOBER 14, 1999, AS
REPORTED ON THE OVER THE COUNTER BULLETIN BOARD.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE
SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
PROSPECTUS PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION - DATED , 1999
THE FEMALE HEALTH COMPANY
4,929,175 SHARES OF COMMON STOCK
This prospectus may be used only by the stockholders listed under the
section entitled "selling stockholders" in this prospectus in connection with
their resale, from time to time, of up to 4,929,175 shares of our common stock.
The 4,929,175 shares are shares of our common stock which these stockholders
currently own or will receive upon conversion of convertible debentures and
exercise of warrants which they currently own. We will not receive any proceeds
from the sale of the shares by the selling stockholders. We have paid the
expenses related to registering the sale of these shares, including legal and
accounting fees, but not including commissions, transfer taxes and certain other
expenses associated with the sale of the shares, which will be paid by the
selling stockholders.
We have agreed to indemnify the selling stockholders against certain
liabilities, including liabilities arising under the Securities Act of 1933, as
amended.
The selling stockholders have a variety of means by which they may sell
the 4,929,175 shares of our common stock. They may sell the shares to purchasers
in transactions on the Over the Counter Bulletin Board, in negotiated
transactions, or otherwise, or by a combination of these methods. The selling
stockholders may sell the shares at fixed prices that may be changed, at market
prices prevailing at the time of the sale, at prices related to the market
prices or at negotiated prices. The selling stockholders may effect these
transactions by selling the shares to or through broker-dealers, who may receive
compensation in the form of discounts or commissions from the selling
stockholders or from the purchasers of the shares for whom the broker-dealers
may act as an agent or to whom they may sell as a principal, or both. For more
information about the selling stockholders' alternative sales methods, see "Plan
of Distribution."
Our common stock is quoted on the Over the Counter Bulletin Board under
the symbol "FHCO." On October 14, 1999, the closing sale price of the common
stock was $1.00.
YOU SHOULD CONSIDER THE "RISK FACTORS" BEGINNING ON PAGE 5 BEFORE PURCHASING OUR
COMMON STOCK.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
THE DATE OF THIS PROSPECTUS IS , 1999
TABLE OF CONTENTS
Page
-----------------------------------------------------------------------------
Prospectus Summary.........................................................3
Risk Factors...............................................................5
Use of Proceeds...........................................................10
Price Range of Common Stock...............................................10
Dividend Policy...........................................................10
Determination of Offering Price...........................................10
Capitalization............................................................11
Management's Discussion and Analysis of Financial Condition
and Results of Operations...............................................12
Business..................................................................18
Management................................................................25
Principal Shareholders....................................................30
Certain Transactions......................................................31
Description of Capital Stock..............................................33
Selling Stockholders......................................................37
Plan of Distribution......................................................41
Legal Matters.............................................................42
Experts...................................................................42
The Female Health Company Index to Consolidated Financial Statements......43
2
PROSPECTUS SUMMARY
THIS SUMMARY PROVIDES AN OVERVIEW OF SELECTED INFORMATION CONTAINED
ELSEWHERE IN THIS PROSPECTUS AND DOES NOT CONTAIN ALL OF THE INFORMATION YOU
SHOULD CONSIDER. THEREFORE, YOU SHOULD ALSO READ THE MORE DETAILED INFORMATION
SET FORTH IN THIS PROSPECTUS, OUR FINANCIAL STATEMENTS AND THE OTHER INFORMATION
THAT IS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.
FORWARD-LOOKING STATEMENTS MAY PROVE TO BE INACCURATE
We have made forward-looking statements in this prospectus and in the
documents that we incorporate by reference that are subject to risks and
uncertainties. When we use the words "believes," "expects," "anticipates" or
similar expressions, we are making forward-looking statements. Because many
factors can materially affect results, including those set forth below, you
should not regard our inclusion of forward-looking information as a
representation by us or any other person that the objectives or plans for the
Company will be achieved. Our assumptions relating to budgeting, research,
sales, results and market penetration and other management decisions are
subjective in many respects and thus are susceptible to interpretations and
periodic revisions based on actual experience and business developments. The
impact of any of which may cause us to alter our capital expenditures or other
budgets, which may in turn affect our business, financial position, results of
operations and cash flows. Therefore, you should not place undue reliance on
forward-looking statements contained in this prospectus, which speak only as of
the date of this prospectus. Factors that might cause actual results to differ
from those anticipated in the forward-looking statements include, but are not
limited to, those described in "Risk Factors."
THE COMPANY
The Female Health Company is essentially a global start-up company. Our
business consists solely of the manufacture and sale of the female condom, known
in the United States as REALITY(R) and under various other trade names in
foreign countries. We were incorporated in Wisconsin in 1971 and established in
our current form as The Female Health Company on February 1, 1996.
Initially, we expended significant time and resources in the
development of the female condom and securing FDA approval to market the female
condom in the United States. During this time, we also operated our original
recreational products business. After considering various alternatives, in 1995
our Board of Directors selected the female condom as the central focus for the
Company's strategic direction. As a result, in January 1996, we sold our
recreational products business, changed our name to The Female Health Company
and devoted ourselves solely to the commercialization of the female condom.
As part of this restructuring, on February 1, 1996, we acquired the
stock of Chartex Resources Limited, the manufacturer and owner of certain
worldwide rights to, and our then sole supplier of, the female condom. As a
result of these transactions, our sole business now consists of the manufacture,
marketing and sale of the female condom. We own global intellectual property
rights for the female condom. These rights include patents in the United States,
the European Union, Japan and various other countries; regulatory approvals in
certain countries, including a Pre-Market Approval granted by the United States
Food and Drug Administration approving and permitting marketing of the female
condom in the United States (which PMA is required to market the product in the
United States since the FDA determined that the product was a Class III medical
device regulated by the FDA), and CE mark in the European Union (representing
that the product, as a medical device, has been approved by the EU for marketing
in the member countries of the EU); and certain proprietary manufacturing
technology. In addition, we lease a state of the art manufacturing facility in
London, England, capable of producing 60 million female condoms per year. The
facility has been inspected and approved by the FDA and the EU.
The Company's principal executive offices are located at 875 North
Michigan Avenue, Suite 3660, Chicago, Illinois 60611, and its telephone number
is 312-280-1119.
3
THE OFFERING
[Enlarge/Download Table]
Securities to be offered
by the selling stockholders (1)........................... Up to 4,929,175 shares of common stock
Common stock outstanding as of September 30, 1999......... 11,804,580 shares(2)
Over the Counter Bulletin Board symbol.................... FHCO
(1) Includes 1,500,000 shares which will be received by the selling
stockholders upon conversion of convertible debentures in the principal
amount of $1,500,000, 2,212,500 shares which will be received upon exercise
of warrants currently owned by certain selling stockholders, 375,000 shares
which will be received by certain selling stockholders upon exercise of
warrants to purchase 375,000 shares which will be issued to certain selling
stockholders if we elect to extend the repayment date for the $1,500,000
convertible debentures for one year and 841,671 shares currently owned by
certain selling stockholders.
(2) Does not include (a) 3,861,034 shares of common stock issuable upon
exercise of warrants outstanding as of September 30, 1999, including the
warrants referenced in footnote 1 above; (b) 2,996,428 shares of common
stock issuable upon exercise of stock options outstanding as of September
30, 1999; (c) 660,000 shares of common stock issuable upon conversion of
outstanding preferred stock; and (d) shares issuable upon conversion of the
$1.5 convertible debentures outstanding.
SUMMARY FINANCIAL INFORMATION
The summary financial information set forth below is derived from our
financial statements appearing elsewhere in this prospectus. You should read
this information in conjunction with those financial statements, including the
notes thereto.
[Enlarge/Download Table]
Year Ended September 30 Nine Months Ended June 30
----------------------- -------------------------
1997 1998 1998 1999
---- ---- ---- ----
STATEMENTS OF OPERATIONS DATA:
Net revenues.................... $2,916,408 $5,451,399 $4,040,672 $3,409,695
Cost of products sold........... 3,475,709 5,273,369 4,082,175 3,787,785
Net loss........................ (6,251,149) (3,357,316) (2,702,645) (3,041,226)
Net loss attributable to common
stockholders................ (6,266,114) (4,306,985) (3,621,365) (3,143,280)
Net loss per common share
outstanding................. $(0.74) $(0.43) $(0.37) $(0.29)
[Download Table]
September 30, 1998 June 30, 1999
------------------ -------------
CONSOLIDATED BALANCE SHEET
DATA:
Working capital................. $1,239,641 $676,546
Total assets.................... 7,558,894 6,324,965
Long-term debt and capital lease
obligations.................... 4,882 0
Stockholders' Equity............ 2,934,577 1,946,138
4
RISK FACTORS
You should carefully consider the risk factors set forth below, as well
as the other information contained in this prospectus, before purchasing our
common stock.
WE NEED ADDITIONAL CAPITAL TO SUPPORT OUR OPERATIONS AND, IF WE RAISE ADDITIONAL
CAPITAL, IT COULD DILUTE THE HOLDINGS OF OUR EXISTING SHAREHOLDERS.
Sales of our sole product, the female condom, are currently
insufficient to cover our fixed manufacturing overhead, advertising and general
and administrative costs. Consequently, we must secure additional capital to
fund operating losses. At this stage in our development, the amount and timing
of our future capital requirements cannot be precisely determined. We believe
that the capital which we may raise through sales of common stock under our
Equity Line Agreement with Kingsbridge Capital Limited which is described below
will be sufficient to satisfy our current and expected funding requirements.
However, if the conditions required to sell common stock to Kingsbridge under
the Equity Line Agreement are not satisfied, we will need to raise additional
capital in the immediate future. One of the conditions which we must satisfy in
order to utilize the Equity Line Agreement is that our common stock trading
price must be at least $1 per share at the time of any stock sale. Kingsbridge
may, however, waive this requirement. We would seek that additional capital
through the sale of debt or equity securities or the sale of Company assets or
rights, or by discounting receivables and/or letters of credit or by other means
available to us. As part of our efforts to raise capital, on May 19, 1999 and
June 3, 1999, we issued an aggregate of $1,500,000 of convertible debentures and
warrants to purchase 1,875,000 shares of our common stock to five accredited
investors. On September 24, 1999, we completed a private placement of 666,671
shares of our common stock to nine investors. Factors affecting our capital
requirements, including new market launches by our international partners and
sales orders from existing customers, are outside of our control. Some of these
factors may increase the amount of capital we need or accelerate the date when
additional capital will be required, or both. We can make no assurance that we
will be successful in raising additional capital. Further, we can make no
assurance that any amount, if raised, will be sufficient to operate the Company
until sales of the female condom generate sufficient revenues to fund
operations. In addition, any funds which we raise may be costly to the Company
and/or dilutive to existing shareholders.
OUR SUCCESS IS COMPLETELY DEPENDENT UPON THE SUCCESS OF THE FEMALE CONDOM.
We expect to derive our future revenues from sales of the female
condom, our sole current product. The product is in the early stages of its
commercialization. Accordingly, the ultimate level of acceptance of the female
condom by public health advocates as well as users around the world, which
includes the decision to use the female condom versus other available products,
is not yet known.
Our current level of expenditures has been established to support a
higher level of revenues. For us to begin generating cash from operations, sales
of the female condom will have to increase approximately $400,000 per month. If
sales do not increase from current levels to this degree or if the cost to
obtain this level of sales is prohibitive, we will continue to incur operating
losses and, ultimately, our viability will be in jeopardy.
SINCE OUR COMMON STOCK IS NO LONGER LISTED ON THE AMERICAN STOCK EXCHANGE, YOU
MAY HAVE GREATER DIFFICULTY BUYING AND SELLING OUR STOCK.
On February 5, 1999, our common stock was delisted from the American
Stock Exchange since it did not meet all of the criteria for continued listing.
Commencing on approximately February 10, 1999, the common stock has been quoted
on the OTC Bulletin Board under the symbol "FHCO." Although we believe that the
OTC Bulletin Board will continue to provide an efficient market for the purchase
and sale of our common stock, you may find it more difficult to obtain accurate
quotations of the price of the our common stock and to sell the common stock on
the open market than was the case when the common stock was listed on the
American Stock Exchange. In addition, companies whose stock is listed on the
American Stock Exchange must adhere to the rules of that exchange. These rules
include various corporate governance procedures which, among other items,
require a company to obtain shareholder approval prior to completing certain
transactions including, among others,
5
issuances of common stock equal to 20% or more of the company's then outstanding
common stock for less than the greater of book or market value or the issuance
of certain stock options. Since our stock is quoted on the OTC Bulletin Board,
we are not subject to those or any comparable rules.
WE HAVE A HISTORY OF SIGNIFICANT LOSSES AND, DUE TO THAT AND OTHER FACTORS, OUR
INDEPENDENT AUDITOR HAS ISSUED A QUALIFIED OPINION ON OUR FINANCIAL STATEMENTS.
We incurred a net loss attributable to common stockholders of $3.1
million for the nine months ended June 30, 1999, a net loss attributable to
common stockholders of $4.3 million for the year ended September 30, 1998 and a
net loss attributable to common stockholders of $6.3 million for the year ended
September 30, 1997. As of June 30, 1999, we had an accumulated deficit of $44.3
million. At June 30, 1999, we had working capital of $0.7 million and
stockholders' equity of $1.9 million. Historically, we have incurred cash
operating losses relating to expenses incurred to develop, manufacture and
promote the female condom. Consistent with the availability of resources, we
expect to incur substantial expenditures in fiscal 1999 and 2000 in an effort to
support our manufacturing operations and increase awareness and distribution of
the female condom around the globe. Until our internally generated funds are
sufficient to meet cash requirements, we will remain dependent upon our ability
to generate sufficient capital from outside sources. There can be no assurance
that we will achieve a profitable level of operations in the near term or at
all.
Our independent auditor's report on our consolidated financial
statements for the years ended September 30, 1998 and 1997 was qualified as to
our ability to continue as a going concern. While many factors are considered by
the auditor in reaching its opinion, the primary reason for the going concern
opinion was due to our continued deficit cash flows from operations, driven
largely by continued operating losses. For the nine months ended June 30, 1999,
our net cash used in operations was $2.9 million. For the year ended September
30, 1998, our net cash used in operations was $2.8 million. For the year ended
September 30, 1997, our net cash used in operations totaled $5 million.
In the near term, we expect operating costs to continue to exceed funds
generated from operations due principally to our fixed manufacturing costs
relative to our current production volumes. While we believe that revenue from
sales of the female condom will eventually exceed operating costs and that
ultimately operations will generate sufficient funds to meet capital
requirements, there can be no assurance that such level of operations will be
achieved in the near term or at all. We believe that the Company must first
achieve, on a continuing basis, positive cash flow from operations and net
operating profits in order for our independent auditors to re-evaluate their
going concern opinion.
OUR PRODUCT FACES SIGNIFICANT COMPETITION FROM OTHER PRODUCTS, SUCH AS THE MALE
CONDOM, WHICH ARE SOLD BY COMPANIES WHICH ARE MUCH LARGER THAN ARE WE.
We believe that there is currently no other female condom sold in the
world. However, other parties may seek to develop an intravaginal pouch which
does not infringe our patents. These products, if developed, could be
distributed by companies with greater financial resources and customer contacts
than us. In addition, there are a number of other products currently marketed
which have a higher degree of accepted efficacy for preventing pregnancy than
does the female condom. These products include male condoms, birth control
pills, Norplant and Depo Provera. However, other than the female condom, only
the latex male condom is generally recognized as being efficacious in preventing
unintended pregnancies and STDs. Companies manufacturing these competing
products are generally much larger than the Company and have access to
significantly greater resources than do we. In addition, the female condom is
generally sold at prices comparatively greater than the price of the latex male
condom. Accordingly, the female condom will not be able to compete with the
latex male condom solely on the basis of price.
FUTURE SALES OF OUR COMMON STOCK IN THE PUBLIC MARKET MAY REDUCE THE STOCK'S
TRADING PRICE.
Virtually all of our 11,804,580 shares of common stock and 660,000
shares of our convertible preferred stock outstanding as of October 1, 1999 may
be immediately resold in the public market by persons who are not our
6
affiliates (generally, a person who has a control relationship with the
Company). In addition, our Equity Line Agreement with Kingsbridge Capital
Limited provides that we will issue at least $1 million (up to a maximum of $6
million) of common stock to Kingsbridge during its term, which commenced on
approximately February 19, 1999 and continues until the earlier of (1) the date
the Company sells $6 million of common stock to Kingsbridge under the Equity
Line Agreement, (2) the date the Company fails to meet certain obligations under
the Equity Line Agreement or (3) February 12, 2001. (If we do not issue the
minimum $1 million of stock to Kingsbridge, we must pay Kingsbridge an amount
equal to the portion of the $1 million not sold, multiplied by 12% (17% if the
failure to sell the required minimum is due to certain specified events).) The
shares of stock which the Company may sell to Kingsbridge under the Equity Line
Agreement will be available for immediate resale to the public pursuant to a
registration statement we previously filed with the Securities and Exchange
Commission. Further, as of October 1, 1999, we have issued options and warrants
to purchase an aggregate of 6,857,462 shares of common stock. We have filed or
intend to file registration statements under the Securities Act to register the
sale of the shares underlying these options and warrants and, accordingly, any
shares received upon exercise of these options or warrants will also be freely
tradable without restriction by persons other than affiliates. Sales of our
common stock in the public market or the perception that such sales may occur,
could adversely affect the market price of our common stock.
IF WE UTILIZE OUR EQUITY LINE AGREEMENT, IT COULD DILUTE OTHER SHAREHOLDERS AND
HAVE OTHER NEGATIVE EFFECTS.
On November 19, 1998, we entered into an Equity Line Agreement with
Kingsbridge Capital Limited, a private investor. Pursuant to this agreement, we
have the right, subject to various conditions, to sell to Kingsbridge shares of
our common stock for cash consideration up to an aggregate of $6 million. Any
stock which we sell to Kingsbridge under this agreement will be sold at a
discount to the stock's then market price determined pursuant to the agreement.
The discount is 12% of the market price of a share of our common stock at the
time if the sale is $2.00 or more and 18% if the market price is less than
$2.00. The agreement gives us the right to determine, in our sole discretion,
the degree to which we will utilize the equity line, subject to a minimum sale
of $1 million of our common stock to Kingsbridge over the life of the agreement.
While our agreement with Kingsbridge will help provide us with additional future
financing, the sale of shares thereunder will have a dilutive impact on other
stockholders of the Company. As a result, if the conditions to its utilization
are satisfied, our net income (loss) per share could be materially decreased
(increased) in future periods, and the market price of the common stock could be
materially and adversely affected. In addition, the common stock to be issued
under the agreement will be issued at a discount to the then prevailing market
price of the common stock. These discounted sales could have an immediate
adverse effect on the market price of the common stock.
We have also agreed to pay Hartinvest-Medical Ventures, the entity that
solicited Kingsbridge, a commission of 7% on all amounts received from
Kingsbridge under the agreement. This commission may, at the option of HMV, be
paid in shares of our common stock valued at the same price at which we sell
shares to Kingsbridge under the agreement. As further consideration, we have
agreed to issue to HMV warrants to purchase shares of common stock equal to 10%
of the number of shares we sell to Kingsbridge under the agreement. The warrants
will have a three-year term and be exercisable at a price per share equal to
$2.17 (which was 120% of the last sale price of our common stock on the date the
agreement was executed). As further consideration for entering into the
agreement, we issued to Kingsbridge a Warrant to purchase 100,000 shares, which
is exercisable over a three-year period at an exercise price of $2.17 (which was
equal to 120% of the last sale price of our common stock on the date the
agreement was executed). The issuance or resale of the shares sold under the
agreement would have a further dilutive effect on our stockholders and could
have an adverse effect on our stock price. The agreement will not be available
under certain conditions which could require us to seek funds from other sources
(with the intendent risk factor set forth in the preceding paragraph).
OUR STOCK PRICE HAS BEEN EXTREMELY VOLATILE AND, AS A RESULT, THE PRICE COULD BE
DOWN AT A TIME WHEN YOU DESIRE TO SELL YOUR SHARES.
The market price of our common stock has been and may continue to be
affected by quarter-to-quarter variations in our operating results,
announcements by our competitors and other factors. In addition, the stock
market has from time to time experienced extreme price and volume fluctuations,
particularly among the stock of
7
emerging growth companies, which have often been unrelated to the operating
performance of particular companies. Factors not directly related to our
performance, such as governmental regulation or negative industry reports, may
also have a significant adverse impact on the market price of our common stock.
WE ARE DEPENDENT ON CERTAIN KEY PERSONNEL, THE LOSS OF ANY OF WHICH COULD
ADVERSELY AFFECT OUR FINANCIAL CONDITION.
Our success will depend in large part upon our ability to attract and
retain highly qualified personnel. We are particularly dependent upon the
services of O.B. Parrish, our Chairman of the Board and Chief Executive Officer,
and Mary Ann Leeper, Ph.D., our President and Chief Operating Officer. We have
entered into an employment agreement with Dr. Leeper. If we lose the services of
these or other key individuals, or fail to attract and retain other skilled
personnel, we could be materially harmed. We have not purchased keyman life
insurance insuring the lives of any of its executive officers or key employees.
BECAUSE OUR COMMON STOCK IS A "PENNY STOCK," TRADING IN IT IS SUBJECT TO THE
PENNY STOCK RULES WHICH COULD AFFECT YOUR ABILITY TO RESELL THE STOCK IN THE
MARKET.
The Securities Enforcement and Penny Stock Reform Act of 1990 requires
additional disclosure in connection with trades in any stock defined as a "penny
stock." The SEC's regulations generally define a penny stock as an equity
security that has a price of less than $5.00 per share, subject to certain
exceptions. Unless an exception is available, the regulations require stock
brokers to deliver to their customers, prior to any transaction involving a
penny stock, a disclosure schedule explaining the penny stock market and the
risks associated therewith.
In addition, as a penny stock, trading in our common stock would be
covered by Rule 15g-9 promulgated under the Exchange Act. Under this rule,
generally broker-dealers who recommend penny stocks to persons other than their
established customers and certain accredited investors must make a special
written suitability determination for the purchaser and receive the purchaser's
written agreement to the transaction prior to the sale of the securities.
As a result of being a penny stock, the market liquidity for our common
stock may be adversely affected since the regulations on penny stocks could
limit the ability of broker-dealers to sell our common stock and thus your
ability to sell our common stock in the secondary market.
AS A MANUFACTURER AND MARKETER OF A CONSUMER PRODUCT, WE COULD INCUR PRODUCT
LIABILITY CLAIMS.
The nature of our product may expose us to significant product
liability risks. We maintain product liability insurance with coverage limits of
$5 million per year on the female condom. There can be no assurance that we will
be able to maintain this insurance on acceptable terms or that the insurance
will provide adequate coverage against product liability claims. While no
product liability claims on the female condom have been brought against us to
date, a successful product liability claim against us in excess of our insurance
coverage could be extremely damaging to the Company.
SINCE WE SELL PRODUCT IN FOREIGN MARKETS, WE ARE SUBJECT TO FOREIGN CURRENCY AND
MARKET RISK.
We manufacture the female condom in a leased facility located in
London, England. In addition, a material portion of our future sales are likely
to be in foreign markets. Manufacturing costs and sales to foreign markets are
subject to normal currency risks associated with changes in the exchange rate of
foreign currencies relative to the United States dollar. To date, we have not
deemed it necessary to utilize currency hedging strategies to manage our
currency risks. On an ongoing basis, we continue to evaluate our commercial
transactions and would consider employing currency hedging strategies if we
believed such strategies were appropriate. Some of our future international
sales may be in developing nations where dramatic political or economic changes
are possible. If any of these changes occur, they could adversely affect our
results of operations and financial condition.
8
OUR PRODUCT IS SUBJECT TO SUBSTANTIAL GOVERNMENT REGULATION.
The female condom is subject to regulation by the FDA, pursuant to the
Food, Drug and Cosmetic Act, and by other state and foreign regulatory agencies.
Under the FDC Act, medical devices must receive FDA clearance before they can be
sold. FDA regulations also require us to adhere to certain "Good Manufacturing
Practices," which include testing, quality control and documentation procedures.
Our compliance with applicable regulatory requirements is monitored through
periodic inspections by the FDA. If we fail to comply with applicable
regulations, we could suffer fines, delays or suspensions of clearances,
seizures or recalls of products, operating restrictions and criminal
prosecutions, any of which could have a material adverse effect on us.
OUR FUTURE SHORT-TERM AND LONG-TERM SUCCESS WILL BE DEPENDENT UPON OUR ABILITY
TO EFFECTIVELY ANTICIPATE, RESPOND TO AND MANAGE CHANGING BUSINESS CONDITIONS.
Our future short-term and long-term success will be dependent upon our
ability to effectively anticipate, respond to and manage changing business
conditions. We believe our current management will be able to properly manage
our future operations. However, there can be no assurance that we will be able
to adapt our manufacturing operations or administrative and financial functions
to manage our growth or to otherwise address the future needs of the business.
THERE IS A POSSIBILITY WE COULD INCUR EXPENSES OR BUSINESS INTERRUPTIONS DUE TO
YEAR 2000 ISSUES.
The Company's State of Readiness. Our main financial and manufacturing
hardware and software systems have been tested and we believe are now Year 2000
compliant. This was accomplished primarily through systems upgrades and
maintenance performed over the last few years. We are in the process of
surveying our major customers and suppliers regarding their Year 2000 readiness
and, to date, we are not aware of any significant Year 2000 issues at these
entities that would materially affect our business. We believe that if a Year
2000 problem develops at any of our vendors whereby the vendor becomes unable to
address our needs, alternative vendors are readily available that could furnish
us with the same or similar supplies or services without material undue delay or
expense.
Costs to Address the Company's Year 2000 Issues. The majority of our
Year 2000 issues were corrected either through systems upgrades or normal
maintenance contracts. The cost of these improvements to date has been
approximately $53,200.
Risks to the Company for Year 2000 Issues. With regard to systems under
our control, we know of no significant exposure that we have to the Year 2000
issue since, if necessary, our systems are capable of accepting manually entered
data. The worst case scenario is that we would have to revert back to certain
manual systems. We believe that our customers and vendors are at various stages
of compliance but we have not been made aware of significant Year 2000 issues
that would materially affect our business with them. We will continue to monitor
Year 2000 compliance with our customers and vendors throughout 1999 but will not
be able to achieve the same degree of certainty that we can with our own
internal systems.
The Company's Contingency Plan. To the extent that we discover minor
internal systems that are not Year 2000 compliant by late 1999, we will have
time to implement manual systems by year-end 1999 which we believe will
significantly reduce our financial risk.
9
USE OF PROCEEDS
The proceeds from the sale of the shares offered pursuant to this
prospectus will be received directly by the selling stockholders. We will not
receive any proceeds from the sale of the shares offered hereby. We will,
however, receive the exercise price for any warrants which are exercised by the
selling stockholders. We will use any funds we receive for general working
capital purposes.
PRICE RANGE OF COMMON STOCK
Our common stock is currently quoted on the OTC Bulletin Board under the symbol
"FHCO." As of September 30, 1999, there were approximately 481 holders of record
of our common stock.
Prior to February 5, 1999, our common stock was listed on the American
Stock Exchange. The following table sets forth the historical high and low sale
prices of a share of our common stock on the American Stock Exchange for periods
prior to February 5, 1999 and on the OTC Bulletin Board for periods thereafter:
[Download Table]
Common Stock Sale Price
-----------------------
High Low
---- ---
1997 Fiscal Year:
Quarter ended:
December 31, 1996 6-1/4 3-5/8
March 31, 1997 4-3/16 1-13/16
June 30, 1997 3-5/8 1-11/16
September 30, 1997 4-1/4 2-3/4
1998 Fiscal Year:
Quarter ended:
December 31, 1997 4-3/8 3
March 31, 1998 3-9/16 2
June 30, 1998 3-5/8 2-3/8
September 30, 1998 3-9/16 1-3/8
1999 Fiscal Year:
Quarter ended:
December 31, 1998 2 1-1/8
March 31, 1999 2-1/16 1-1/16
June 30, 1999 2 7/8
The sale price quotations above reflect inter-dealer prices, without
retail mark-ups, mark-downs or commissions.
DIVIDEND POLICY
The Company has not paid a dividend on its common stock and does not
anticipate paying any dividends in the foreseeable future.
DETERMINATION OF OFFERING PRICE
The common stock offered by this prospectus may be offered for sale by
the selling stockholders from time to time in transactions on the OTC Bulletin
Board, in negotiated transactions, or otherwise, or by a combination of these
methods, at fixed prices which may be changed, at market prices at the time of
sale, at prices related to market prices or at negotiated prices. As such, the
offering price is indeterminate as of the date of this prospectus. See "Plan of
Distribution."
10
CAPITALIZATION
The following table sets forth the unaudited short-term indebtedness
and stockholders' equity of the Company as of June 30, 1999.
[Enlarge/Download Table]
June 30, 1999
-------------
(Unaudited)
Short-term indebtedness:
Debt due within one year...................................... $ 57,785
Convertible debentures, net of
unamortized discount*..................................... 557,106
Notes payable, related party, net
of unamortized discount................................... 1,113,118
----------
Total short-term indebtedness......................... $ 1,728,009
==========
Stockholders' equity:
Class A Convertible Preferred Stock--Series 1, par value $.01 per
share, 1,040,000 shares authorized, 660,000 shares issued and
outstanding as of June 30................................. $ 6,600
Class A Convertible Preferred Stock--Series 2, par value $.01 per
share, 1,500,000 shares authorized, no shares issued and
outstanding...............................................
Common stock, par value $.01 per share, 22 million shares
authorized, 11,137,904 shares issued and outstanding as of
June 30, 1999............................................. 111,380
Additional paid-in capital (3)................................ 46,227,312
Unearned consulting compensation.............................. (339,517)
Accumulated deficit........................................... (44,344,476)
Foreign currency translation gain............................. 316,915
Treasury stock, at cost....................................... (32,076)
-----------
Total stockholders' equity............................ $ 1,946,138
==========
* On June 1, 1999, we completed a private placement of convertible debentures in
the principal amount of $1.5 million and warrants to purchase 1,875,000 shares
of common stock. The convertible debentures are convertible into shares of our
common stock as follows: the first 50% of the original principal balance plus
any accrued but unpaid interest thereon may be converted into common stock at
the investor's election at any time after one year based on a per share price
equal to the lesser of 70% of the market price of our common stock at the time
of conversion or $1.25; the second 50% of the original principal balance plus
any accrued but unpaid interest thereon may be converted into common stock at
the investor's election at any time after one year based on the per share price
equal to the lesser of 70% of the market price of the Company's common stock at
the time of conversion or $2.50. The convertible debentures are payable one year
after issuance or, if the Company's elects, two years after issuance. If the
term is extended for the extra one year, the Company must issue to the investors
at the time of the extension, additional warrants to purchase 375,000 shares of
common stock upon the same terms as the other warrants. Interest on the
convertible debentures is payable at 8% quarterly in cash or, at the investors'
option, common stock at its then current fair market value. Repayment of the
convertible debentures is secured by a first security interest in all the
Company's assets. Additionally, warrants to purchase 337,500 shares of common
stock were issued to the Company's placement agent in the offering in which the
convertible debentures were sold. The convertible debentures' beneficial
conversion feature is valued at $336,400 and the warrants to purchase 1,875,000
shares of common stock are valued at $715,100. In accordance with SEC reporting
requirements for such transactions, the Company recorded the value of the
beneficial conversion feature and warrants (a total of $1,051,500) as additional
paid in capital. The corresponding amount of $1,051,500 was recorded as a
discount on convertible debentures and is amortized over one year using the
interest rate method.
11
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following discussion is intended to provide an analysis of our
financial condition and results of operations and should be read in conjunction
with our financial statements and the notes thereto contained elsewhere in this
prospectus. The discussion also includes certain forward-looking statements. As
indicated in "PROSPECTUS SUMMARY--Forward-Looking Statements May Prove to be
Inaccurate," you should not place undue reliance on forward looking statements.
OVERVIEW
We completed significant aspects of the development and
commercialization of the female condom. These initiatives have resulted in our
attainment of proprietary manufacturing technology and product design patents,
necessary regulatory approvals, endorsements from various organizations within
the world medical community and the development of significant manufacturing
capacity. These steps, taken as part of our plan to develop and sell a product
with global commercial and humanitarian value, have required the expenditure of
significant amounts of capital and resulted in significant operating losses
including the period 1996 through the present.
We have begun the process of developing the market for the female
condom around the world. As part of this plan, we have entered into a number of
distribution agreements and are pursuing other arrangements for the marketing
and sale of the female condom. We believe that as the number of markets in which
the female condom is sold increases, sales will grow and, at certain levels, we
will become profitable. However, there can be no assurance that such level of
sales will be achieved in the near term or at all.
RESULTS OF OPERATIONS
NINE MONTHS ENDED JUNE 30, 1999 COMPARED TO NINE MONTHS ENDED JUNE 30, 1998
We had net revenues of $3,409,695 and a net loss of $3,041,226 for the
nine months ended June 30, 1999 compared to net revenues of $4,040,672 and a net
loss of $2,702,645 for the nine months ended June 30, 1998. As discussed in more
detail in the following paragraphs, the increase in our net loss was principally
related to a decrease in sales volume, a less than proportionate decline in cost
of goods and an increase in nonoperating expenses.
For the nine months ended June 30, 1999, our sales decreased $630,977,
or 16%, compared with the same period last year. This reflects quarterly
variations during the first half of the calendar year as the business develops.
We expect that fluctuations will continue, as various new countries launch the
product, until reorders account for a substantial portion of our sales.
Our cost of goods sold decreased $294,390 or 7%, to $3,787,785 for the
nine months ended June 30, 1999 from $4,082,175 for the same period last year.
Decreases in the costs of goods sold were a result of lower sales volume,
offset, in part, by a change between years in our reserve for inventory
obsolescence. During the nine months ended June 30, 1998 a $649,387 reduction in
our reserve for inventory obsolescence occurred. The FDA's decision to extend
the useful life of the female condom to five years from three years and the
reduction of finished goods inventories resulting from the increased level of
sales were the factors leading to the inventory reserve adjustment in the prior
year. We did not materially adjust inventory reserves during the same period
this year.
Advertising and promotional expenditures decreased $152,088 or 41%, to
$219,333 for the nine months ended June 30, 1999 from $371,421 for the same
period in the prior year.
Selling, general and administrative expenses increased $33,754 or 2%,
to $2,198,761 in the current period from $2,165,007 for the same period last
year. The increase reflected higher legal and professional fees related to
12
our effort to raise capital and communicate with the investor community offset
by temporary staff reductions and a corresponding drop in fringe benefits.
Net interest and nonoperating expenses increased $228,328 to $353,042
for the current period from $124,714 for the same period the prior year. During
the current year period, we had a higher level of debt outstanding than the
prior fiscal year period largely due to the issuance of convertible debentures.
A substantial increase in interest expense during the current year period
principally from amortization of the discounts on the notes payable and the
convertible debenture is a result of the additional debt.
FISCAL YEAR ENDED SEPTEMBER 30, 1998 ("1998") COMPARED TO FISCAL YEAR ENDED
SEPTEMBER 30, 1997 ("1997")
We had revenues of $5.5 million and a net loss attributable to
stockholders of ($4.3) million (($0.43) per share) in 1998 compared to net
revenues of $2.9 million and a net loss attributable to common stockholders of
($6.3) million (($0.74 per share) in 1997.
As discussed more fully below, the $2.0 million reduction (31%) in the
net loss attributable to stockholders from ($6.3) million in 1997 to ($4.3)
million in 1998 is the result of increased sales volume, reduced expenditures
for advertising and promotion, reduced interest expense and adjusted reserves
for inventory obsolescence. Net losses for both 1998 and 1997 are attributable
to fixed manufacturing overhead and administrative costs associated with
operating the manufacturing facility configured to support significantly greater
volume levels.
Net revenues increased $2.5 million (87%) in 1998 over the prior year.
Rapidly growing sales into both the global public sector and city and state
agencies within the United States accounted for all of the increase. Net sales
to commercial accounts declined, principally as a result of reduced expenditures
for product advertising and promotional support.
The results reflect our strategy to act as a manufacturer supplying the
public sector and commercial partners throughout the world. Our partners pay for
all marketing and shipping costs. Consequently, as our sales volume increases,
our operating expenses will not increase significantly.
In 1998, the cost of products sold of $5.3 million was 97% of net sales
compared with 1997 cost of products sold of $3.5 million which was 119% of net
sales. The reduction of costs of products sold as a percentage of net sales
resulted in an increase in gross profit (loss) of $0.8 million from a loss of
($0.6) million in 1997 to a profit of $0.2 million in 1998. The reduction in
cost of products sold as a percentage of net sales in 1998 resulted from
improved absorption of fixed manufacturing overheard costs over the increased
manufacturing unit volume. Our UK-based manufacturing facility utilized
approximately 12% of its capacity in 1998 compared with approximately 5% of its
capacity in 1997. In 1997, we recorded a favorable adjustment to our reserves
for inventory obsolescence reducing cost of products sold by $1.1 million.
During 1998, we further adjusted inventory obsolescence reserves, reducing cost
of products sold by $0.9 million. Our reserve for inventory obsolescence was
$40,734 and $894,000 at September 30, 1998 and 1997, respectively.
Advertising and promotion expenditures decreased 74% to $0.4 million in
1998 compared to $1.6 million in 1997. The 1997 expenditures reflect costs for
our previous print advertising campaign and single market test of our television
commercial which was not repeated in 1998. Advertising and promotion relates
exclusively to the U.S. market and includes the cost of print advertising, trade
and consumer promotions, product samples and other marketing costs incurred to
increase consumer awareness and purchases of the female condom. Through
expenditures since the product launch, we have established that the female
condom is responsive to promotion, but due to our size, we do not possess the
resources to conduct a significant consumer marketing program. Accordingly, we
are seeking potential partners for the United States that have the resources to
conduct such a marketing program.
Selling, general and administrative expenses decreased $0.1 million, or
5%, from $3.0 million in 1997 to $2.9 million in 1998. As a percentage of net
revenues, the selling, general and administrative expenses were 53% in 1998
compared with 104% in 1997. Our initiatives to reduce spending in all
administrative areas have resulted in reductions in the expenses associated with
telecommunications, legal and financial matters in the United States and the
United Kingdom. These reductions were offset by increased compensation expense.
13
Net nonoperating expense for 1998 decreased $0.8 million (80%) to $0.2
million from $1.0 million in 1997. The decrease is the result of lower interest
expense for 1998 ($0.5 million) compared with 1997 ($1.3 million). The prior
year interest expense included interest paid on convertible debentures which
were all converted during 1997 as well as the amortized cost of a beneficial
conversion feature associated with the issuance of the convertible debentures.
Comparable interest costs were not incurred during 1998.
In order for us to cover fixed manufacturing overhead costs and realize
a break-even at the gross profit level, annual unit sales of approximately 7.1
million female condoms are required based upon the current average selling price
per unit. Our unit sales for fiscal 1998 were 7.4 million female condoms.
Additionally, in order to cover administrative expenses and achieve a break-even
before advertising and promotional expenses, we must achieve cumulative annual
unit sales of approximately 13.0 million female condoms based upon the current
average selling price per unit or approximately 22.0% of manufacturing capacity.
FISCAL YEAR ENDED SEPTEMBER 30, 1997 ("1997") COMPARED TO FISCAL YEAR ENDED
SEPTEMBER 30, 1996 ("1996")
We had net revenues of $2.9 million and a net loss of ($5.6) million
(($0.67) per share) in 1997 compared to net revenues of $2.1 million and a net
loss of ($8.7) million (($1.31) per share) in 1996.
As discussed more fully below, the 1997 loss principally resulted from
fixed manufacturing overhead and administrative costs, configured to support
significantly greater volume levels. Over the past two years, we have acquired
manufacturing capacity and created an organizational structure which we believe
will enable us to increase the sales of the female condom and manage the
accompanying growth.
Net revenues increased $0.8 million (41%) in 1997 over the prior year.
The increase in revenues principally related to initial shipments to developing
countries under our agreement with UNAIDS and increased U.S. trade sales,
partially offset by a decline in U.S. public sector sales due, in part, to a
reduction in selling price.
In 1997, cost of goods sold decreased $1.2 million from $4.7 million in
1996 to $3.5 million in 1997, principally due to a $1.1 million favorable
adjustment to our inventory reserves in the fourth quarter, as a result of the
FDA's approval of an extension in the product's useful life to five years from
three years. In 1996, based on the then existing three-year useful life, cost of
goods sold included a $1.0 million charge for a reduction in the expected
realizable value of our inventory.
Excluding the effects of the inventory reserves, cost of goods sold
increased $0.9 million (23%) in 1997 due to both increased sales and the
inclusion of a full year of costs from our manufacturing operations compared to
eight months in 1996. During 1997 and 1996, gross margins were negatively
affected by excess capacity at our U.K.-based manufacturing facility. For both
1997 and 1996, output at our manufacturing facility was less than 5% of the
facility's annual capacity.
Advertising and promotional expenditures decreased 17% to $1.6 million
in 1997 compared to $2.0 million in 1996. Advertising and promotion relates
almost exclusively to the U.S. market and includes the costs of print
advertising, trade and consumer promotions, product samples and other marketing
costs incurred to increase consumer awareness and purchases of the female
condom. Our decision to secure a marketing and distribution partner for the U.S.
and European markets limited such spending in the second half of 1997.
Selling, general and administrative expenses totaled $3.0 million for
1997 compared to $3.3 million for 1996 representing an 8% reduction. Research
and development expenditures decreased by $0.3 million (83%) from $0.4 million
in 1996 to $0.1 million in 1997 while reductions in selling expenses were offset
by increased expenditures for investor relations, legal and compensation.
Nonoperating expense for 1997 decreased $0.3 million (49%) to $0.4
million from $0.7 million in 1996. Additional nonoperating income of $0.1
million for 1997 and a 1996 charge of $0.2 million to reduce the estimated value
of warehouse space provided as part of the consideration for the sale of the
recreational products business accounted for the overall decrease.
14
LIQUIDITY AND SOURCES OF CAPITAL
Historically, we have incurred cash operating losses relating to
expenses incurred to develop and promote the female condom. During the first
nine months of fiscal 1999, cash used in operations totaled $2.9 million. We
used existing cash balances to fund cash used in operations, thereby reducing
our cash position by $0.7 million. We funded cash used in operations in the
third quarter with the $1.3 million net proceeds received from the private
placement offering of convertible debentures. See Note 9 of "Notes to Unaudited
Condensed Consolidated Financial Statements."
Additionally, effective November 19, 1998, we entered into a private
equity line of credit agreement with Kingsbridge Capital Limited, a private
investor. Pursuant to this agreement, we have the right, subject to various
conditions, to issue and sell to Kingsbridge shares of our common stock for cash
consideration up to an aggregate of $6 million. Any stock sold by us to
Kingsbridge under the agreement will be sold at a discount to the stock's then
market price as determined pursuant to the agreement. The discount is 12% if the
market price of a share of our common stock at the time of the sale is $2.00 or
more and 18% if the market price is less then $2.00. The agreement gives us the
right to determine, in our sole discretion, the degree to which we will utilize
the equity line, subject to a minimum sale of $1 million of common stock to
Kingsbridge over the life of the agreement.
The agreement expires 24 months after the effective date of the
registration statement filed to register Kingsbridge's public resale of any
stock it purchases under the agreement. The agreement provides for, among other
things, minimum and maximum stock sales ranging from $100,000 to $1 million
depending on our stock price and trading volume at the time of the stock sale.
The timing and amount of the stock sales under the agreement are totally at our
discretion, subject to certain conditions. We are required to sell a minimum of
$1 million of common stock to Kingsbridge during the two-year period. If we do
not sell this minimum, we are required to pay Kingsbridge a 12% fee on the
portion of the $1 million minimum not sold. As of June 30, 1999, we have sold a
total of $485,000 of stock (482,964 shares) to Kingsbridge. Each sale was made
while our stock price was below $2.00 per share and, therefore, was sold at an
18% discount.
While we believe that our existing capital resources (including
expected proceeds from sales of common stock pursuant to the Equity Line
Agreement) will be adequate to fund our currently anticipated capital needs, if
they are not, we will need to raise additional capital until our sales increase
sufficiently to cover operating expenses. Until internally generated funds are
sufficient to meet cash requirements, we will remain dependent upon our ability
to generate sufficient capital from outside sources. At June 30, 1999, we had
current liabilities of $2.7 million including a $1.0 million note payable due
March 25, 2000 and a $250,000 note payable due February 12, 2000 both to Mr.
Dearholt, a director of the Company. As of September 30, 1999, Mr. Dearholt
beneficially owned 1,769,451 shares of our common stock.
We also secured a $50,000 note payable due February 18, 2000 from Mr.
Parrish, our Chairman of the Board and Chief Executive Officer. As of June 30,
1999, Mr. Parrish beneficially owned 281,251 shares of our common stock.
On April 6, 1999, we restructured the $602,360 (370,000 British pounds
sterling) Aage V. Jensen Charity Foundation loan note payable. The terms
included immediate payment of $177,000 (110,000 British pounds sterling) as of
the date of the restructuring agreement and required nine installment payments
beginning April 15, 1999 and concluding on December 10, 1999. To avoid incurring
additional interest related to the loan, we paid off the entire loan on June 10,
1999.
In the near term, we expect operating and capital costs to continue to
exceed funds generated from operations, due principally to our fixed
manufacturing costs relative to current production volumes and the ongoing need
to commercialize the female condom around the world. We estimate that our cash
burn rate, without revenues, is approximately $0.3 million per month.
While we believe that revenue from sales of the female condom will
eventually exceed operating costs, and that, ultimately, operations will
generate sufficient funds to meet capital requirements there can be no
15
assurance that such level of operations will be achieved in the near term, or
ever. Likewise, there can be no assurance that we will be able to source all or
any portion of our required capital through the sale of debt or equity or, if
raised, the amount will be sufficient for us to operate until sales of the
female condom generate sufficient revenues to fund operations. In addition, any
funds raised may be costly to us and/or dilutive to our stockholders.
If we are not able to source the required funds or any future capital
which becomes required, we may be forced to sell certain of our assets or rights
or cease operations. Further, if we are not able to source additional capital,
the lack of funds to promote the female condom may significantly limit our
ability to realize value from the sale of such assets or rights or otherwise
capitalize on the investments we have made in the female condom.
NEW ACCOUNTING PRONOUNCEMENTS
Earnings Per Share
Statement of Financial Accounting Standards No. 128, "Earnings per
Share," which supersedes APB Opinion No 15, was issued in February 1997 by the
Financial Accounting Standards Board. The Statement changes the computation and
presentation of earnings per share by all entities that have common stock or
potential common stock, such as options, warrants and convertible securities,
outstanding that trade in a public market. Those entities that have only common
stock outstanding are required to present basic earnings per-share amounts. All
other entities are required to present basic and diluted per-share amounts.
Diluted per share amounts assume the conversion, exercise or issuance of all
potential common stock instruments unless the effect is to reduce a loss or
increase the income per common share from continuing operations. All entities
required to present per-share amounts must initially apply Statement No. 128 for
annual and interim periods ending after December 15, 1997.
The Company has numerous issues of potential common stock outstanding,
including options to employees and stock purchase warrants that become
exercisable if certain conditions are met and preferred stock that is
convertible to common stock. Each of these potential common stock instruments
must be separately evaluated to determine whether they are dilutive, and various
adjustments to income and share amounts are computed. Due to the complexities
involved, management has not completed its assessment of the effects that the
application of Statement No. 128 will have on the per-share information
presented in the accompanying financial statements.
Capital Structure
Statement of Financial Accounting Standard No. 129, "Disclosure of
Information about Capital Structure," was issued in February 1997 by the
Financial Accounting Standards Board. The Statement requires an entity to
explain the pertinent rights and privileges of the various securities
outstanding. The standard is effective for financial statement periods ending
after December 15, 1997. The Company does not believe the adoption of the
Standard will have a material impact on the consolidated financial statements.
Comprehensive Income
The Financial Accounting Standards Board has issued Statement No. 130,
"Reporting Comprehensive Income," that the Company will be required to adopt for
its year ended September 30, 1998, and disclose in its interim financial
statements beginning with the period ending December 31, 1997. This
pronouncement is not expected to have a significant impact on the Company's
financial statements. The Statement establishes standards for the reporting and
presentation of comprehensive income and its components. The statement requires
that items recognized as components of comprehensive income be reported in a
financial statement. The statement also requires that a company classify items
of other comprehensive income by their nature in a financial statement, and
display the accumulated balance of other comprehensive income separately from
retained earnings and additional paid-in capital in the equity section of a
statement of financial position. For the years ended September 30, 1997 and
1996, the Company's components of comprehensive income (loss) consisted of its
reported net (loss) and foreign currency translation adjustments.
16
Segments of an Enterprise
Statement of Financial Accounting Standard No. 131, "Disclosures about
Segments of an Enterprise and Related Information," was issued in July 1997 by
the Financial Accounting Standards Board. The Statement requires the Company to
disclose the factors used to identify reportable segments including the basis of
organization, differences in products and services, geographic areas, and
regulatory environments. The Statement additionally requires financial results
to be reported in the financial statements for each reportable segment. The
Statement is effective for financial statement periods beginning after December
15, 1997. The Company does not believe the adoption of the statement will have a
material impact on the consolidated financial statements.
Derivatives
In June 1998, the FASB issued Statement No. 133, Accounting for
Derivative Instruments and Hedging Activities (FAS 133). FAS 133 requires
companies to record derivatives on the balance sheet as assets or liabilities at
fair value. Depending on the use of the derivative and whether it qualifies for
hedge accounting, gains or losses resulting from changes in the value of those
derivatives would either be recorded as a component of net income or as a change
in stockholders' equity. The Company is required to adopt this new standard for
the quarter and year beginning October 1, 2000. The Company currently has no
derivative instruments and, accordingly, the adoption of this statement has no
impact on its consolidated financial statements.
17
BUSINESS
GENERAL
We market, manufacture and sell the female condom, the only
FDA-approved product under a woman's control which can prevent unintended
pregnancy and sexually transmitted diseases ("STDs"), including HIV/AIDS.
The female condom has undergone extensive testing for efficacy, safety
and acceptability, not only in the United States but also in over 25 additional
countries. Certain of these studies show that having the female condom available
provides women with more options, resulting in an approximately 30% increase in
protected sex acts. Furthermore, studies show that when the female condom is
available as a choice, there is an approximately 35% decrease in STDs, including
HIV/AIDS.
The product is currently sold or available on a trial basis in either
or both commercial (private sector) and public sector markets in 40 countries.
It is commercially marketed directly by us in the United States and the United
Kingdom and through marketing partners in Canada, Holland, Brazil, Venezuela,
South Korea and Taiwan. We have signed distribution agreements in Japan and
Bangladesh, and we anticipate that the product will be marketed in these
countries in the coming months. Our partner in Japan, Taiho Pharmaceutical Co.,
Ltd., submitted a formal application for regulatory approval with Koseisho, the
Japanese regulatory agency in October 1997 and expects to receive approval to
begin marketing the female condom early in our 2000 fiscal year. We are
currently in discussions with potential distributors for key European countries,
India, The People's Republic of China and other countries.
As noted above, the female condom is sold to the public sector. In
particular, the product is marketed to city and state public health clinics as
well as not-for-profit organizations such as Planned Parenthood in the United
States. Following several years of testing the efficacy and acceptability of the
female condom, the product received a formal endorsement by The World Health
Organization ("WHO") and the Joint United Nations Programme on AIDS ("UNAIDS").
In 1996, we entered into a three-year agreement with UNAIDS, whereby UNAIDS will
facilitate the availability and distribution of the female condom in the
developing world and we will sell the product to developing countries at a
reduced price based on the total number of units purchased. The current price is
38 pence sterling (approximately $0.64 per unit). Pursuant to this agreement,
the product is currently available through government clinics and social
marketing efforts in Zambia, Zimbabwe, Tanzania, Cote d' Ivoire, Bolivia, Haiti,
South Africa and other countries. We anticipate multiple launches will occur
during the next two years under this agreement, including launches in Kenya,
Nigeria, Uganda, Ghana, Cambodia, Bangladesh, Columbia and Central American
countries.
PRODUCT
The female condom is made of polyurethane, a thin but strong material
which is resistant to rips and tears during use. The female condom consists of a
soft, loose fitting sheath and two flexible rings. One of the rings is used to
insert the device and hold it in place. The other ring remains outside the
vagina after insertion. The female condom lines the vagina, preventing skin from
touching skin during intercourse. The female condom is prelubricated and
disposable and is intended for use during only one sex act.
GLOBAL MARKET POTENTIAL
WHO estimates there are more than 300 million new cases of STDs
worldwide each year, excluding HIV, and most of those diseases are more easily
transmitted to women than to men. UNAIDS estimates that there are currently
approximately 34 million people worldwide who are infected with HIV/AIDS and
there are approximately 16,000 people per day who are newly infected. In the
United States, the Center for Disease Control noted that in 1995, five of the
ten most frequently reported diseases were STDs. The Center also has noted that
one in five Americans over the age of 12 has Herpes. Women are currently the
fastest growing group infected with
18
HIV and are expected to comprise the majority of new cases by the year 2000. The
following highlights the substantial and growing market for protection against
STDs.
[Download Table]
Worldwide:
Number of people with HIV/AIDS* 34 million
Number of new cases of HIV/AIDS daily* 16,000
Number of children expected to be orphaned by AIDS by 40 million
2010 (at current rate)*
Examples of decreases in life expectancy due to
HIV/AIDS*
Zimbabwe 22 years
Cote d'Ivoire 11 years
Number of Sub-Saharan African countries where more 13
than 10% of population is HIV positive*
* Source: UNAIDS
United States:
Number of top ten most frequently reported diseases 5
in the United States in 1995 that were STDs(1)
Ratio of individuals over 12 years of age with 1 in 5
Herpes(1)
Annual expenditures to treat STDs(2) $17 billion
Dollars spent on STD treatment for every $1.00 spent $43
on prevention(2)
The United States has one of the highest rates of teenage
pregnancy in Western nations--Each year one in nine teenage women
(ages 15-19) becomes pregnant(3)
(1) Source: Center for Disease Control
(2) Source: National Academy of Sciences
(3) Source: Alan Guttmacher Institute
At the 1988 World AIDS Conference, the following points were emphasized:
- New drugs help some AIDS patients in Western nations. However, they are of
little value in developing countries due to their cost and the complexity
of their administration.
19
- Simple, inexpensive treatments for HIV/AIDS--or a vaccine to prevent
infection from HIV--are unlikely in the near term.
- Prevention is essential.
Currently, there are only two products that prevent the transmission of HIV/AIDS
through sexual intercourse--the latex male condom and the female condom.
MALE CONDOM MARKET: It is estimated the global annual market for male condoms is
5.4 billion units. However, the majority of all acts of sexual intercourse,
excluding those intended to result in pregnancy, are completed without
protection. As a result, it is estimated the potential market for protection is
much larger than the identified male condom market.
ADVANTAGES VERSUS THE MALE CONDOM
The female condom is currently the only available barrier method which
is controlled by the woman and allows her to protect herself against STDs,
including HIV/AIDS, and unintended pregnancy. Although latex male condoms also
offer protection against STDs, the female condom possesses a certain number of
advantages over the male condom. The most important advantage is that a woman
can control whether or not she is protected. Many men do not like to wear male
condoms and may refuse to do so.
The material that is used for the female condom, polyurethane, offers a
number of benefits over latex, the material that is most commonly used in male
condoms. Polyurethane is 40% stronger than latex, reducing the probability that
the female condom sheath will tear during use. Clinical studies and everyday use
have shown that latex male condoms can tear between 4% to 8% of the times they
are used, while studies show that the female condom tears in less than 1% of
uses. Unlike latex, polyurethane quickly transfers heat, so the female condom
immediately warms to body temperature when it is inserted, which may result in
increased pleasure and sensation during use. The product offers an additional
benefit to the 7% to 10% of the population that is allergic to latex and who, as
a result, may be irritated by latex male condoms. To our knowledge, there is no
reported allergy to date to polyurethane. The female condom is also more
convenient, providing the option of insertion hours before sexual arousal and as
a result is less disruptive during moments of intimacy than the male condom
which requires sexual arousal for application.
SAFETY AND EFFICACY
Based on use of the product in clinical trials and approximately five
years of worldwide marketing, the female condom has been proven to be safe and
effective. The following information reflects the results of various trials:
[Enlarge/Download Table]
Reduction in STDs(1) 34% (Results when female condom was
Reduction in Acts of Unprotected Sex(1) 25% available as an option vs. when only
the male condom was available.)
Effectiveness in Preventing Pregnancy(2) 95%(3) (When used properly with every sex act.)
(1) Supported by UNAIDS
(2) Supported by The U.S. Agency for International Development and
conducted by Family Health International.
(3) Recent studies completed in Japan evaluating the female condom's
effectiveness in preventing pregnancy, which were submitted to the
Japanese regulatory authorities in connection with their review of
the product, showed the female condom to be approximately 98%
effective when used consistently and correctly.
20
COST EFFECTIVENESS
At the 1998 World AIDS Conference held in Geneva, Switzerland, UNAIDS
presented the results from its cost-effectiveness study which indicated that
making the female condom available is highly cost effective in reducing public
health costs in developing countries.
ENDORSEMENTS
Currently, the female condom is endorsed for use by the World Health
Organization, the United Nations Joint Programme on AIDS, the United States
Agency for International Development, many nongovernment organizations around
the world and a number of city and state public health departments in the United
States.
WORLDWIDE REGULATORY APPROVALS
The female condom received PMA approval as a Class III Medical Device
from the FDA in 1993. The extensive clinical testing and scientific data
required for FDA approval laid the foundation for approvals throughout the rest
of the world, including receipt of a CE Mark in 1997 which allows the Company to
market the female condom throughout the European Union. In addition to the
United States and the European Union, several other countries have approved the
female condom for sale, including Canada, Russia, Australia, South Korea and
Taiwan. We expect the female condom to receive approval in Japan early in our
2000 fiscal year.
We believe the female condom's PMA approval and FDA classification as a
Class III Medical Device create a significant barrier to entry by competitive
products. We estimate that it would take a minimum of four to six years to
implement, execute and receive FDA approval or a PMA to market another type of
female condom.
We believe there are no material issues or material costs associated
with our compliance with environmental laws related to the manufacture and
distribution of the female condom.
STRATEGY
Our strategy is to act as a manufacturer, selling the female condom to
the global public sector, United States public sector and commercial partners
for country-specific marketing. The public sector and commercial partners assume
the cost of shipping and marketing the product. As a result, as volume
increases, our operating expenses will not increase significantly.
COMMERCIAL MARKETS
We market the product directly in the United States and United Kingdom.
We have commercial partners which have recently launched the product in Canada,
Brazil, Venezuela, Taiwan, South Korea and Holland. We have also signed
agreements with partners in Japan and Bangladesh where launches are expected
during the coming year.
JAPANESE MARKET
In Japan, the market for male condoms exceeds 600 million units. Oral
contraceptives have only recently been approved in Japan and, as a result, 85%
of Japanese couples seeking protection use condoms. Our partner in Japan is
Taiho, a $1 billion subsidiary of Otsuka Pharmaceutical Co., Ltd., a $5 billion
Japanese health care company. Our agreement with Taiho requires Taiho to perform
clinical testing of the product in Japan and obtain the necessary regulatory
approvals. After approval, we will manufacture the product and supply it to
Taiho, which will have responsibility for marketing and distributing the female
condom in Japan. Studies completed in Japan show an acceptance rate of 70% among
Japanese women. Taiho plans to market the female condom under the name "Mylura
Femy."
21
RELATIONSHIPS AND AGREEMENTS WITH PUBLIC SECTOR ORGANIZATIONS
Currently, it is estimated that more than 1.5 billion male condoms are
distributed worldwide by the public sector each year. The female condom is seen
as an important addition to prevention strategies by the public sector because
studies show that the availability of the female condom decreases the incidence
of unprotected sex by as much as 30% over male condoms alone.
We have a multi-year agreement with UNAIDS to supply the female condom
to developing countries at a reduced price which is negotiated each year based
on volume. The current price is 38 pence sterling (approximately $0.63) per
unit. During the last year, the female condom has been launched in the countries
of Zimbabwe, Tanzania, Bolivia, Haiti, South Africa and Zambia. It is
anticipated that multiple product launches will occur in several countries
during the next two years, including in the countries of Kenya, Nigeria, Uganda,
Ghana, Cambodia, Bangladesh, Columbia and Central America.
In the United States, the product is marketed to city and state public
health clinics, as well as not-for-profit organizations such as Planned
Parenthood. Currently, 10 major cities and 15 state governments, including New
York, Pennsylvania, Florida, Connecticut, Hawaii, Louisiana, Maryland, New
Jersey, South Carolina, Illinois, Chicago, Philadelphia, New York and Houston,
have purchased the product for distribution with a number of others expressing
interest. All major cities and states have re-ordered product since their
initial shipments.
STATE-OF-ART MANUFACTURING FACILITY
We manufacture the female condom in a 40,000 square foot leased
facility in London, England. The facility is currently capable of producing 60
million units per year. With additional equipment, this capacity can be
significantly increased.
GOVERNMENT REGULATION
In the U.S., the female condom is regulated by the FDA. Pursuant to
section 515(a)(3) of the Safe Medical Amendments Act of 1990 (the "SMA Act"),
the FDA may temporarily suspend approval and initiate withdrawal of the PMA if
the FDA finds that the female condom is unsafe or ineffective, or on the basis
of new information with respect to the device, which, when evaluated together
with information available at the time of approval, indicates a lack of
reasonable assurance that the device is safe or effective under the condition of
use prescribed, recommended or suggested in the labeling. Failure to comply with
the conditions of FDA approval invalidates the approval order. Commercial
distribution of a device that is not in compliance with these conditions is a
violation of the SMA Act.
COMPETITION
The female condom competes in part with male condoms. Latex male
condoms cost less and have brand names that are more widely recognized than the
female condom. In addition, male condoms are generally manufactured and marketed
by companies with significantly greater financial resources than the Company. It
is also possible that other parties may develop a female condom. Any such
competing products could be manufactured, marketed and sold by companies with
significantly greater financial resources than those of the Company.
EMPLOYEES
As of September 30, 1999, we had 82 full-time employees within the U.S.
and the U.K. and __ part-time employees. None of our employees are represented
by a labor union. We believe that our employee relations are good.
22
BACKLOG
At September 30, 1999, we had unfilled orders of $2.1 million. The
comparable amount as of the same date of the prior year was $1 million. All of
these unfilled orders are expected to be filled during fiscal 2000.
PATENTS AND TRADEMARKS
We currently hold product and technology patents in the United States,
Japan, the United Kingdom, France, Italy, Germany, Spain, the European Patent
Convention, Canada, The People's Republic of China, New Zealand, Singapore, Hong
Kong and Australia. Additional product and technology patents are pending in
Brazil, South Korea, Germany, Japan and several other countries. The patents
cover the key aspects of the female condom, including its overall design and
manufacturing process. We license the trademark "Realty" in the United States
and have trademarks on the names "femidom" and "femy" in certain foreign
countries. We have also secured, or applied for, 27 trademarks in 14 countries
to protect the various names and symbols used in marketing the product around
the world. In addition, the experience that has been gained through years of
manufacturing the female condom has allowed us to develop trade secrets and
know-how, including certain proprietary production technologies, that further
secure our competitive position.
RESEARCH AND DEVELOPMENT
In FY1998 and FY1997, we incurred research and development costs from
continuing operations of $2,500 and $60,811, respectively. For the nine months
ended June 30, 1999 and 1998, respectively, we incurred research and development
costs of $113,797 and $0, respectively. These expenditures are related to
conducting acceptability studies and research on a second generation product.
INDUSTRY SEGMENTS AND FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC
OPERATIONS
See Note 10 to Notes to Consolidated Financial Statements, included
herein.
HISTORY
The female condom was invented by a Danish physician who obtained a
U.S. patent for the product in 1988. The physician subsequently sold certain
rights to the condom to Chartex Resources Limited. In the years that followed,
Chartex, with resources provided by a nonprofit Danish foundation, developed the
manufacturing processes and completed other activities associated with bringing
the female condom to market in certain non-U.S. countries. Wisconsin Pharmacal
Company, Inc., which then owned certain rights to the female condom in the U.S.,
Canada and Mexico, pursued the pre-clinical and clinical studies and overall
development of the product for worldwide use and U.S. FDA approval of the
product.
We are the successor to Wisconsin Pharmacal Company, Inc., a company
which previously manufactured and marketed a wide variety of disparate specialty
chemical and branded consumer products in addition to owning certain rights to
the female condom described above. A summary of our origins follows.
In fiscal 1995, our Board of Directors approved a plan to complete a
series of actions designed, in part, to maximize the potential of the female
condom. First, we restructured and transferred all of our assets and
liabilities, other than those related primarily to the female condom, to a
newly-formed, wholly-owned company, WPC Holdings, Inc. In January 1996, we sold
WPC Holdings to an unrelated third party. Then, in February 1996, we acquired
Chartex (renamed The Female Health Company - UK in 1997), the manufacturer and
owner of certain worldwide rights to, and our then sole supplier of, the female
condom. As a result of the sale of WPC Holdings and the acquisition of Chartex,
we evolved to our current state with our sole business consisting of the
manufacture, marketing and sale of the female condom.
The FDA approved the female condom for distribution in 1993 and our
manufacturing facility in 1994. Since that time, we have sold over 27 million
female condoms around the world.
23
PROPERTIES
We lease approximately 4,500 square feet of office space at 875 North
Michigan Avenue, Suite 3660, Chicago, Illinois 60611 under a lease that expires
in 2001. We also lease approximately 1,900 square feet for corporate offices at
919 North Michigan Avenue, Suite 2208, Chicago, Illinois 60611 under a lease
that expires January 31, 2001. However, we have subleased these premises to a
third party. We utilize warehouse space and sales fulfillment services of an
independent public warehouse located near Minneapolis, Minnesota, for storage
and distribution of the female condom. We manufacture the female condom in a
40,000 square foot leased facility located in London, England. The FDA-approved
manufacturing process is subject to periodic inspections by the FDA. Current
capacity at the manufacturing facility is approximately 60 million female
condoms per year. We believe the properties are adequately insured.
LEGAL PROCEEDINGS
We are not involved in any material pending legal proceedings.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We file reports, proxy statements and other information with the
Securities and Exchange Commission. You may read and copy any reports, proxy
statements or other information we file at the SEC's public reference room at
450 Fifth Street, N.W., Washington, D.C. or at the SEC's public reference rooms
in Los Angeles, California, New York, New York and Chicago, Illinois. You can
obtain information concerning the operation of the public reference rooms by
calling the SEC at 1-800-SEC-0330. In addition, we have filed the registration
statement of which this prospectus is a part and other filings pursuant to the
Securities Exchange Act of 1934, as amended, with the SEC through its Electronic
Data Gathering, Analysis and Retrieval system, and such filings are publicly
available through the SEC's site on the World Wide Web on the Internet located
at www.sec.gov.
This prospectus does not contain all of the information set forth in
the registration statement of which this prospectus is a part and which we have
filed with the SEC. For further information with respect to the Company and the
securities offered by this prospectus, you should review the registration
statement, including the exhibits filed as a part thereof, at the public
reference rooms. We may update information with respect to the Company by filing
appendices or supplements to this prospectus.
24
MANAGEMENT
DIRECTORS AND EXECUTIVE OFFICERS
The Company's directors and executive officers are as follows:
[Download Table]
Name Title Age
O.B. Parrish Chairman of the Board, Chief
Executive Officer and Director 65
Mary Ann Leeper, Ph.D. President, Chief Operating Officer
and Director 59
Robert R. Zic Chief Financial Officer 36
William R. Gargiulo, Jr. Secretary and Director 70
Jack Weissman Vice President-Trade Sales 50
Michael Pope Vice President of the Company,
Director of Chartex
Resources Limited, Director and
General Manager of Chartex
International, Plc 42
David R. Bethune Director 59
Stephen M. Dearholt Director 52
Michael R. Walton Director 61
James R. Kerber Director 67
O.B. Parrish has served as Chief Executive Officer of the Company since
1994, and as the Chairman of the Board and a Director of the Company since 1987.
Mr. Parrish is a shareholder and has served as the President and as a Director
of Phoenix Health Care of Illinois, Inc. ("Phoenix of Illinois") since 1987.
Phoenix of Illinois owns approximately 294,000 shares of the Company's
outstanding common stock. Mr. Parrish also was the Co-Chairman and a Director of
Inhalon Pharmaceuticals, Inc. until its sale to Medeva, Plc. and is Chairman and
a Director of ViatiCare, Ltd. From 1977 until 1986, Mr. Parrish was the
President of the Global Pharmaceutical Group of G.D. Searle & Co. ("Searle") and
a director of Microbyx. Mr. Parrish is also a trustee of Lawrence University.
From 1974 until 1977, Mr. Parrish was the President of Searle International, the
foreign sales operation of Searle. Prior to that, Mr. Parrish was Executive Vice
President of Pfizer's International Division.
William R. Gargiulo, Jr. has served as Secretary of the Company from
1996 to present, as Vice President from 1996 to September 30, 1998, as Assistant
Secretary of the Company from 1989 to 1996, as Vice President International of
The Female Health Company Division from 1994 until 1996, as Chief Operating
Officer of the Company from 1989 to 1994, and as General Manager of the Company
from 1988 to 1994. Mr. Gargiulo has also served as a Director of the Company
since 1987. Mr. Gargiulo is a Trustee of a trust which is a shareholder of
Phoenix of Illinois. From 1984 until 1986, Mr. Gargiulo was the Executive
Vice-President of Searle's European operations. From 1976 until 1984, Mr.
Gargiulo was the Vice President of Searle's Latin American operations.
Dr. Leeper has served as the President and Chief Operating Officer of
the Company since 1996 and as President and Chief Executive Officer of The
Female Health Company Division from May 1994 until January
25
1996, as Senior Vice President - Development of the Company from 1989 until
January 1996 and as a Director of the Company since 1987. Dr. Leeper is a
shareholder and has served as a Vice President and Director of Phoenix of
Illinois since 1987. Previously, Dr. Leeper served as Vice President - Market
Development for Searle's Pharmaceutical Group and in various Searle research and
development management positions. As Vice President - Market Development, Dr.
Leeper was responsible for worldwide licensing and acquisition, marketing and
market research. In earlier positions, she was responsible for preparation of
new drug applications and was a liaison with the FDA.
Mr. Weissman has served as Vice President - Trade Sales of The Female
Health Company since June 1995. From 1992 until 1994, Mr. Weissman was Vice
President - Sales for Capital Spouts, Inc., a small manufacturing company.
During the period from 1989 to 1992, Mr. Weissman acted as General Manager - HTV
Group, an investment group involved in the development of retail stores. Mr.
Weissman joined Searle's consumer products group in 1979 and held positions of
increasing responsibility, including National Account Manager and Military Sales
Manager from 1985 to 1989. Mr. Weissman was Account Manager - Retail Business
Development, for the NutraSweet Company, a Searle subsidiary. Prior to Searle,
Mr. Weissman worked in the consumer field as Account Manager and Territory
Manager for Norfolk Thayer & Whitehall Laboratories.
Mr. Pope has served as Vice President of the Company since 1996 and as
General Manager of Chartex International, Plc since the Company's 1996
acquisition of Chartex. Mr. Pope has also served as a Director of Chartex
Resources Limited and Chartex International, Plc since 1995. Previously, Mr.
Pope was Director of Technical Operations for Chartex which included
responsibility for manufacturing, engineering, process development and quality
assurance. Mr. Pope was responsible for the development of the high speed
proprietary manufacturing technology for the female condom and securing the
necessary approvals of the manufacturing process by regulatory organizations,
including the FDA. Mr. Pope was also instrumental in developing and securing
Chartex's relationship with its Japanese marketing partner. Prior to joining
Chartex, Mr. Pope was Production Manager and Technical Manager for Franklin
Medical, a manufacturer of disposable medical devices. Prior to that, Mr. Pope
was Site Manager, Engineering and Production Manager, Development Manager and
Silicon Manager for Warne Surgical Products.
Mr. Zic has served as the Company's Chief Financial Officer since March
1999. Mr. Zic's career began as an auditor with Arthur Andersen & Co. After his
time with Arthur Andersen, Mr. Zic pursued a career in the insurance industry,
gaining ten years experience with three property and casualty insurers. He
started as a senior accountant responsible for the statutory-based financials of
All State Insurance Company, after which he became the Assistant Controller of
CalFarm Insurance Company, where he was responsible for the company's external
financial reporting duties. Later, he became the Chief Accounting Manager and
Assistant Controller at Argonaut Insurance Company. In this capacity, he was
responsible for the financial and accounting operations at Argonaut's ten
divisions and the external and internal financial reporting of Argonaut and its
four subsidiaries. Prior to joining The Female Health Company, Mr. Zic held the
dual positions of Acting Controller and Acting Chief Financial Officer at
Ladbroke's Pacific Racing Association.
Mr. Bethune has served as a Director of the Company since January 1996.
Mr. Bethune is an interim Chief Executive Officer of Atrix Pharmaceuticals and a
business consultant to the pharmaceutical industry and previously held the
position of President and Chief Operating Officer of the IVAX Corporation. Prior
to IVAX, Mr. Bethune was Group Vice President of American Cyanamid Company and a
member of its Executive Committee until the sale of the company to American Home
Products. He had global executive authority for human biologicals, consumer
health products, pharmaceuticals and opthalmics, as well as medical research.
Previously, he was President of the Lederle Laboratories Division of American
Cyanamid Company. Mr. Bethune rejoined Lederle from Searle, where he was
President of Operations in the United States, Canada and the Caribbean since
December 1986. From 1984 until his appointment as President of Operations, Mr.
Bethune served as Vice President and General Manager, United States
Pharmaceuticals. Mr. Bethune is on the Board of Directors of the Southern
Research Institute, Atrix Pharmaceuticals and the American Foundation for
Pharmaceutical Education, Partnership for Prevention. He is a founding trustee
of the American Cancer Society Foundation and an associate member of the
National Wholesale Druggists' Association and the National Association of Chain
Drug
26
Stores. He is the founding chairman of the Corporate Council of the Children's
Health Fund in New York City and served on the Arthritis Foundation Corporate
Advisory Council.
Mr. Dearholt has served as a Director of the Company since April 1996.
Mr. Dearholt is a co-founder and partner in Response Marketing, one of the
largest privately owned life insurance marketing organizations in the United
States. He has over 23 years of experience in direct response advertising and
data based marketing of niche products. Since 1985, he has been a 50% owner of
R.T. of Milwaukee, a private investment holding company which operates a stock
brokerage business in Milwaukee, Wisconsin. In late 1995, Mr. Dearholt arranged,
on very short notice, a $1 million bridge loan which assisted the Company in its
purchase of Chartex.
Mr. Kerber has served as a Director of the Company since April 1, 1999.
Mr. Kerber is currently a business consultant to the insurance industry. He has
over 40 years of experience in operating insurance companies, predominantly
those associated with life and health. From October 1994 until January 1996, he
was Chairman, President, Chief Executive Officer and director of the 22 life and
health insurance companies which comprise the ICH Group. In 1990, Mr. Kerber was
founding partner in the Life Partners Group where he was Senior Executive Vice
President and a director. Prior to that, he was involved with operating and
consolidating over 200 life and health companies for ICH Corporation, HCA
Corporation and US Life Corporation.
Mr. Walton is President and owner of Sheboygan County Broadcasting Co.,
Inc., a company he founded in 1972. In addition to its financial assets,
Sheboygan County Broadcasting Co. currently owns four radio stations. The
company has focused on start-up situations, and growing value in
underperforming, and undervalued business situations. It has purchased and sold
properties in Wisconsin, Illinois and Michigan, and has grown to a multi-million
dollar asset base from a start-up capital contribution of less than $100,000.
Prior to 1972, Mr. Walton was owner and President of Walton Co., an advertising
representative firm which he founded in New York City. He has held sales and
management positions with Forbes Magazine, The Chicago Sun Times and Gorman
Publishing Co., a trade magazine publisher specializing in new magazines which
was subsequently sold to a large international publishing concern. Mr. Walton
has served on the Board of the American Red Cross, the Salvation Army and the
Chamber of Commerce.
The Company's Board of Directors has an Audit Committee and a
Compensation Committee. The Board's Audit Committee is comprised of Messrs.
Bethune and Dearholt. The responsibilities of the Audit Committee, in addition
to such other duties as may be specified by the Board of Directors, include the
following: (1) recommendation to the Board of Directors of independent auditors
for the Company; (2) review of the timing, scope and results of the independent
auditors' audit examination; (3) review of periodic comments and recommendations
by the auditors and of the Company's response thereto; and (4) review of the
scope and adequacy of internal accounting controls. The Audit Committee did not
meet during the fiscal year ended September 30, 1998.
The Board's Compensation Committee is comprised of Messrs. Gargiulo and
Bethune. The responsibility of the Compensation Committee, in addition to such
other duties as may be specified by the Board of Directors, is to make
recommendations to the Board of Directors with respect to compensation for the
executive officers and to administer the Company's 1989, 1990, 1994 and Outside
Director Stock Option Plans. The Compensation Committee met two times during the
fiscal year ended September 30, 1998.
There is no standing nominating or similar committee of the Board of
Directors.
Directors who are not also employees of the Company receive a one-time
grant of options to purchase 30,000 shares of the Company's common stock upon
their initial election to the Company's Board of Directors. The options are
granted at an exercise price equal to the last sale price of the Company's
common stock on the date of grant. The Company also pays each such outside
director $1,000 for each meeting of the Board of Directors attended by such
director and reimburses the outside director for his expenses incurred in
attending the meeting.
27
All directors serve until the next annual meeting of the Company's
shareholders and until his or her successor has been duly elected or until his
or her prior death, resignation or removal. Each executive officer holds office
until his or her successor has been duly appointed or until his or her prior
death, resignation or removal.
EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The table below sets forth all annual, long-term and other compensation
paid by the Company to each of our executive officers whose total annual salary
and bonus exceeded $100,000 for services rendered during any of the years
indicated below. The individuals listed in this table are referred to elsewhere
in this prospectus as the "named executive officers."
[Download Table]
Annual Long-Term Compensation
Compensation Awards
------------ ----------------------
Restricted Securities
Name and Stock Underlying
Principal Fiscal Salary Awards(1) Options/SARs
Position Year ($) ($) (#)
------------ ---------- --------------- ------------ ------------
O.B. Parrish 1998 90,000 117,955(2) --
Chairman and 1997 90,000 -- 100,000*
Chief Executive 1996 90,000 -- 120,000
Officer
Mary Ann Leeper, 1998 225,000 84,210(2) --
Ph.D. President and 1997 225,000 -- 90,000
Chief Operating 1996 225,000 -- --
Officer
(1) Represents fair market value of restricted common stock on the date of grant
based on the $2.88 closing price of the Company's common stock on such date.
(2) At September 30, 1998, the named executive officer owned 25,000 shares of
restricted common stock, having a fair market value of $71,875 on that date,
based on the closing price of the Company's common stock on that date. For Mr.
Parrish, also includes his pro rata portion of 25,000 shares of restricted stock
granted to Phoenix of Illinois, based on his 64% ownership of Phoenix of
Illinois. For Dr. Leeper, also includes her pro rata portion of the restricted
stock based on her approximately 16.7% ownership of Phoenix of Illinois. All of
these shares were granted on May 5, 1998 and vested in full on the first
anniversary of the grant date. The owner is entitled to receive any dividends
declared on these shares of restricted stock.
FISCAL YEAR-END OPTION/SAR VALUES
The following table sets forth the number and value of unexercised
options held by the named executive officers at September 30, 1998:
[Enlarge/Download Table]
Number of Securities Underlying
Unexercised Options at Value of Unexercised In-the-Money
Fiscal Year End September 30, 1998 Options at Year-End
Name Exercisable/Unexercisable Exercisable/Unexercisable
------ ---------------------------------- ---------------------------------
O.B. Parrish 88,000/176,000 $0
Mary Ann Leeper, Ph.D. 96,667/193,333 $0
EMPLOYMENT AGREEMENTS
Dr. Leeper entered into an employment agreement with the Company
effective May 1, 1994. The original term of Dr. Leeper's employment extended to
April 30, 1997 and thereafter her employment term renews automatically for
additional three-year terms unless notice of termination is given. The
employment agreement is terminable by the Company at any time for cause (as
defined in the employment agreement). If Dr. Leeper is
28
terminated without cause, the Company is obligated to continue to pay Dr. Leeper
her base salary and any bonus to which she would otherwise have been entitled
for a period equal to the longer of two years from date of termination or the
remainder of the then applicable term of the employment agreement. In addition,
the Company is obligated to continue Dr. Leeper's participation in any health,
life insurance or disability plan sponsored by the Company and in which Dr.
Leeper participated prior to her termination of employment. Dr. Leeper's
employment agreement provided for a base salary of $175,000, $195,000 and
$225,000, respectively, for each of the first three years of her employment
term, subject to the achievement of certain performance goals established by Dr.
Leeper and the Company. If the employment agreement is renewed beyond the
initial three-year term, it requires her base salary to be increased annually by
the Board of Directors based upon her performance and such other factors as the
Board of Directors deems appropriate. For fiscal 1998 and 1999, Dr. Leeper's
base salary was set at $225,000. The employment agreement also provides Dr.
Leeper with various fringe benefits including an annual cash bonus of up to 100%
of her base salary if certain performance goals established by the Board of
Directors are achieved.
CHANGE OF CONTROL AGREEMENTS
In fiscal 1999, the Company entered into Change of Control Agreements
with each of O.B. Parrish, the Company's Chairman and Chief Executive Officer,
Mary Ann Leeper, the Company's President and Chief Operating Officer, and
Michael Pope, the Company's Vice President. These agreements essentially act as
springing employment agreements which provide that, upon a change of control of
the Company (as defined in the agreement), the executive shall continue to be
employed by the Company for a period of three years in the same capacities and
with the same compensation and benefits as the executive was receiving prior to
the change of control (all as specified in the agreements). If the executive is
terminated without cause or if he or she quits for good reason (both as defined
in the agreements) after the change of control, the executive is generally
entitled to receive a severance payment from the Company equal to the amount of
compensation remaining to be paid to the executive under the agreement for the
balance of the three-year term.
29
PRINCIPAL SHAREHOLDERS
The following table sets forth certain information regarding the
beneficial ownership of common stock as of September 30, 1999 by (1) each
stockholder known by the Company to be the beneficial owner of more than 5% of
the common stock; (2) each director; (3) each named executive officer; and (4)
all directors and executive officers as a group.
[Download Table]
Shares
Beneficially Owned
------------------
Name Number Percent
---- ------ -------
O.B. Parrish (1)
683,501 5.64%
William R. Gargiulo, Jr. (1) 341,168 2.88%
Mary Ann Leeper, Ph.D. (1) 459,568 3.85%
David R. Bethune (2) 50,000 * %
Michael R. Walton (3) 577,800 4.9 %
James R. Kerber (3) 393,710 3.3 %
Stephen M. Dearholt (5) 1,497,784 11.7%
Phoenix Health Care of
Illinois, Inc.(6) 324,001 2.78%
All directors and executive
officers as a group (ten
persons) %
-----------------------------
* Less than 1%.
(1) Includes 294,001 shares owned by and 30,000 shares under option to
Phoenix of Illinois. Messrs. Parrish and Gargiulo and Dr. Leeper may be
deemed to share voting and dispositive power as to such shares since
Mr. Gargiulo is a trustee of a trust which is a shareholder, and Mr.
Parrish and Dr. Leeper are officers, directors and shareholders, of
Phoenix of Illinois. For Dr. Leeper, also includes 38,900 shares owned
by and 96,667 shares under option to her (which options are exercisable
within 60 days); for Mr. Parrish, also includes 71,500 shares owned by
and 288,000 shares under option to him (which options are exercisable
within 60 days); and for Mr. Gargiulo, also includes 500 shares owned
by and 16,667 shares under option to him, which options are exercisable
within 60 days.
(2) Represents options which are currently exercisable.
(3) Includes 50,000 shares under option (which options are exercisable
within 60 days).
(4)
(5) Includes 258,075 shares owned directly by Mr. Dearholt. Also includes
69,500 shares held by the Dearholt, Inc. Profit Sharing Plan, 9,680
shares held by Response Marketing Money Purchase Plan, 148,129 shares
held by trusts (of which Mr. Dearholt is a trustee) and 18,100 shares
held by Mr. Dearholt's minor child, 6,200 shares held in a
self-directed IRA, 18,100 shares held by a trust of which Mr. Dearholt
is a trustee and 60,000 shares of preferred stock held by a trust of
which Mr. Dearholt is a trustee and which are convertible one-for-one
into common stock. Also includes warrants to purchase 860,000 shares of
common stock and options to purchase 50,000 shares.
(6) Includes 294,001 shares owned by and 30,000 shares under options to
Phoenix of Illinois.
30
CERTAIN TRANSACTIONS
On February 18, 1999, the Company extended for an additional one year
its one-year, $50,000 promissory note payable to O.B. Parrish, the Company's
Chairman and Chief Executive Officer. The extension was completed through the
execution of promissory note and Note Purchase and Warrant Agreement and Stock
Issuance Agreement. Pursuant to this transaction, Mr. Parrish was granted
warrants to purchase 10,000 shares of our common stock at an exercise price of
$1.35 per share. The warrants expire upon the earlier of their exercise or five
years after the date of their issuance. Under the Stock Issuance Agreement, if
we fail to pay the $50,000 promissory note when due, we must issue 10,000 shares
of our common stock to Mr. Parrish. The issuance will not, however, alleviate
our liability under the note. We also granted Mr. Parrish securities
registration rights with respect to any common stock he receives from us under
these warrants or the Stock Issuance Agreement.
On February 12, 1999, we borrowed $250,000 from Mr. Dearholt. The
borrowing was effectuated in the form of a $250,000, one-year promissory note
payable by us to Mr. Dearholt. As part of this transaction, the Company entered
into a Note Purchase and Warrant Agreement and a Stock Issuance Agreement.
Pursuant to the Note Purchase and Warrant Agreement, Mr. Dearholt received a
warrant to purchase 50,000 shares of our common stock at an exercise price of
$1.248 per share. The warrants expire upon the earlier of their exercise or five
years after the date of their issuance. Under the Stock Issuance Agreement, if
we fail to pay the $250,000 under the note when due, we must issue 50,000 shares
of our common stock to Mr. Dearholt. This issuance will not, however, alleviate
our liability under the note. We also granted Mr. Dearholt securities
registration rights with respect to any common stock he receives from us under
these warrants or the Stock Issuance Agreement.
During 1998, as compensation for consulting services, we awarded
Phoenix Health Care of Illinois, Inc., a corporation which is owned in part and
controlled by O. B. Parrish, Mary Ann Leeper and Bill Gargiulo, 25,000 shares of
restricted stock with a market value of approximately $93,750.
On March 25, 1997, 1998 and 1999, we extended a $1 million, one-year
promissory note payable by us to Mr. Dearholt in connection with a previous loan
Mr. Dearholt made to the Company. The promissory note is now payable in full on
March 25, 2000 and bears interest at 12% per annum, payable monthly. The note
proceeds were initially used by us to provide working capital needed to fund the
initial stages of our U.S. marketing campaign ($0.2 million) and to fund
operating losses ($0.8 million). The borrowing transactions were effected in the
form of a promissory note from us to Mr. Dearholt and related Note Purchase and
Warrant Agreements and a Stock Issuance Agreement. Under the 1997, 1998 and 1999
Note Purchase and Warrant Agreements, we issued to Mr. Dearholt warrants to
purchase 200,000, 200,000 and 200,000 shares of the Company's common stock in
1997, 1998 and 1999, respectively, at exercise prices of $1.848, $2.25 and $1.16
per share, respectively. The warrants expire upon the earlier of their exercise
or five years after the date of their issuance. Under the Stock Issuance
Agreement, if we fail to pay the $1 million under the note when due, we must
issue 200,000 shares of our common stock to Mr. Dearholt. This issuance will
not, however, alleviate our liability under the note. We also granted Mr.
Dearholt securities registration rights with respect to any common stock he
receives from us under these warrants or the Stock Issuance Agreement. In
consideration of Mr. Dearholt's agreement to extend the note's due date to March
25, 2000, the Company extended the term of certain warrants held by Mr. Dearholt
to purchase 200,000 shares of the Company's common stock which were to expire
March 25, 2001 to March 25, 2002.
On September 24, 1999, we completed a private placement of 666,671
shares of our common stock to various investors at a purchase price of $0.75 per
share, representing a discount of 12% from the closing price of a share of our
common stock on the Over the Counter Bulletin Board on that date. Stephen M.
Dearholt, a director of Company, purchased 266,667 shares for $200,000 in this
private placement. The terms of Mr. Dearholt's purchase were identical to the
terms offered to the other, unrelated investors. As part of this private
placement, the Company granted all of the investors, including Mr. Dearholt,
registration rights which require the Company to register the investors' resale
of these shares. The registration statement, of which this prospectus is a part,
registers these investors' resale from time to time of those shares.
It has been and currently is our policy that transactions between us
and our officers, directors, principal shareholders or affiliates are to be on
terms no less favorable to us than could be obtained from unaffiliated parties.
31
We intend that any future transactions between us and our officers, directors,
principal shareholders or affiliates will be approved by a majority of the
directors who are not financially interested in the transaction.
32
DESCRIPTION OF CAPITAL STOCK
The authorized capital stock of the Company consists of 22 million
shares of common stock, $.01 par value per share and 5 million shares of Class A
Preferred Stock, $.01 par value per share (the "Class A Preferred Stock"). The
Class A Preferred Stock may be issued in series, at such times and with such
terms, as the Board of Directors deems appropriate. To date, the Board of
Directors has authorized for issuance 1,040,000 shares of Class A Preferred
Stock--Series 1, of which 660,000 shares are currently outstanding and 1,500,000
shares of Class A Preferred Stock--Series 2, of which no shares are currently
issued and outstanding since the 729,927 shares of Class A Preferred
Stock--Series 2 which were previously issued have all converted into a like
number of shares of common stock. The Company's Amended and Restated Articles of
Incorporation provide that any shares of Class A Preferred Stock which are
issued and subsequently converted into common stock may not be reissued by the
Company. Accordingly, the Company currently has 2,460,000 shares of Class A
Preferred Stock authorized and available for issuance in series designated by
the Board.
COMMON STOCK
Holders of common stock are entitled to one vote for each share held of
record on all matters to be voted on by the shareholders. Subject to the prior
rights of the holders of Class A Preferred Stock, as described below, holders of
common stock are entitled to receive dividends when and as declared by the Board
of Directors out of funds legally available therefor. Upon liquidation or
dissolution of the Company, holders of common stock are entitled to share
ratably in the remaining assets of the Company which may be available for
distribution after payment of the Company's creditors and satisfaction of any
accrued but unpaid dividends on, and the liquidation preferences, if any, of,
the Class A Preferred Stock. Holders of common stock have no preemptive,
subscription or redemption rights. The common stock has no cumulative voting
rights. As a result, holders of more than 50% of the outstanding shares of
common stock can elect all of the directors of the Company.
All outstanding shares of common stock, currently outstanding, are
fully paid and nonassessable. Wisconsin law, however, may make shareholders of
the Company personally liable for unpaid wages due employees for up to six
months' services, but not in an amount greater than the consideration paid for
such shares.
CLASS A PREFERRED STOCK
The Company's Board of Directors is authorized, subject to the
limitations described below, to issue from time to time, without shareholder
authorization, in one or more designated series, shares of Class A Preferred
Stock and to determine the dividend, redemption, liquidation, sinking fund and
conversion rights of each particular series. No dividends or other distributions
will be payable on the common stock unless dividends are paid in full on the
Class A Preferred Stock and all sinking fund obligations for the Class A
Preferred Stock, if any, are fully funded. Dividends on the Class A Preferred
Stock will be cumulative from the date of issuance. In the event of a
liquidation or dissolution of the Company, the Class A Preferred Stock would
have priority over the common stock to receive the amount of the liquidation
preference as specified in each particular series, together with any accrued but
unpaid dividends thereon out of the remaining assets of the Company. Holders of
shares of Class A Preferred Stock will have the right, at any time on or before
the redemption of such shares, to surrender the certificate evidencing the
shares of Class A Preferred Stock and receive upon conversion thereof, a
certificate evidencing one share of common stock for each share of Class A
Preferred Stock so surrendered. The holders of Class A Preferred Stock are
entitled to cast one vote per share held of record by them at all meetings of
the shareholders of the Company.
Class A Preferred Stock--Series 1
Pursuant to the Company's Articles of Incorporation, on August 15,
1997, the Board of Directors by resolution designated the relative rights and
preferences of the first series of Class A Preferred Stock which was designated
"Class A Preferred Stock--Series 1." The Board authorized for issuance 1,040,000
shares of this Series 1 Preferred Stock and 680,000 shares were issued, 660,000
of which are currently outstanding. The Company has no present intention of
issuing any additional shares of Series 1 Preferred Stock. The Series 1
33
Preferred Stock accrues dividends on a daily basis at the rate of 8% per year on
the "liquidation value" of the Series 1 Preferred Stock ($2.50 per share subject
to adjustment and increase for accrued dividends). The dividends will accrue
through the earliest of the date of repurchase of the Series 1 Preferred Stock,
its conversion into common stock or the liquidation of the Company. Dividends on
the Series 1 Preferred Stock must be paid in full before dividends may be paid
on any other class of stock of the Company or before any sums may be set aside
for the redemption or purchase of any of the Preferred Stock. Dividends will
accrue whether or not they have been declared and whether or not there are funds
legally available therefore. Dividends are payable on October 1 of each year.
Dividends which are not paid on such dividend reference date will accrue and be
added to the liquidation value of each share of Series 1 Preferred Stock. No
dividends can be declared and set aside for any shares of common stock unless
the Board declares a dividend payable on the outstanding shares of Series 1
Preferred Stock, in addition to the dividends which the Series 1 Preferred Stock
is otherwise entitled as described above. Such additional dividends on the
Series 1 Preferred Stock must be declared in the same amount per share of Series
1 Preferred Stock as would be declared payable on the shares of common stock
into which each share of Series 1 Preferred Stock could be converted.
On or after August 1, 1998, each share of Series 1 Preferred Stock is
convertible into one share of common stock. Upon conversion, certificates for
shares of common stock will be issued together with, to the extent legally
available, an amount of cash equal to the remaining accrued but unpaid dividends
on the shares of Series 1 Preferred Stock so converted. The Series 1 Preferred
Stock is redeemable by the Company on or after August 1, 2000 (subject to prior
conversion by the holder) at a price of $2.50 per share plus all accrued but
unpaid dividends. Upon a liquidation of the Company, the Series 1 Preferred
Stock is entitled to a liquidation preference equal to $2.50 per share plus any
accrued but unpaid dividends. This amount must be paid prior to any distribution
on shares of common stock. Except as provided above, the Series 1 Preferred
Stock will have the same rights, preferences and limitations as any other series
of Preferred Stock to be issued in the future, whenever designated and issued.
Class A Preferred Stock--Series 2
On December 30, 1997, the Company's Board of Directors by resolution
designated the relative rights and preferences of the second series of Class A
Preferred Stock which is designated "Class A Preferred Stock--Series 2." The
Board authorized for issuance 1,500,000 shares of this Series 2 Preferred Stock
and, shortly thereafter, 729,927 shares were issued. However, as of the date of
this prospectus, no shares of Series 2 Preferred Stock are issued and
outstanding since they all converted into shares of common stock on a
one-for-one basis on April 3, 1998. The Series 2 Preferred Stock does not carry
any dividend preference. Upon a liquidation of the Company, each share of the
Series 2 Preferred Stock outstanding at the time of such liquidation is entitled
to a liquidation preference equal to the purchase price paid for such share.
This amount must be paid prior to any distribution on shares of common stock,
however, the liquidation preference on the Series 1 Preferred Stock must be paid
before the liquidation preference on the Series 2 Preferred Stock is paid.
The issuance of one or more series of Class A Preferred Stock could
have an adverse effect on certain rights, including voting rights, of the
holders of common stock. The Preferred Stock could also be issued by us to
defend against the threat of a takeover, if the Board of Directors deemed such
takeover not to be in the best interests of the Company or its shareholders.
This could occur even if such a takeover was favored by a majority of
shareholders and was at a premium to the market price of the common stock. We
have no current plans or intention to issue additional shares of Class A
Preferred Stock.
CONVERTIBLE DEBENTURES
The Company issued convertible debentures to certain of the selling
stockholders in the principal amount of $1,500,000. The convertible debentures
bear interest at 8% per annum and have a one-year term; provided, however, that
the Company may elect to extend the repayment term for an additional one year
if, upon such extension, the Company issues to the selling stockholders warrants
to purchase 375,000 shares of the Company's common stock having the same terms
and conditions as the warrants issued to the selling stockholders described
below. One million dollars of the convertible debentures is payable on May 19,
2000, subject to the one year
34
extension, with the remaining $500,000 payable on June 3, 2000, also subject to
the one-year extension. Interest on the convertible debentures is payable
quarterly either in cash or, at the selling stockholders' option, common stock
based on the stock's then fair market value.
The selling stockholders may elect to convert the convertible
debentures into common stock at any time after one year from the date they were
issued as follows: (a) the first 50% of the original principal balance of the
convertible debentures, plus any accrued but unpaid interest thereon, is
convertible into common stock based on a per share price equal to the lesser of
(i) 70% of the market price of the common stock at the time of conversion or
(ii) $1.25; and (b) the second 50% of the original principal balance plus any
accrued but unpaid interest thereon is convertible into common stock based on a
per share price equal to the lesser of (i) 70% of the market price of the common
stock at the time of conversion or (ii) $2.50.
Payment of the convertible debentures is secured by a first priority
security interest in all of the Company's assets. In addition, if the Company
defaults in payment of principal or interest on the convertible debentures, it
must immediately issue 1,500,000 shares of its common stock to the investors at
no cost and that issuance will not in any way impair the other rights the
selling stockholders possess, including the right to demand payment of the
convertible debentures.
WARRANTS
In connection with the issuance of the $1,500,000 convertible
debentures, the Company also issued to the purchasers of the convertible
debentures warrants to purchase 1,875,000 shares of the Company's common stock.
These warrants are exercisable by the selling stockholders at any time within
five years after the date of their issuance at an exercise price per share equal
to the lesser of (a) 70% of the market price of the Company's common stock on
the date of exercise or (b) $1.00. In addition, as part of the consideration
that the Company paid R.J. Steichen & Company, the Company's placement agent in
the offering of the convertible debentures and warrants, the Company also issued
warrants to purchase a total of 337,500 shares of the Company's Common to R.J.
Steichen. The warrants issued to R.J. Steichen are exercisable at any time
commencing one year after the date of the private placement and for a period of
four years thereafter at an exercise price of $1.00 per share.
The warrants issued to the selling stockholders and R.J. Steichen
contain provisions that protect the holder against dilution by adjustment of the
exercise price and number of shares to be received upon exercise. Such
adjustments will occur in the event, among others, of a merger, stock split or
reverse stock split, stock dividend or recapitalization. The Company is not
required to issue fractional shares upon the exercise of the warrants. The
holder of the warrants will not possess any rights as a stockholder of the
Company until the holder exercises the warrants.
The warrants may be exercised upon surrender on or before the
expiration date of the warrants at the offices of the Company, with an exercise
form completed and executed as indicated, accompanied by payment of the exercise
price for the number of shares with respect to which the Warrant is being
exercised. The exercise price is payable by check or bank draft payable to the
order of the Company or by wire transfer to an account designated by the Company
or, in the case of the R.J. Steichen, by a "cashless exercise," in which the
number of shares of common stock underlying the Warrant having a fair market
value equal to the aggregate exercise price are cancelled as payment of the
exercise price.
For the life of the warrants and the convertible debentures, the holder
has the opportunity to profit from a rise in the market price of the common
stock without assuming the risk of ownership of the shares of Common stock
issuable upon the exercise of the Warrant or conversion of the convertible
debentures. The Warrant or convertible debenture holder should be expected to
exercise the Warrant or convertible debenture at a time when the Company would,
in all likelihood, be able to obtain any needed capital by an offering of common
stock on terms more favorable than those provided for by the Warrant or
convertible debenture. Furthermore, the terms on which the Company could obtain
additional capital during the life of the Warrant or convertible debenture may
be adversely affected.
35
TRANSFER AGENT
The transfer agent and registrar for the common stock is Firstar Trust
Company, Milwaukee, Wisconsin.
CERTAIN STATUTORY PROVISIONS
Section 180.1150 of the Wisconsin Business Corporation Law provides
that the voting power of shares of public corporations, such as the Company,
which are held by any person holding in excess of 20% of the voting power of
such Company shall be limited to 10% of the full voting power of such shares.
This statutory voting restriction is not applicable to shares acquired directly
from the Company, acquired in a transaction incident to which the shareholders
of the Company vote to restore the full voting power of such shares and under
certain other circumstances more fully described in section 180.1150. In
addition, this statutory voting restriction is not applicable to shares of
common stock acquired before April 22, 1986.
Section 180.1141 of the Wisconsin Business Corporation Law provides
that a "resident domestic corporation," such as the Company, may not engage in a
"business combination" with an "interested shareholder" (a person beneficially
owning 10% or more of the aggregate voting power of the stock of the Company)
for three years after the date (the "stock acquisition date") the interested
shareholder acquired his 10% or greater interest, unless the business
combination (or the acquisition of the 10% or greater interest) was approved
before the stock acquisition date by the Company's Board of Directors. After the
three-year period, a business combination that was not so approved can be
consummated only if it is approved by a majority of the outstanding voting
shares not held by the interested shareholder or is made at a specified price
intended to provide a fair price for the shares held by noninterested
shareholders. Section 180.1141 is not applicable to shares of common stock
acquired by a shareholder prior to the registration of the common stock under
the Exchange Act and shares acquired before September 10, 1987.
INDEMNIFICATION
The Company's directors and officers are entitled to certain statutory
rights to be indemnified by the Company against certain litigation-related
liabilities and expenses, provided the director or officer is either successful
in the defense of such litigation or is otherwise determined not to have engaged
in willful misconduct, knowingly violated the law, failed to deal fairly with
the Company or its shareholders or derived an improper personal benefit in the
performance of his duties to the Company. These rights are incorporated in the
Company's By-Laws. Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the Company pursuant to the foregoing provisions or otherwise, the Company
has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable.
36
SELLING STOCKHOLDERS
The following table sets forth certain information regarding beneficial
ownership of the Company's common stock by the selling stockholders as of
September 30, 1999.
[Enlarge/Download Table]
Shares Owned Shares Being Shares Owned
Selling Stockholder Before Offering Offered After Offering
------------------- --------------- ------- --------------
Number Percent Number Percent
------ ------- ------ -------
Gary Benson 2,680,450(1) 1.9% 2,500,000(2) 180,450(3) %
2925 Dean Parkway
Minneapolis, MN 55416
Daniel Bishop 310,800(4) 2.6% 250,000(2) 60,800(3) *%
17235 Two Mile Road
Franksville, WI 53126
Mike Snow 588,800(5) 4.8% 500,000(2) 88,800(3) *%
3300 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402
Robert Johander 250,000(4) 2.1% 250,000(2) 0(3) 0%
8480 Montgomery Court
Eden Prairie, MN 55347
W.G. Securities Limited 250,000(4) 2.1% 250,000(2) 0(3) 0%
Partnership
PMB 452
774 Mays Boulevard, No. 10
Incline Village, NV 89451
R.J. Steichen & Company 337,500(6) 2.8% 337,500(2) 0(3) 0%
Suite 100
120 South Sixth Street
Minneapolis, MN 55402
Stephen M. Dearholt 1,497,784(7) 11.7% 266,671(8) 1,231,113(9) 10.4%
741 North Milwaukee Street
Suite 500
Milwaukee, WI 53202
Thomas W. Bodine and 138,000(10) 1.2% 80,000(11) 58,000(9) *%
Peggy L. Bodine as
Joint Owners with righT
of survivorship
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
37
[Download Table]
Leo B. Schmid Trust 20,000(12) *% 20,000(13) 0(9) 0%
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
Jerome F. Martin and 33,334(14) *% 33,334(15) 0(9) 0%
Diane M. Martin as
Joint Tenants
c/o PaineWebber, Inc.
Suite 1500
8000 Maryland Avenue
St. Louis, MO 63105
John H. Biggs Revocable 133,334(16) *% 133,334(17) 0(9) 0%
Trust
Apt. 23D
240 East 47th Street
New York, NY 10097
Love Family Charitable 36,334(18) *% 33,334(15) 3,000(9) *%
Foundation
Suite 201
212 South Central
St. Louis, MO 63105
Andrew Sproule Love 33,334(18) *% 33,334(15) 0(9) 0%
Suite 201
212 South Central
St. Louis, MO 63105
Love Group Joint Venture 80,934(18) *% 33,334(15) 47,600(9) *%
Suite 201
212 South Central
St. Louis, MO 63105
Love Real Estate Company 33,334(18) *% 33,334(15) 0(9) 0%
Profit Sharing Plan (1994)
Suite 201
212 South Central
St. Louis, MO 63105 ________
James Chase 210,000 1.8% 175,000(19) 35,000(9) *%
7815 North River Road ===========
Milwaukee, WI 53217
Total 4,929,175
=========
----------------------
* less than 1%
(1) Represents 180,450 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, 1 million shares receivable
by the selling stockholder upon conversion of the $1 million
convertible debenture owned by him (assuming a conversion price of
$1.00 per share) and 1,500,000 shares receivable upon exercise of
warrants owned by the selling stockholder (including warrants to
purchase
38
250,000 shares which will be issued to the selling stockholder if the
Company elects to extend the repayment term of the convertible
debenture for an additional year after its initial term).
(2) The shares being offered by the selling stockholder represent the
shares which will be received by the selling stockholder upon exercise
of the convertible debenture and warrants held by the selling
stockholder.
(3) Assumes that all shares acquired pursuant to conversion of the
convertible debenture and the warrants owned by the selling stockholder
are sold pursuant to this prospectus.
(4) Represents 60,800 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, 100,000 receivable by the
selling stockholder upon conversion of the $100,000 convertible
debenture owned by him (assuming a conversion price of $1.00 per share)
and 150,000 shares receivable upon exercise of warrants owned by the
selling stockholder (including warrants to purchase 25,000 shares which
will be issued to the selling stockholder if the Company elects to
extend the repayment term of the convertible debenture for an
additional year after its initial term).
(5) Represents 88,800 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, 200,000 receivable by the
selling stockholder upon conversion of the $200,000 convertible
debenture owned by him (assuming a conversion price of $1.00 per share)
and 300,000 shares receivable upon exercise of warrants owned by the
selling stockholder (including warrants to purchase 50,000 shares which
will be issued to the selling stockholder if the Company elects to
extend the repayment term of the convertible debenture for an
additional year after its initial term).
(6) Represents shares which will be received by the selling stockholder
upon exercise of warrants currently owned by the selling stockholder.
The warrants are not exercisable until June 1, 2000.
(7) Represents 1,497,784 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, including the 266,667 shares
purchased from the Company on September 24, 1999 and offered for sale
by the selling stockholder pursuant to this prospectus.
(8) Represents 266,671 shares of common stock which the selling stockholder
purchased from the Company on September 24, 1999.
(9) Assumes all of the shares offered by the selling stockholder are sold
pursuant to this prospectus.
(10) Represents 58,000 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, including the 80,000
shares purchased from the Company on September 24, 1999 and offered for
sale by the selling stockholder pursuant to this prospectus.
(11) Represents the 80,000 shares of common stock which the selling
stockholder purchased from the Company on September 24, 1999.
(12) Represents 20,000 shares purchased from the Company on September 24,
1999 and offered for sale by the selling stockholder pursuant to this
prospectus.
(13) Represents 20,000 shares of common stock which the selling stockholder
purchased from the Company on September 24, 1999.
(14) Represents 33,334 shares purchased from the Company on September 24,
1999 and offered for sale by the selling stockholder pursuant to this
prospectus.
39
(15) Represents 33,334 shares of common stock which the selling stockholder
purchased from the Company on September 24, 1999.
(16) Represents 133,334 shares purchased from the Company on September 24,
1999 and offered for sale by the selling stockholder pursuant to this
prospectus.
(17) Represents 133,334 shares of common stock which the selling stockholder
acquired from the Company on September 24, 1999.
(18) Represents 47,600 shares of common stock beneficially owned by the
selling stockholder as of October 1, 1999, including the 33,334
shares purchased from the Company on September 24, 1999 and offered for
sale by the selling stockholder pursuant to this prospectus. Also
includes the shares owned by Love Family Charitable Foundation, Andrew
Sproule Love, Love Group Joint Venture and Love Real Estate Company
Profit Sharing Plan (1994).
(19) Represents shares which the selling stockholder received as
compensation for certain investor relations and other consulting
services which the selling stockholder performed for the Company.
None of the selling stockholders, except R.J. Steichen & Company, James
Chase and Stephen M. Dearholt, has had any material relationship with the
Company or any of its affiliates within the past three years other than as a
result of the ownership of common stock. R.J. Steichen & Company has acted as
the Company's placement agent in the offering of the convertible debentures and
warrants to Messrs. Benson, Bishop, Snow and Johander and to W.G. Securities
Limited. In addition, in 1997, R.J. Steichen & Company also acted as the
Company's placement agent in connection with the Company's private placement of
Class A Preferred Stock--Series 1. R.J. Steichen received customary compensation
for its services as placement agent in those private placements. James Chase has
served as an investor relations consultant to the Company for the past three
years and has assisted the Company in various private placements of securities.
Stephen M. Dearholt has been a director of the Company since April 1996.
The shares offered by Messrs. Benson, Bishop, Snow, Johander and by
W.G. Securities Limited Partnership and R.J. Steichen & Company will be acquired
by conversion of the convertible debentures and exercise of warrants owned by
them. As part of the private placements to the selling stockholders, the Company
agreed to register the shares for resale by the selling stockholders to permit
the resale of such shares from time to time by the selling stockholders in the
market or in privately-negotiated transactions. The Company will prepare and
file such amendments and supplements to the registration statement as may be
necessary in accordance with the rules and regulations of the Securities Act to
keep it effective for a period of approximately 24 months.
The Company has agreed to bear certain expenses (other than broker
discounts and commissions, if any) in connection with the registration
statement.
40
PLAN OF DISTRIBUTION
The Company has been advised by the selling stockholders that the
selling stockholders may sell the shares from time to time in transactions on
the OTC Bulletin Board, in negotiated transactions, or otherwise, or by a
combination of these methods, at fixed prices which may be changed, at market
prices at the time of sale, at prices related to market prices or at negotiated
prices. The selling stockholders may effect these transactions by selling the
shares to or through broker-dealers, who may receive compensation in the form of
discounts, concessions or commissions from the selling stockholders or the
purchasers of the shares for whom the broker-dealer may act as an agent or to
whom they may sell the shares as a principal, or both. The compensation to a
particular broker-dealer may be in excess of customary commissions.
Broker-dealers who act in connection with the sale of the shares may be
deemed to be underwriters. Profits on any resale of the shares as a principal by
such broker-dealers and any commissions received by such broker-dealers may be
deemed to be underwriting discounts and commissions under the Securities Act.
Any broker-dealer participating in such transactions as agent may
receive commissions from a selling stockholder (and, if they act as agent for
the purchaser of such shares, from such purchaser). Broker-dealers may agree
with a selling stockholder to sell a specified number of shares at a stipulated
price per share and, to the extent such a broker-dealer is unable to do so
acting as agent for the selling stockholder, to purchase as principal any unsold
shares at the price required to fulfill the broker-dealer commitment to the
selling stockholder. Broker-dealers who acquire shares as principal may
thereafter resell such shares from time to time in transactions (which may
involve crosses and block transactions and which may involve sales to and
through other broker-dealers, including transactions of the nature described
above) in the over-the-counter market, in negotiated transactions or otherwise
at market prices prevailing at the time of sale or at negotiated prices, and in
connection with such resales may pay to or receive from the purchasers of such
shares commissions computed as described above. To the extent required under the
Securities Act, a supplemental prospectus will be filed, disclosing (a) the name
of any such broker-dealers; (b) the number of shares involved; (c) the price at
which such shares are to be sold; (d) the commissions paid or discounts or
concessions allowed to such broker-dealers, where applicable; (e) that such
broker-dealers did not conduct any investigation to verify the information set
out or incorporated by reference in this prospectus, as supplemented; and (f)
other facts material to the transaction.
Under applicable rules and regulations under the Exchange Act, any
person engaged in a distribution of the shares may not simultaneously engage in
market making activities with respect to such securities for a period beginning
when such person becomes a distribution participant and ending upon such
person's completion of participation in a distribution, including stabilization
activities in the common stock to effect covering transactions, to impose
penalty bids or to effect passive market making bids. In addition and without
limiting the foregoing, in connection with transactions in the shares, the
Company and the selling stockholders will be subject to applicable provisions of
the Exchange Act and the rules and regulations thereunder, including, without
imitation, Rule 10b-5 and, insofar as the Company and the selling stockholders
are distribution participants, Regulation M and Rules 100, 101, 102, 103, 104
and 105 thereof. All of the foregoing may affect the marketability of the
shares.
The selling stockholders, other than Mr. Dearholt who is a director of
the Company, may enter into any short sale or other hedging arrangement they
deem appropriate.
The selling stockholders will pay all commissions and certain other
expenses associated with the sale of the shares. The shares offered hereby are
being registered pursuant to contractual obligations of the Company, and the
Company has paid the expenses of the preparation of this prospectus. The Company
has also agreed to indemnify the selling stockholder with respect to the shares
offered hereby against certain liabilities, including, without limitation,
certain liabilities under the Securities Act, or, if such indemnity is
unavailable, to contribute toward amounts required to be paid in respect of such
liabilities.
41
LEGAL MATTERS
The validity of the securities offered hereby will be passed upon for
the Company by Reinhart, Boerner, Van Deuren, Norris & Rieselbach, s.c.,
Milwaukee, Wisconsin.
EXPERTS
The consolidated financial statements of the Company at September 30,
1998 and for the two years in the period ended September 30, 1998 included in
this prospectus have been audited by McGladrey & Pullen LLP, independent
auditors, as set forth in their report (which contains an explanatory paragraph
with respect to conditions which raise substantial doubt about the Company's
ability to continue as a going concern), in reliance upon such report given upon
the authority of such firm as experts in accounting and auditing. The
consolidated financial statements do not include any adjustments to reflect the
possible future effects on the recoverability and classification of assets or
amounts and classification of liabilities that might result from the outcome of
that uncertainty.
42
THE FEMALE HEALTH COMPANY
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
[Enlarge/Download Table]
Document Page No.
-------- --------
Audited Consolidated Financial Statements.
Report of McGladrey & Pullen, LLP, Independent Auditors. F-1
Consolidated Balance Sheet as of September 30, 1998. F-2
Consolidated Statements of Operations for the years ended
September 30, 1998 and 1997. F-3
Consolidated Statements of Stockholders' Equity for the years ended
September 30, 1998 and 1997. F-4 and F-5
Consolidated Statements of Cash Flows for the years ended
September 30, 1998 and 1997. F-6 and F-7
Notes to Consolidated Financial Statements. F-8 through F-21
Unaudited Condensed Interim Financial Statements.
Consolidated Balance Sheet as of June 30, 1999. F-22
Condensed Consolidated Statements of Operations for the Nine Months ended
June 30, 1999 and 1998. F-23
Condensed Consolidated Statements of Cash Flows for the Nine Months ended
June 30, 1999 and 1998. F-24
Notes to Condensed Consolidated Financial Statements. F-25 through F-28
43
INDEPENDENT AUDITOR'S REPORT
To the Board of Directors and Stockholders
The Female Health Company
Chicago, Illinois
We have audited the accompanying consolidated balance sheet of The Female Health
Company and subsidiaries, as of September 30, 1998, and the related consolidated
statements of operations, stockholders' equity, and cash flows for the years
ended September 30, 1998 and 1997. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of The Female Health
Company and subsidiaries as of September 30, 1998, and the results of their
operations and their cash flows for the years ended September 30, 1998 and 1997,
in conformity with generally accepted accounting principles.
The accompanying consolidated financial statements have been presented assuming
that The Female Health Company will continue as a going concern. As more fully
described in Note 15, the Company has experienced slower than expected growth in
revenues from its sole product, which has adversely affected the Company's
current results of operations and liquidity. These conditions raise substantial
doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 15. The consolidated
financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts
of classification of liabilities that may result from the outcome of this
uncertainty.
Schaumburg, Illinois
November 5, 1998, except for the fourth paragraph
of Footnote 15 as to which the date is
November 19, 1998
F-1
THE FEMALE HEALTH COMPANY
CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 1998
[Download Table]
ASSETS
Current Assets
Cash $ 1,480,287
Accounts receivable, net of allowance for doubtful accounts
of $80,000 and allowance for product returns of $230,000 1,138,274
Inventories 925,425
Prepaid expenses and other current assets 395,293
----------------
TOTAL CURRENT ASSETS 3,939,279
----------------
Other Assets
Intellectual property, net of accumulated amortization of
$336,098 924,319
Other assets 165,701
----------------
1,090,020
----------------
Property, Plant and Equipment
Equipment, furniture and fixtures 4,114,371
Less: accumulated depreciation (1,584,776)
----------------
2,529,595
----------------
$ 7,558,894
================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Notes payable, related party, net of unamortized discount of
$162,861 $ 837,139
Current maturities of long-term debt and capital lease
obligations 626,066
Accounts payable 473,979
Accrued expenses and other current liabilities 614,820
Preferred dividends payable 147,634
----------------
Total current liabilities 2,699,638
----------------
Long-Term Liabilities
Long term debt and capital lease obligations, less current
maturities 4,882
Deferred gain on sale of facility 1,766,611
Other long term liabilities 153,186
----------------
1,924,679
----------------
Stockholders' Equity
Convertible Preferred Stock, Series I, par value $.01 per share.
Authorized 5,000,000 shares; issued and outstanding 680,000
shares. 6,800
Common Stock, par value $.01 per share. Authorized 15,000,000
shares; issued and outstanding 10,417,757 shares. 104,158
Additional paid-in capital 43,833,843
Foreign currency translation gain 304,980
Accumulated deficit (41,295,874)
----------------
2,953,907
Treasury Stock, at cost, 10,000 shares (19,330)
----------------
2,934,577
----------------
$ 7,558,894
================
See Notes to Financial Statements.
F-2
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 1998 AND 1997
[Enlarge/Download Table]
1998 1997
------------------------------------------------------------------------------------------------------------------------
Net Revenues $ 5,451,399 $ 2,916,408
---------------------------------------
Cost of Products Sold:
Cost of goods sold
6,130,819 4,530,185
Change in obsolescence allowance (857,450) (1,054,476)
---------------------------------------
Total Cost of Products Sold 5,273,369 3,475,709
---------------------------------------
GROSS PROFIT (LOSS) 178,030 (559,301)
---------------------------------------
Operating expenses:
Advertising and promotion 433,821 1,642,347
Selling, general and administrative 2,895,108 3,036,765
---------------------------------------
Total Operating Expenses 3,328,929 4,679,112
---------------------------------------
OPERATING (LOSS) (3,150,899) (5,238,413)
---------------------------------------
Nonoperating income (expense):
Interest expense (456,662) (1,268,980)
Interest income 133,104 176,717
Nonoperating income/(expense) 117,141 79,527
---------------------------------------
(206,417) (1,012,736)
---------------------------------------
NET (LOSS) (3,357,316) (6,251,149)
Preferred dividends accreted, Series 2 817,000 -
Preferred dividends, Series 1 132,669 14,965
---------------------------------------
Net (loss) attributable to common stockholders $ (4,306,985) $ (6,266,114)
=======================================
Net (loss) per common share outstanding (0.43) (0.74)
Weighted average common shares outstanding 9,971,493 8,453,266
See Notes to Financial Statements
F-3
THE FEMALE HEALTH COMPANY
STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED SEPTEMBER 30, 1998 AND 1997
[Enlarge/Download Table]
Foreign
Additional Currency Cost of
Preferred Common paid-in Translation Accumulated Treasury
Stock Stock capital Gain (Loss) Deficit Stock Total
-----------------------------------------------------------------------------------------------------------------------------------
Balance, September 30, 1996 $ - $ 72,117 $ 33,755,072 83,858 $ (30,722,775) $ - $ 3,188,272
Net loss - - - - (6,251,149) (6,251,149)
Issuance of 2,128,371 shares of
Common Stock upon conversion of debt - 21,284 3,670,281 - - - 3,691,565
Issuance of 39,833 shares of
Common Stock upon exercise of
stock options - 398 178,268 - - - 178,666
Issuance of 124,564 shares of
Common Stock for consulting
services - 1,246 206,617 - - - 207,863
Issuance of 10,000 shares of
Common Stock
under Stock Bonus Plan - 100 53,025 - - - 53,125
Issuance of warrants with
convertible debentures - - 30,176 - - - 30,176
Issuance of beneficial conversion
feature with convertible debentures - - 398,000 - - - 398,000
Issuance of warrants with short-
term notes payable - - 250,000 - - - 250,000
Issuance of 680,000 shares of
Preferred Stock (net of
offering costs of $96,252) 6,800 - 1,596,948 - - - 1,603,748
Issuance of warrants for consulting
services - - 89,500 - - - 89,500
Revaluation of options for
legal services - - 10,500 - - - 10,500
Preferred stock dividends - - - - (14,965) - (14,965)
Translation adjustment - - - 119,337 - - 119,337
---------------------------------------------------------------------------------------------
Balance at September 30, 1997 6,800 95,145 40,238,387 203,195 (36,988,889) - 3,554,638
F-4
THE FEMALE HEALTH COMPANY
STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED SEPTEMBER 30, 1998 AND 1997
[Enlarge/Download Table]
Foreign
Additional Currency Cost of
Preferred Common paid-in Translation Accumulated Treasury
Stock Stock capital Gain (Loss) Deficit Stock Total
----------------------------------------------------------------------------------------------------------------------------------
Net loss $ - $ - $ - $ - $ (3,357,316) $ - $ (3,357,316)
Issuance of 729,927 shares of
Preferred Stock (net of offering
costs of $156,616) 7,299 - 1,836,085 - - 1,843,384
Issuance of 729,927 shares of
Common Stock upon conversion of
Preferred Stock (7,299) 7,299 - - - - -
Issuance of 29,400 shares of
Common Stock upon exercise of
stock options - 294 58,506 - - - 58,800
Issuance of 25,000 shares of
Common Stock for consulting
services - 250 93,500 - - - 93,750
Issuance of 107,000 shares of
Common Stock under stock bonus plan - 1,070 306,555 - - - 307,625
Issuance of 10,000 shares of
Common Stock upon exercise of
warrants - 100 19,900 - - - 20,000
Issuance of 18,000 options to
employees - - 51,660 - - - 51,660
Issuance of warrants with short-
term notes payable - - 297,500 - - - 297,500
Issuance of warrants for
professional services - - 114,750 - - - 114,750
Preferred Stock dividends - - - (132,669) (132,669)
Preferred Stock dividends accreted - - 817,000 - (817,000) - -
Purchase of 10,000 Shares of
Common Stock held in Treasury - - - - - (19,330) (19,330)
Translation adjustment - - - 101,785 - - 101,785
----------------------------------------------------------------------------------------------
Balance at September 30, 1998 $ 6,800 $ 104,158 $43,833,843 $ 304,980 $ (41,295,874) $ (19,330) $ 2,934,577
See Notes to Financial Statements.
F-5
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 1998 AND 1997
[Enlarge/Download Table]
1998 1997
-----------------------------------------------------------------------------------------------------------------------
OPERATING ACTIVITIES
Net (loss) $(3,357,316) $(6,251,149)
Adjustments to reconcile net loss to net cash (used in)
operating activities:
Depreciation 533,994 553,298
Amortization of intellectual property rights 123,437 121,741
Provision for (recovery of) inventory obsolescence (857,450) (1,054,476)
Provision for doubtful accounts, returns and discounts 24,717 119,274
(Gain) loss on disposal of equipment - (84,646)
Issuance of common stock for bonuses and
Consulting services 401,375 -
Issuance and revaluation of warrants and options 166,410 360,988
Amortization of debenture issuance costs - 27,507
Amortization of discounts on notes payable
and convertible debentures 329,327 954,820
Amortization of deferred income realized
on U.K. grant (61,274) (39,870)
Write down of note receivable to realizable value - 92,471
Amortization of deferred gain on sale and leaseback
of building (94,795) (70,119)
Changes in operating assets and liabilities:
Accounts receivable (538,219) (271,173)
Inventories 891,421 1,086,999
Prepaid expenses and other current assets (92,058) 28,260
Accounts payable (411,286) 138,532
Accrued expenses and other current liabilities 188,798 (730,929)
---------------------------------
Net cash (used in) operating activities $(2,752,919) (5,018,472)
---------------------------------
INVESTING ACTIVITIES
Capital expenditures (58,827) (24,597)
Proceeds from sale of property and equipment - 3,376,056
Proceeds from repayment of note receivable 750,000 -
Proceeds from return of lease deposits 90,859 62,031
Payments for lease deposits - (245,953)
--------------------------------
Net cash provided by investing activities 782,032 3,167,537
--------------------------------
FINANCING ACTIVITIES
Proceeds from issuance of preferred stock 1,843,384 1,603,748
Proceeds from issuance of common stock upon exercise
of options and warrants 78,800 178,666
Purchase of Common Stock held in Treasury (19,330) -
Proceeds from related party notes issued 1,000,000 1,000,000
Proceeds from convertible debentures issued - 2,020,000
Payments on notes payable, related party (1,000,000) (2,160,000)
Costs to issue convertible debentures - (155,400)
Payments on long-term debt and capital lease obligations (113,131) (1,872,560)
-------------------------------
Net cash provided by financing activities 1,789,723 614,454
-------------------------------
F-6
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 1998 AND 1997
[Enlarge/Download Table]
1998 1997
------------------------------------------------------------------------------------------------------------------------
Effect of exchange rate changes on cash $ $
27,984 (44,132)
------------------ -------------------
Net (decrease) in cash (153,180) (1,280,613)
Cash at beginning of year 1,633,467 2,914,080
------------------ -------------------
Cash at end of year $ 1,480,287 $ 1,633,467
================== ===================
Supplemental cash flow disclosures:
Interest paid $ 125,246 $ 273,714
Supplemental schedule of noncash investing and financing activities:
Convertible debentures converted to common stock, net of
unamortized discounts and issuance costs $ - $ 3,691,565
Issuance of warrants on convertible debentures and
notes payable 297,500 280,176
Capital lease obligations incurred for equipment - 56,588
Preferred dividends declared, Series 1 132,669 14,965
Preferred dividends accreted, Series 2 817,000 -
Sale of manufacturing facility:
Proceeds from sale - $ 3,365,000
Depreciated cost of property - (1,398,819)
------------------ -------------------
Deferred gain on sale $ 1,966,181
================== ===================
See Notes to Financial Statements.
F-7
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation and nature of operations: The consolidated financial
statements include the accounts of the Company and its wholly-owned
subsidiaries, The Female Health Company - UK and The Female Health Company - UK,
plc. All significant intercompany transactions and accounts have been eliminated
in consolidation. The Female Health Company ("FHC" or the "Company") is
currently engaged in the marketing, manufacture and distribution of a consumer
health care product known as the Reality female condom, "Reality," in the U.S.
and "femidom" or "femy" outside the U.S. The Female Health Company - UK, is the
holding company of The Female Health Company - UK, plc, which operates a 40,000
sq. ft. leased manufacturing facility located in London, England.
The product is currently sold or available in either or both commercial (private
sector) and public sector markets in 30 countries. It is commercially marketed
directly by the Company in the United States and the United Kingdom and through
marketing partners globally.
Use of estimates: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and use assumptions that affect certain reported amounts and disclosures. Actual
results may differ from those estimates.
Significant accounting estimates include the following:
Trade receivables include a provision for sales returns and trade allowances,
which is based on management's estimate of future product returns from customers
in connection with unsold product which has expired or is expected to expire
before it is sold. The estimated cost for product returns, price discounts and
trade allowances are accrued when the initial sale is recorded.
The market value of inventory is based on management's best estimate of future
sales and the time remaining before the existing inventories reach their
expiration dates.
The Company evaluates intellectual property rights for impairment by comparing
the net present value of the asset's estimated future income stream to the
asset's carrying value.
Although management uses the best information available, it is reasonably
possible that the estimates used by the Company will be materially different
from the actual results. These differences could have a material effect on the
Company's future results of operations and financial condition.
Cash: Substantially all of the Company's cash was on deposit with one financial
institution.
Inventories: Inventories are valued at the lower of cost or market. The cost
is determined using the first-in, first-out (FIFO) method.
Foreign currency translation: In accordance with Financial Accounting Standards
No. 52, "Foreign Currency Translation", the financial statements of the
Company's international subsidiaries are translated into U.S. dollars using the
exchange rate at each balance sheet date for assets and liabilities, the
historical exchange rate for stockholders' equity and a weighted average
exchange rate for each period for revenues, expenses, and gains and losses.
Translation adjustments are recorded as a separate component of stockholders'
equity as the local currency is the functional currency.
F-8
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Equipment, furniture and fixtures and assets under capital leases: Depreciation
and amortization is computed by the estimated useful lives of the respective
assets which range as follows:
Equipment
5 - 10 years
Furniture and fixtures
3 years
Amortization of assets under capital lease is included with depreciation and
amortization for owned assets.
Intellectual property rights: The Company holds patents on the female condom in
the United States, the European Union, Japan, Canada, Australia and The People's
Republic of China and holds patents on the manufacturing technology in various
countries. The Company also licenses the trademark "Reality" in the United
States and has trademarks on the names "femidom" and "femy" in certain foreign
countries. Intellectual property rights are amortized on a straight-line basis
over their estimated useful life of twelve years.
Financial instruments: The Company has no financial instruments for which the
carrying value materially differs from fair value.
Revenue Recognition: Revenues from product sales are recognized as the products
are shipped to the customers.
Research and Development Costs: Research and development costs are expensed as
incurred. The amount of costs expensed for the years ended September 1998 and
1997 was $2,500 and $60,811, respectively.
Stock-Based Compensation: The value of stock options awarded to employees is
measured using the intrinsic value method prescribed by Accounting Principles
Board Opinion No. 25 (APB 25), "Accounting for Stock Issued to Employees." The
Company has provided pro forma disclosures of net income as if the fair
value-based method prescribed by Financial Accounting Standard No. 123,
"Accounting for Stock-Based Compensation", ("FAS 123"). was used in measuring
compensation expense in Note 7.
Income Taxes: The Company files separate income tax returns for its foreign
subsidiaries. Statement of Financial Accounting Standards No. 109, "Accounting
for Income Taxes" (FAS 109) requires recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been
included in the financial statements or tax returns. Under this method, deferred
tax assets and liabilities are determined based on the differences between the
financial statements and tax basis of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to reverse.
Deferred tax assets are also provided for carryforwards for income tax purposes.
In addition, the amount of any future tax benefits is reduced by a valuation
allowance to the extent such benefits are not expected to be realized.
Advertising: The Company's policy is to expense production costs in the period
in which the advertisement is initially presented to consumers.
Net (Loss) Per Common Share: Net (loss) per common share is computed using the
weighted average number of shares of common stock outstanding. Fully diluted
income per share is not presented for each of the periods since the effect of
including common equivalent shares would be anti-dilutive.
F-9
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Reclassifications: Certain prior year amounts have been reclassified on the
Consolidated Statements of Cash Flows to conform to the 1998 presentation.
NOTE 2. INVENTORIES
The components of inventory consist of the following at September 30, 1998:
[Download Table]
Raw materials $ 309,390
Work in process 138,409
Finished goods 518,360
Less allowance for obsolescence (40,734)
--------------
Net inventory $ 925,425
==============
NOTE 3. LEASES
Equipment, furniture and fixtures include the following amounts for leases which
have been capitalized at September 30, 1998:
[Download Table]
Leasehold interest in equipment, furniture and fixtures $ 73,539
Less accumulated depreciation (28,727)
--------------
$ 44,812
==============
The Company entered into a seven year operating lease with a third party for
office space effective September 12, 1994. The lease is cancelable at the end of
the 60th month of the term of the lease upon payment of a termination fee of
$63,867. The Company also has an informal agreement to reimburse an affiliate
for office space used by the officers of the Company. Reimbursement for the
affiliate rent expense was $48,146 and $51,256 in 1998 and 1997, respectively.
The affiliate's lease is with an unrelated third party which expires January 31,
2001. On November 1, 1998 the affiliate sublet the office space for the
remaining term of the lease.
On December 10, 1996, the Company entered into what is in essence a sale and
leaseback agreement with respect to its 40,000 square foot manufacturing
facility located in London, England. The Company received $3,365,000 (Pounds)
1,950,000 for leasing the facility to a third party for a nominal annual rental
charge and for providing the third party with an option to purchase the facility
for one pound during the period December 2006 to December 2027.
As part of the same transaction, the Company entered into an agreement to lease
the facility back from the third party for base rents of $336,000 (Pounds)
195,000 per year payable quarterly until 2016. The lease is renewable through
December 2027. The Company was also required to make a security deposit of
$336,000 (Pounds) 195,000 to be reduced in subsequent years. The facility had a
net book value of $1,398,819 (Pounds) 810,845 on the date of the transaction.
The $1,966,181 (Pounds) 1,139,155 gain which resulted from this transaction will
be recognized ratably over the initial term of the lease. Unamortized deferred
gain as of September 30, 1998 was $1,766,611 (Pounds) 1,039,489. Concurrent with
this transaction, the Company repaid the mortgage loan on this property of
$1,834,000 (Pounds) 1,062,500.
In 1987, a subsidiary entered into a lease for office and factory space expiring
January 31, 2001. These offices and factory space were vacated and subsequently
this space was subleased to a third party for a period expiring
F-10
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 3. LEASES (CONTINUED)
January 31, 2001. At the time the sublease was entered into a liability was
established for all future costs to the end of the lease, net of expected
sublease receipts. Details of operating lease expense in total and separately
for transactions with related parties is as follows:
[Download Table]
September 30,
1998 1997
-------------------------------
Operating lease expense:
Factory and office leases $ 820,695 $ 579,197
Office space used by officers 48,146 51,255
Other 17,811 88,772
-------------------------------
$ 886,652 $ 719,224
===============================
Future minimum payments under capital and operating leases, including planned
reimbursement of an affiliate for office space used by officers, consisted of
the following at September 30, 1998:
[Download Table]
Rentals
Receivable
Under
Capital Operating Subleases
--------------------------------------------
1999 19,526 514,502 46,850
2000 4,882 490,416 39,204
2001 459,839 13,068
2002 331,403
2003 331,403
Thereafter 4,376,536
--------------------------------------------
Total minimum payments 24,408 6,504,099 99,122
==============================
Amount representing interest (5,138)
-------------
19,270
=============
NOTE 4. NOTES PAYABLE AND LONG-TERM DEBT
During 1997, the Company repaid and then subsequently borrowed $1,000,000 from
Mr. Dearholt, a current director of the Company. The outstanding note payable
bears interest at 12% and is payable in full in 1998. As part of the
transaction, the Company issued Mr. Dearholt warrants to purchase 200,000 shares
of the Company's common stock at $1.848 per share, which represented the average
trading price for the five trading days prior to the closing date for the
transaction and resulted in an initial discount on the note of $250,000. Any
stock issued under the warrants carry certain registration rights. The warrants
expire in 2004. In addition, if the Company defaults on its obligation under the
note, the Company is required to issue an additional 200,000 shares of its
common stock to Mr. Dearholt in addition to all other remedies to which Mr.
Dearholt may be entitled. The discount in combination with the note's 12% coupon
resulted in an effective interest rate of 53 percent on the note.
During 1998, the Company repaid and then subsequently borrowed $1,000,000 from
Mr. Dearholt, a current director of the Company. The outstanding note payable
bears interest at 12% and is payable in full in 1999. As part of the
F-11
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 4. NOTES PAYABLE AND LONG-TERM DEBT (CONTINUED)
transaction, the Company issued Mr. Dearholt warrants to purchase 200,000 shares
of the Company's common stock at $2.25 per share, which represented the average
trading price for the five trading days prior to the closing date for the
transaction and resulted in an initial discount on the note of $297,500. Any
stock issued under the warrants carry certain registration rights. The warrants
expire in 2006. In addition, if the Company defaults on its obligation under the
note, the Company is required to issue an additional 200,000 shares of its
common stock to Mr. Dearholt in addition to all other remedies to which Mr.
Dearholt may be entitled. The note is recorded at September 30, 1998, net of
unamortized discount of $162,861. The discount in combination with the note's
12% coupon resulted in an effective interest rate of 63 percent on the note.
On February 20, 1997, the Company issued convertible debentures for $1,989,824
which is net of $30,176 in unamortized discount; (the Debentures) at 8% maturing
in 1999. These Debentures are convertible in the Company's common stock at the
lesser of $2.875 (representing the average market price for the five days
preceding the date the Debentures were sold) or 80% of the market price at the
time the debentures are converted into FHC common stock. The discount relates to
the valuation of the detachable warrants for 67,333 shares of common stock.
During fiscal 1997, the debentures were all converted into 1,364,625 shares of
common stock. These convertible debentures included a beneficial conversion
feature valued at $398,000. The Company recorded the value of the beneficial
conversion feature as additional paid-in capital and interest expense during the
year ended September 30, 1997.
At September 30, 1996, there were convertible debentures of $1,910,000 (net of
$90,000 in unamortized discount) with detachable warrants for 40,201 shares of
common stock (the Debentures) at 8% maturing in 1999. These Debentures were
convertible into the Company's common stock at the lesser of $5.275
(representing the average market price for the five days preceding the date the
Debentures were sold) or 80% of the market price at the time the debentures are
converted into FHC common stock. All of these debentures were converted in
763,746 shares of common stock in fiscal 1997.
Upon conversion of the debentures, $277,610 of issuance costs and $110,007 of
unamortized discount were charged to equity and $59,182 of accrued interest was
credited to equity.
Long-term debt and capital lease obligations at September 30, 1998, consisted of
the following:
Foundation note, noninterest bearing, due 1999, net of unamortized discount of
$22,275, interest imputed at 11%
[Download Table]
$ 606,540
Capital lease obligations 24,408
---------------
Total long-term debt and capital leases 630,948
Less current maturities 626,066
---------------
Long-term portion $ 4,882
===============
The Foundation note for $606,450 (Pounds) 356,893 is a noninterest bearing
$628,815 (Pounds) 370,000 note payable to the Aage V. Jensen Charity Foundation
and due on January 31, 1999.
NOTE 5. INCOME TAXES
A reconciliation of income tax expense and the amount computed by applying the
statutory Federal income tax rate to loss before income taxes as of September
30, 1998 and 1997, are as follows:
F-12
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 5. INCOME TAXES (CONTINUED)
[Enlarge/Download Table]
September 30,
1998 1997
-----------------------------------
Tax credit statutory rates $ (1,141,490) $ (2,130,479)
Nondeductible expenses 47,900 223,368
State income tax, net of federal benefits (159,100) (241,660)
Benefit of net operating loss not recognized, increase in valuation allowance 1,252,690 2,073,129
Other - 75,642
-----------------------------------
$ - $ -
===================================
As of September 30, 1998, the Company had federal and state net operating loss
carryforwards of approximately $29,675,000 for income tax purposes expiring in
years 2005 to 2014. The benefit relating to $1,537,800 of these net operating
losses relates to exercise of Common stock options and will be credited directly
to stockholders' equity when realized. The Company also has investment tax and
research and development credit carryforwards for income tax purposes
aggregating approximately $173,000 at September 30, 1998, expiring in years 1999
to 2009. The Company's U.K. subsidiary, The Female Health Company - UK, plc
subsidiary has U.K. net operating loss carryforwards of approximately
$71,910,000 as of September 30, 1998. These U.K. net operating loss
carryforwards can be carried forward indefinitely to be used to offset future
U.K. taxable income. Significant components of the Company's deferred tax assets
and liabilities are as follows at September 30, 1998:
[Download Table]
Deferred tax assets:
Federal net operating loss carryforwards $ 10,089,000
State net operating loss carryforwards 1,938,000
Foreign net operating loss carryforwards 21,573,000
Foreign capital allowances 3,886,000
Tax credit carryforwards 173,000
Accounts receivable allowances 119,000
Other 15,000
-------------------
Total gross deferred tax assets 37,793,000
Valuation allowance for deferred tax assets (37,775,000)
-------------------
Deferred tax assets net of valuation allowance 18,000
Deferred tax liabilities: Equipment, furniture and fixtures (18,000)
-------------------
Net deferred tax assets $ -
===================
Reconciliations of the valuation allowance for deferred tax assets for the year
ended September 30, 1998, is as follows:
[Download Table]
Balance, beginning $ (36,522,310)
Increase in valuation allowance charged to operations (1,252,690)
------------------
Balance, ending $ (37,775,000)
==================
The beginning of the year valuation allowance balance has been revised due to a
change in the foreign net operating loss carryforward and the foreign capital
allowances deferred tax asset. This change has no impact on the Company's net
loss for 1998 or 1997.
F-13
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 6. ROYALTY AGREEMENTS
The Company has royalty agreements for sales of its products which provide for
royalty payments based on sales quantities and achievement of specific sales
levels. The amount of royalty expense was $38,451 and $24,894 for 1998 and 1997,
respectively.
NOTE 7. COMMON STOCK
Stock Option Plans
The Company has various stock option plans that authorize the granting of
options to officers, key employees and directors to purchase the Company's
Common Stock at prices generally equal to the market value of the stock at the
date of grant. Under these plans, the Company has 282,000 shares available for
future grants as of September 30, 1998. The Company has also granted options to
one of its legal counsel and an affiliate. Certain options are vested and
exercisable upon issuance, others over periods up to four years and still others
based on the achievement of certain performance criteria by the Company and
market prices of its Common Stock.
During 1997 the option prices of 749,865 options outstanding which were
exercisable at prices ranging from $5.9375 to $3.875 per share were lowered to
$2.00 per share. In connection therewith, additional expense of $10,500 was
recognized related to options that had been granted to legal counsel.
Summarized information regarding all of the Company's stock options is as
follows:
[Download Table]
Weighted
Average
Number of Exercise
Shares Price
-----------------------------------
Outstanding at September 30, 1996 1,014,804 $ 4.89
Granted 504,600 2.00
Exercised (39,833) 4.49
Expired or canceled (18,825) 6.53
---------------
Outstanding at September 30, 1997 1,460,746 2.92
Granted 18,000 0.01
Exercised (29,400) 2.00
Expired or canceled (274,868) 5.50
---------------
Outstanding at September 30, 1998 $ 1,174,478 2.29
===============
[Download Table]
September 30,
1998 1997
------------------------------
Exercisable shares 463,410 495,513
Available for future grants 282,000 200,533
F-14
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 7. COMMON STOCK (CONTINUED)
During 1998, the Company granted options to employees to purchase 18,000 shares
of the Company's common stock at $.01. Commission expense of $51,660 was
recognized regarding this issuance.
All other stock options have been granted to employees at, or in excess of, fair
market value at the date of grant. Accordingly, in accordance with APB 25 and
related interpretations, no compensation cost has been recognized related to
such stock option grants.
Had compensation cost for the Company's stock option plans been determined based
on the fair value at the grant dates for all awards during Fiscal 1997 and 1998
consistent with the method set forth under FASB Statement No. 123, "Accounting
for Stock-Based Compensation" ("FAS 123") the Company's net loss and loss per
share would have been increased to the pro forma amounts indicated below:
[Enlarge/Download Table]
Year Ending September 30,
Loss Loss
1998 Per Share 1997 Per Share
---------------------------------------------------------------
Net loss attributable to common stockholders
$ (4,306,985) $ (0.43) $ (6,266,114) $ (0.74)
Compensation expense related to stock options
granted (615,776) (0.06) (688,975) (0.08)
---------------------------------------------------------------
$ (4,922,761) $ (0.49) $ (6,955,059) $ (0.82)
===============================================================
As the provisions of FAS 123 have been applied only to options granted since
September 30, 1995, the resulting pro forma compensation cost is not
representative of that to be presented in future years, when the pro forma cost
would be fully reflected.
The fair value of options was estimated at the date of grant using the
Black-Scholes option pricing model assuming expected volatility of 69.1% and
risk-free interest rates of 4.43% and 5.86% for 1998 and 1997, respectively; and
expected lives of one to three years and 0.0% dividend yield in both periods.
The weighted average fair value of options granted or options with reduced
exercise price was $2.87 and $0.84 for the years ended September 30, 1998 and
1997, respectively.
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options which have no vesting restrictions and are fully
transferable. Because the Company's employee stock options have characteristics
different from those of traded options, and because changes in the input
assumptions can materially affect the fair value estimate, the model may not
provide a reliable single measure of the fair value of its employee stock
options.
Stock Bonus Plan
During 1997, the Company adopted a stock bonus plan ("1997 Bonus Plan") to
provide stock bonuses in lieu of cash bonuses to key employees who are
responsible for the Company's future growth and financial success. The 1997
Bonus Plan provides for the award of up to 200,000 shares which are
nontransferable and subject to a risk of forfeiture for one year subsequent to
grant date. At September 30, 1998, 107,000 shares of restricted stock had been
issued to key employees and consultants. Expense under the plan was $307,625 and
$53,125 for the years ended September 30, 1998 and 1997, respectively.
F-15
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 7. COMMON STOCK (CONTINUED)
Common Stock Purchase Warrants
During 1997 and 1998 the Company entered into consulting agreements with
separate third party professionals to provide investor relations services and
financial advisory services. In connection with the consulting agreements, the
Company granted common stock purchase warrants to purchase an aggregate 225,000
shares of the Company's common stock. In 1997, the Company adjusted warrants
previously issued under consulting agreements reducing the exercise price to
$2.00 per share. The Company recognized expense of $114,750 and $89,500 in 1998
and 1997, respectively, under FAS 123 in connection with the exercisable shares.
At September 30, 1998, 165,000 warrants were exercisable.
10,000 warrants were exercised during 1998. At September 30, 1998, the following
warrants were outstanding:
[Download Table]
Number
Outstanding
--------------
Warrants issued in connection with:
Investor relations services contract 90,000
Financial advisory services contract 75,000
Convertible Debentures (See Note 4) 107,534
Convertible Preferred Stock (See Note 8) 296,000
Notes Payable (See Note 4) 640,000
--------------
Outstanding at September 30, 1998 1,208,534
==============
At September 30, 1998, the Company had reserved a total of 2,955,813 shares of
its common stock for the exercise of options and warrants outstanding. This
amount includes shares reserved to satisfy obligations due if the Company
defaults on the payment of interest or principal on an $1 million note due March
25, 1999.
Issuance of Stock
The Company issued 25,000 shares of common stock with a market value of
approximately $93,750, and 124,564 shares of common stock with a market value of
approximately $207,863 in 1998 and 1997, respectively. The stock was issued to
consultants for providing investor relation services. Consulting expense of
$93,750 and $207,863 was recognized during the years ended September 30, 1998
and 1997, respectively.
NOTE 8. PREFERRED STOCK
In 1997, FHC raised approximately $1.6 million of proceeds, net of issuance
costs of $96,252, in a private placement of 680,000 shares of 8% cumulative
convertible preferred stock (Series I) sold at $2.50 per share. In addition,
52,000 common stock purchase warrants were issued to the placement agents.
Each share of preferred stock is convertible into one share of the Company's
common stock on or after August 1, 1998. Annual preferred stock dividends will
be paid if and as declared by the Company's Board of Directors. No dividends or
other distributions will be payable on the Company's common stock unless
dividends are paid in full on the preferred stock. The preferred stock may be
redeemed at the option of FHC, in whole or in part, on or after August 1, 2000,
subject to certain conditions, at $2.50 per share plus accrued and unpaid
dividends. In the event of a
F-16
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 8. PREFERRED STOCK (CONTINUED)
liquidation or dissolution of the Company, the preferred stock would have
priority over the Company's common stock.
On December 31, 1997, the Company completed a private placement of 729,927
shares of Class A Convertible Preferred Stock - Series 2 (the "Series 2
Preferred Stock") and warrants to purchase 240,000 shares of Common Stock. The
Series 2 Preferred Stock was sold at a per share price of $2.74, resulting in
net proceeds to the Company of $1.84 million, net of insurance costs of
$156,616. The Series 2 Preferred Stock automatically converted into Common Stock
on a one-for-one basis, on April 3, 1998, the date in which the registration
statement registering the resale of the Common Stock was declared effective by
the SEC. The investors received four-year warrants to purchase 240,000 shares of
Common Stock exercisable at a price per share equal to the lesser of $3.425 or
the average of the three closing bid prices per share of Common Stock for any
three consecutive trading days chosen by the investor during the 30 trading day
period ending on the trading day immediately prior to the exercise of the
warrants. Individuals providing services to the Company's placement agent for
the above convertible Preferred Stock received warrants to purchase 4,000 shares
of Common Stock exercisable at any time prior to December 31, 2001, at $4.11 per
share.
The Company's private placement of convertible Preferred Stock - Series 2 on
December 31, 1997 included a beneficial conversion feature valued at $500,000
and four-year warrants to purchase additional shares of common stock valued at
$317,000. In accordance with new SEC reporting requirements for such
transactions, the Company recorded the value of the beneficial conversion
feature and warrants, a total of $817,000 as additional paid-in capital. The
corresponding discount of $817,000, associated with the issuance of the
convertible preferred stock is a one-time, non-recurring charge that has been
fully amortized and reflected as preferred dividends accreted in the
consolidated statements of operations for the year ended June 30, 1998. The
dividend accretion had no impact on the Company's cash flow from operations.
NOTE 9. EMPLOYEE RETIREMENT PLAN
Effective October 1, 1997, the Company adopted a Simple Individual Retirement
Account (IRA) plan for its employees. Employees are eligible to participate in
the plan if their compensation reaches certain minimum levels and are allowed to
contribute up to a maximum of $6,000 annual compensation to the plan. The
Company has elected to match 100% of employee contributions to the plan up to a
maximum of 1% of employee compensation for the year. Company contributions were
$11,947 for 1998.
NOTE 10. INDUSTRY SEGMENTS AND FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC
OPERATIONS
The Company currently operates primarily in one industry segment which includes
the development, manufacture and marketing of consumer health care products.
The Company operates in foreign and domestic regions. Information about the
Company's operations in different geographic areas (determined by the location
of the operating unit) is as follows.
F-17
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 10. INDUSTRY SEGMENTS AND FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC
OPERATIONS (CONTINUED)
[Download Table]
September 30,
(Amounts in Thousands) 1998 1997
----------------------------------
Net revenues:
United States $ 2,481 $ 2,050
International 2,970 866
Operating profit (loss):
United States (2,731) (3,120)
International (420) (2,118)
Identifiable assets
United States 2,088 3,349
International 5,471 4,990
On occasion, the Company's U.S. unit sells product directly to customers located
outside the U.S. Were such transaction reported by geographic destination of the
sale rather than the geographic location of the unit, U.S. revenues would be
decreased and International revenues increased by $396,000 and $293,000 in 1998
and 1997, respectively.
NOTE 11. CONTINGENT LIABILITIES
The Company's future obligations under the terms of an employment agreement and
a facilities lease were assigned by the Company and assumed by the buyer as part
of the 1996 sale of the Company's subsidiary WPC Holdings, Inc. However, because
the third party creditor did not release the Company from any future liability
under these employment and lease agreements at the time of their assignment, the
Company remains contingently liable if Holdings defaults in making any payments
under the agreements. At September 30, 1998, the total future payments for these
contingent liabilities was $2.8 million for the lease of Holdings' facilities
and $0.3 million for the employment agreement.
The testing, manufacturing and marketing of consumer products by the Company
entail an inherent risk that product liability claims will be asserted against
the Company. The Company maintains product liability insurance coverage for
claims arising from the use of its products. The coverage amount is currently
$5,000,000 for FHC's consumer health care product.
The Year 2000 compliance issue exists because many computer systems and
applications currently use two-digit fields to designate a year. As the century
date change occurs, date-sensitive systems may either fail or not operate
properly unless the underlying programs are modified or replaced. The Company is
assessing the extent of programming changes required to address this issue.
Although final cost estimates have not been determined, it is not expected that
these expenses will have a material impact on the Company's financial condition,
liquidity, or results of operations.
F-18
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 12. RELATED PARTY TRANSACTIONS
For 1998, the Company paid the rent for office space leased by Phoenix Health
Care of Illinois, Inc. ("Phoenix"), a company that owns approximately 270,000
shares of the Company's outstanding Common Stock and has two officers and
directors that are also officers and directors of the Company. This leased space
was used by an officer of the Company.
During 1998 the Company awarded Phoenix 25,000 shares of restricted Common stock
with a market value of approximately $93,750 for consulting services provided to
the Company.
It has been and currently is the policy of the Company that transactions between
the Company and its officers, directors, principal shareholders or affiliates
are to be on terms no less favorable to the Company than could be obtained from
unaffiliated parties. The Company intends that any future transactions between
the Company and its officers, directors, principal shareholders or affiliates
will be approved by a majority of the directors who are not financially
interested in the transaction.
NOTE 13. EARNINGS PER SHARE
Net (loss) per Common share outstanding and diluted net (loss) per Common share
outstanding is based on the weighted average of shares of Common Stock
outstanding during the period.
In February 1997, the Financial Accounting Standards Board issued Statement No.
128, Earnings Per Share. Statement No. 128 replaced the previously reported
primary and fully diluted earnings per share with basic and diluted earnings per
share. Unlike primary earnings per share, basic earnings per share excludes any
dilutive effects of options, warrants, and convertible securities. Diluted
earnings per share is very similar to the previously reported fully dilutive
earnings per share. All earnings per share in the accompanying financial
statements have been presented to conform to Statement No. 128 requirements. The
Company has "in the money" options and warrants outstanding of 200,000 and
764,319 as of September 30, 1998 and 1997, respectively (see Note 7). The
Company also has preferred stock outstanding as of September 30, 1998, which is
convertible into 680,000 shares of Common Stock (see Note 8). The inclusion of
the options, warrants and convertible preferred stock in the computation of
diluted earnings per share would have resulted in a reduction of the loss per
share (antidilutive) and therefore both basic and diluted earnings per share
amounts were the same for each of the periods presented in the accompanying
financial statements.
NOTE 14. CURRENT ACCOUNTING PRONOUNCEMENTS
Comprehensive Income
The Financial Accounting Standards Board has issued Statement No. 130,
"Reporting Comprehensive Income," that the Company will be required to adopt for
its year ended September 30, 1999, and disclose in its interim financial
statements beginning with the period ending December 31, 1998. This
pronouncement is not expected to have a significant impact on the Company's
financial statements. The Statement establishes standards for the reporting and
presentation of comprehensive income and its components. The statement requires
that items recognized as components of comprehensive income be reported in a
financial statement. The statement also requires that a company classify items
of other comprehensive income by their nature in a financial statement, and
display the accumulated balance of other comprehensive income separately from
retained earnings and additional paid-in capital in the equity section of a
statement of financial position. For the years ended September 30, 1998 and
1997, the
F-19
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 14. CURRENT ACCOUNTING PRONOUNCEMENTS (CONTINUED)
Company's components of comprehensive income (loss) consisted of its reported
net (loss) and foreign currency translation adjustments.
Segments of an Enterprise
Statement of Financial Accounting Standard No. 131, "Disclosures about Segments
of an Enterprise and Related Information," was issued in July 1997 by the
Financial Accounting Standards Board. The Statement requires the Corporation to
disclose the factors used to identify reportable segments including the basis of
organization, differences in products and services, geographic areas, and
regulatory environments. The Statement additionally requires financial results
to be reported in the financial statements for each reportable segment. The
Statement is effective for financial statement periods beginning after December
15, 1997.
Derivatives
In June 1998, the FASB issued Statement No. 133, Accounting for Derivative
Instruments and Hedging Activities (FAS 133). FAS 133 requires companies to
record derivatives on the balance sheet as assets or liabilities at fair value.
Depending on the use of the derivative and whether it qualifies for hedge
accounting, gains or losses resulting from changes in the value of those
derivatives would either be recorded as a component of net income or as a change
in stockholders' equity. The Company is required to adopt this new standard for
the quarter and year beginning October 1, 1999. The Company currently has no
derivative instruments and, accordingly, the adoption of this statement has no
impact on its consolidated financial statements.
NOTE 15. CONTINUING OPERATIONS AND SUBSEQUENT EVENT
The Company's consolidated financial statements have been prepared on a going
concern basis which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company
incurred a loss of $3.4 million for the year ended September 30, 1998, and as of
September 30, 1998, had an accumulated deficit of $41.3 million. At September
30, 1998, the Company had working capital of $1.2 million and stockholders'
equity of $2.9 million. In the near term, the Company expects operating and
capital costs to continue to exceed funds generated from operations due
principally to the Company's fixed manufacturing costs relative to current
production volumes and the ongoing need to commercialize the female condom
around the world. As a result, operations in the near future are expected to
continue to use working capital. Management recognizes that the Company's
continued operations depend on its ability to raise additional capital through a
combination of equity or debt financing, strategic alliances and increased sales
volumes.
At various points during the developmental stage of the product, the Company was
able to secure resources, in large part through the sale of equity and debt
securities, to satisfy its funding requirements. As a result, the Company was
able to obtain FDA approval, worldwide rights, manufacturing facilities and
equipment and to commercially launch the female condom. Management believes that
recent developments, including the Company's agreement with the UNAIDS, a joint
United Nations program on HIV/AIDS, provide an indication of the Company's early
success in broadening awareness and distribution of the female condom and may
benefit efforts to raise additional capital and to secure additional agreements
to promote and distribute the female condom throughout other parts of the world.
On September 29, 1997, the Company entered into an agreement with Vector
Securities International, Inc. (Vector), an investment banking firm specializing
in providing advice to healthcare and life-science companies. Pursuant to this
agreement, for a one-year period, Vector will act as the Company's exclusive
financial advisor for the purposes of
F-20
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
NOTE 15. CONTINUING OPERATIONS AND SUBSEQUENT EVENT (CONTINUED)
identifying and evaluating opportunities available to the Company for increasing
shareholder value. These opportunities may include selling all or a portion of
the business, assets or stock of the Company or entering into one or more
distribution arrangements relating to the Company's product. This agreement has
been extended for an additional six months. There can be no assurance that any
such opportunities will be available to the Company or, if so available, that
the Company will ultimately elect or be able to consummate any such transaction.
On November 19, 1998, the Company executed an agreement with a private investor
(the Equity Line Agreement). This agreement provides for the Company, at its
sole discretion, subject to certain restrictions, to sell ("put") to the
investor up to $6.0 million of the Company's Common Stock, subject to a minimum
put of $1.0 million over the duration of the agreement. The Equity Line
Agreement expires 24 months after the effective date of the pending registration
statement and, among other things, provides for minimum and maximum puts ranging
from $100,000 to $1,000,000 depending on the Company's stock price and trading
volume. The timing and amount of drawdowns on this line of credit are totally at
the Company's discretion, subject to certain conditions. The Company is required
to draw down a minimum of $1 million during the two-year period. If the Company
does not draw down the minimum, the Company is required to pay the investor a
12% fee on that portion of the $1 million minimum not drawn down at the end of
the two-year period.
While the Company believes that its existing capital resources (including
expected proceeds from sales of Common Stock pursuant to the Equity Line
Agreement) will be adequate to fund its currently anticipated capital needs, if
they are not or the Company does not receive shareholder approval to amend its
Articles of Incorporation to increase its authorized Common Stock, enabling the
Company to sell sufficient Shares under the Equity Line Agreement, the Company
may need to raise additional capital until its sales increase sufficiently to
cover operating expenses. In addition, there can be no assurance that the
Company will satisfy the conditions required for it to exercise puts under the
Equity Line Agreement. Accordingly, the Company may not be able to realize all
or any of the funds available to it under the Equity Line Agreement.
Further, there can be no assurance, assuming the Company successfully raises
additional funds or enters into business agreements with third parties, that the
Company will achieve profitability or positive cash flow. If the Company is
unable to obtain adequate financing, management will be required to sharply
curtail the Company's efforts to promote the female condom and to curtail
certain other of its operations or, ultimately, cease operations.
F-21
THE FEMALE HEALTH COMPANY
CONSOLIDATED BALANCE SHEET (UNAUDITED)
JUNE 30, 1999
[Download Table]
ASSETS
Current Assets
Cash $ 730,315
Accounts receivable, net 1,301,374
Inventories, net 816,027
Prepaid expenses and other current assets 508,939
-----------------
TOTAL CURRENT ASSETS 3,356,656
Other Assets
Intellectual property, net 156,269
Other assets 785,940
-----------------
942,209
-----------------
Property, Plant and Equipment
Equipment, furniture and fixtures 3,924,245
Less: accumulated depreciation (1,898,144)
-----------------
2,025,100
-----------------
$ 6,324,965
=================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Notes payable, related party, net of unamortized discount $ 1,113,118
Convertible debenture, net of unamortized discount 557,106
Current maturities of long-term debt and capital lease
obligations 57,785
Accounts payable 495,374
Accrued expenses and other current liabilities 356,438
Preferred dividends payable 100,289
-----------------
Total current liabilities 2,680,110
Deferred Gain on Lease of Facility 1,597,591
Other Long-term Liabilities 101,126
-----------------
Total liabilities 4,378,827
-----------------
Stockholders' Equity
Convertible Preferred Stock 6,600
Common Stock 111,380
Additional paid-in capital 46,227,312
Unearned consulting compensation (339,517)
Accumulated deficit (44,344,476)
Foreign currency translation gain 316,915
Treasury Stock, at cost (32,076)
-----------------
1,946,138
-----------------
$ 6,324,965
=================
See Notes to Financial Statements.
F-22
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
NINE MONTHS ENDED JUNE 30, 1999 AND 1998
[Enlarge/Download Table]
1999 1998
------------------------------------------------------------------------------------------------------------------------
Net Revenues $ 3,409,695 $ 4,040,672
Cost of Products Sold 3,787,785 4,082,175
----------------------------------------
GROSS PROFIT (LOSS) (378,090) (41,503)
----------------------------------------
Operating expenses:
Advertising and promotion 219,333 371,421
Selling, general and administrative 2,090,761 2,165,007
----------------------------------------
Total Operating Expenses 2,310,094 2,536,007
----------------------------------------
OPERATING (LOSS) (2,688,184) (2,577,931)
Interest, net, and other expense 353,042 124,714
----------------------------------------
PRETAX (LOSS) (3,041,226) (2,702,645)
Provision for income taxes - -
----------------------------------------
NET (LOSS) (3,041,226) (2,702,645)
Preferred dividends accreted, Series 2 - 817,000
Preferred dividends, Series 1 102,054 101,720
----------------------------------------
Net (loss) attributable to common stockholders $ (3,143,280) $ (3,621,365)
========================================
Net (loss) per common share outstanding $ (0.29) $ (0.37)
Weighted average common shares outstanding 10,719,690 9,821,778
See Notes to Financial Statements.
F-23
THE FEMALE HEALTH COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
NINE MONTHS ENDED JUNE 30, 1999 AND 1998
[Enlarge/Download Table]
1999 1998
--------------------------------------------------------------------------------------------------------------------------
OPERATIONS:
Net (loss) $ (3,041,226) $ (2,702,645)
Adjusted for noncash items:
Depreciation and amortization 425,016 442,140
Amortization of discounts on notes payable
and convertible debentures 332,994 243,419
Reduction in inventory reserves (30,411) (652,192)
Reduction in accounts receivable reserves 22,640 (101,386)
Amortization of other assets - 8,008
Changes in operating assets and liabilities (647,331) (148,006)
----------------------------------------
NET CASH (USED IN) OPERATING ACTIVITIES (2,938,318) (2,614,650)
----------------------------------------
INVESTING ACTIVITIES:
Capital expenditures (22,129) (16,918)
Proceeds from repayment of note receivable - 750,000
----------------------------------------
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES (22,129) 733,082
----------------------------------------
FINANCING ACTIVITIES:
Proceeds from related-party notes issued 1,300,000 1,000,000
Payments on notes payable, related party (1,558,043) (1,040,347)
Proceeds from the issuance of convertible
Debenture 1,500,000 -
Proceeds from the issuance of preferred stock - 1,843,384
Purchase of Common Stock held in Treasury (12,746) -
Proceeds from the issuance of common stock 485,000 -
Proceeds from the issuance of common stock
upon exercise of options and warrants 226,878 480,175
----------------------------------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 1,953,835 2,283,212
----------------------------------------
Effect of exchange rate change on cash 256,640 168,370
----------------------------------------
INCREASE (DECREASE) IN CASH (749,972) 570,014
Cash at beginning of period 1,480,287 1,633,467
----------------------------------------
CASH AT END OF PERIOD $ 730,315 $ 2,203,481
========================================
Schedule of noncash financing and investing activities:
Preferred dividends declared, Series 1 $ 100,289 $ 101,720
Preferred dividends accreted, Series 2 - 817,000
Issuance of warrants on notes payable 1,304,515 297,500
Conversion of Preferred Stock into common stock 10,718 7,299
See Notes to Financial Statements.
F-24
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
--------------------------------------------------------------------------------
NOTE 1. BASIS OF PRESENTATION
The accompanying financial statements are unaudited but in the opinion of
management contain all the adjustments (consisting of those of a normal
recurring nature) considered necessary to present fairly the financial position
and the results of operations and cash flow for the periods presented in
conformity with generally accepted accounting principles for interim financial
information and the instructions to Form 10-QSB and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements.
Operating results for the nine months ended June 30, 1999 are not necessarily
indicative of the results that may be expected for the fiscal year ending
September 30, 1999. For further information, refer to the consolidated financial
statements and footnotes thereto included in the Company's annual report on Form
10-KSB for the fiscal year ended September 30, 1998.
NOTE 2. EARNINGS PER SHARE
Basic and diluted net (loss) per Common share outstanding is based on the
weighted average of shares of Common Stock outstanding during the period.
As of June 30, 1999 the Company has 1,154,428 options and 3,861,034 warrants
outstanding including no "in the money" options and warrants. As of June 30,
1998 the Company had 1,175,778 options and 1,133,534 warrants outstanding
including 1,357,866 "in the money" options and warrants. As of June 30, 1999 and
1998 the Company also has 660,000 and 680,000 shares, respectively, of preferred
stock outstanding which is convertible into an equal number of shares of common
stock (see Note 6). The inclusion of the options, warrants and convertible
preferred stock in the computation of diluted earnings per share would have
resulted in a reduction of the loss per share (antidilutive) and therefore both
basic and diluted earnings per share amounts were the same for each of the
periods presented in the accompanying financial statements.
NOTE 3. COMPREHENSIVE INCOME (LOSS)
Total Comprehensive Loss was $(3,131,345) for the nine months ended June 30,
1999, and $(2,479,199) for the nine months ended June 30, 1998.
NOTE 4. LEASE OF MANUFACTURING FACILITY
On December 10, 1996, the Company entered into what is in essence a sale and
leaseback agreement with respect to its 40,000 square foot manufacturing
facility located in London, England. The Company received $3,365,000 (1,950,000
British pounds sterling) for leasing the facility to a third party for a nominal
annual rental charge and for providing the third party with an option to
purchase the facility for one pound during the period December 2006 to December
2027. Concurrent with this transaction, the Company repaid the mortgage loan on
this property of $1,834,000 (1,062,500 British pounds sterling).
As part of the same transaction, the Company entered into an agreement to lease
the facility back from the third party for base rents of $336,000 (195,000
British pounds sterling) per year payable quarterly until 2016. The lease is
renewable through 2027. The Company was also required to make a security deposit
of $336,000 (195,000 British pounds sterling) to be reduced in subsequent years.
The facility had a net book value of $1,398,819 (810,845 British pounds
sterling) on the date of the transaction. The $1,966,181 (1,139,155 British
pounds sterling) gain which resulted from this transaction will be recognized
ratably over the initial term of the lease. Unamortized deferred gain as of June
30, 1999 was $1,597,591 (996,775 British pounds sterling).
F-25
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
--------------------------------------------------------------------------------
NOTE 5. INVENTORIES
The components of inventory consist of the following at June 30, 1999:
[Download Table]
Raw materials and work in process $ 368,298
Finished goods 478,142
--------------
846,440
Less inventory reserves (30,413)
--------------
Net inventory $ 816,027
==============
NOTE 6. SALE OF CONVERTIBLE PREFERRED STOCK
In September 1997, the Company raised approximately $1.6 million net proceeds,
after issuance costs of $96,252, in a private placement of 680,000 shares of 8%
cumulative convertible Preferred Stock - Series 1. In addition, warrants to
purchase 52,000 shares of Common Stock were issued to the placement agents. Each
share of Preferred Stock is convertible into one share of the Company's Common
Stock on or after August 1, 1998. Annual Preferred Stock dividends will be paid
if and as declared by the Company's Board of Directors. No dividends or other
distributions will be payable on the Company's Common Stock unless dividends are
paid in full on the Preferred Stock. The shares may be redeemed at the option of
the Company, in whole or in part, on or after August 1, 2000, subject to certain
conditions, at $2.50 per share plus accrued and unpaid dividends. In the event
of a liquidation or dissolution of the Company, the Preferred Stock Series 1
would have priority over the Company's Common Stock.
On December 31, 1997, the Company completed a private placement of 729,927
shares of Class A Convertible Preferred Stock - Series 2 (the "Series 2
Preferred Stock") and Warrants to purchase 240,000 shares of Common Stock. The
Series 2 Preferred Stock was sold at a per share price of $2.74, resulting in
net proceeds to the Company of $1.82 million, after commissions and expenses.
The Series 2 Preferred Stock automatically converted into Common Stock on a
one-for-one basis, on April 3, 1998, the date on which the registration
statement registering the resale of the Common Stock was declared effective by
the SEC. The investors received four-year Warrants to purchase 240,000 shares of
Common Stock exercisable at a price per share equal to the lesser of $3.425 or
the average of the three closing bid prices per share of Common Stock for any
three consecutive trading days chosen by the investor during the 30 trading day
period ending on the trading day immediately prior to the exercise of the
Warrants. Individuals providing services to the Company's placement agent for
the above convertible Preferred Stock received Warrants to purchase 4,000 shares
of Common Stock exercisable at any time prior to December 31, 2001, at $4.11 per
share.
NOTE 7. FINANCIAL CONDITION
The Company's consolidated financial statements have been prepared on a going
concern basis which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company
incurred a net loss of $3.4 million for the year ended September 30, 1998, a net
loss of $3.2 million for the nine months ended June 30, 1999 and as of June 30,
1999 had an accumulated deficit of $44.4 million.
At June 30, 1999, the Company had working capital of $0.7 million and
stockholders' equity of $1.9 million. In the near term, the Company expects
operating and capital costs to continue to exceed funds generated from
operations due principally to the Company's fixed manufacturing costs relative
to current production volumes and the ongoing need to commercialize the Female
Condom around the world. As a result, operations in the near future are expected
to continue to use working capital. Management recognizes that the Company's
continued operations depend on its ability to raise additional capital through a
combination of equity or debt financing, strategic alliances and increased sales
volumes.
F-26
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
--------------------------------------------------------------------------------
NOTE 7. FINANCIAL CONDITION (CONTINUED)
At various points during the developmental stage of the product, the Company was
able to secure resources, in large part through the sale of equity and debt
securities, to satisfy its funding requirements. As a result, the Company was
able to obtain FDA approval, worldwide rights, manufacturing facilities and
equipment and to commercially launch the Female Condom. Management believes that
recent developments, including the Company's agreement with the UNAIDS, a joint
United Nations program on HIV/AIDS, provide an indication of the Company's early
success in broadening awareness and distribution of the Female Condom and may
benefit future efforts to raise additional capital and to secure additional
agreements to promote and distribute the Female Condom throughout other parts of
the world.
On September 29, 1997, the Company entered into an agreement with Vector
Securities International, Inc. (Vector), an investment banking firm specializing
in providing financial advisory services to healthcare and life-science
companies. Pursuant to this agreement, as extended, Vector will act as the
Company's exclusive financial advisor through December 31, 1999 for the purposes
of identifying and evaluating opportunities available to the Company for
increasing shareholder value. These opportunities may include selling all or a
portion of the business, assets or stock of the Company or entering into one or
more distribution arrangements relating to the Company's product. There can be
no assurance that any such opportunities will be available to the Company or, if
so available, that the Company will ultimately elect or be able to consummate
any such transaction. Management is currently determining whether the Company
should seek to extend this arrangement.
In May and June 1999 the Company completed a private placement of $1.5 million
convertible debentures and 1,875,000 warrants. See Note 9 of the Notes to
Unaudited Condensed Consolidated Financial Statements for additional detail.
On November 19, 1998, the Company entered into a private Equity Line of Credit
Agreement (the "Equity Line Agreement") with Kingsbridge Capital Limited, a
private investor (the "Selling Stockholder"). Under the Equity Line Agreement,
the Company has the right, subject to various conditions, to issue and sell to
the Selling Stockholder, from time to time, shares of its Common Stock for cash
consideration up to an aggregate of $6 million.
The Equity Line Agreement gives the Company, in its sole discretion and subject
to certain restrictions, the right to sell ("put") to the Selling Stockholder up
to $6.0 million of the Company's Common Stock, subject to a minimum put of $1.0
million over the duration of the agreement. The Equity Line Agreement expires 24
months after the effective date of the registration statement filed to register
the Selling Stockholder's public resale of any stock it purchases under the
agreement. The Equity Line Agreement provides for, among other things, minimum
and maximum puts ranging from $100,000 to $1,000,000 depending on the Company's
stock price and trading volume. The timing and amount of puts under the Equity
Line Agreement are totally at the Company's discretion, subject to certain
conditions. The Company is required to put a minimum of $1 million during the
two-year period. If the Company does not put the minimum, the Company is
required to pay the investor a 12% fee on that portion of the $1 million minimum
not put at the end of the two-year period. As of June 30, 1999, the Company had
placed three puts for the combined cash proceeds of $485,000 providing the
Selling Stockholders with a total of 482,964 shares of the Company's Common
Stock. Each put was executed while the Company's stock price was below $2.00 per
share.
While the Company believes that its existing capital resources will be adequate
to fund its currently anticipated capital needs, if they are not, the Company
may need to raise additional capital until its sales increase sufficiently to
cover operating expenses. In addition, there can be no assurance that the
Company will satisfy the conditions required for it to exercise puts under the
Equity Line Agreement. Accordingly, the Company may not be able to realize all
of the funds available to it under the Equity Line Agreement.
F-27
THE FEMALE HEALTH COMPANY
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
--------------------------------------------------------------------------------
NOTE 7. FINANCIAL CONDITION (CONTINUED)
Further, there can be no assurances, assuming the Company successfully raises
additional funds or enters into business agreements with third parties, that the
Company will achieve profitability or positive cash flow. If the Company is
unable to obtain adequate financing, management will be required to sharply
curtail the Company's efforts to commercialize the Female Condom and to curtail
certain other of its operations or, ultimately, cease operations.
NOTE 8. PREFERRED DIVIDENDS, SERIES 2
The Company's $2.0 million private placement of convertible Preferred Stock -
Series 2 on December 31, 1997 included a beneficial conversion feature valued at
$500,000 and four-year warrants to purchase additional shares of common stock
valued at $317,000. In accordance with SEC reporting requirements for such
transactions, the Company recorded the value of the beneficial conversion
feature and warrants, a total of $817,000, as additional paid-in capital. The
corresponding discount of $817,000, associated with the issuance of the
convertible preferred stock is a one-time, non-recurring charge that has been
fully amortized and reflected as preferred dividends accreted in the
consolidated statements of operations for the nine months ended June 30, 1998.
The dividend accretion had no impact on the Company's cashflow from operations.
NOTE 9. SALE OF CONVERTIBLE DEBENTURES
On June 1, 1999, the Company completed a private placement of convertible
debentures in the principal amount of $1.5 million and warrants to purchase
1,875,000 shares of Common Stock. The convertible debentures are convertible
into shares of the Company's common Stock as follows: the first 50% of the
original principal balance and any accrued but unpaid interest, be converted
into Common Stock at the investor's election at any time after one year based on
a per share price equal to the lesser of 70% of the market price of the
Company's Common Stock at the time of conversion or $1.25, the second 50% of the
original principal balance and any accrued but unpaid interest thereon may be
converted into Common Stock at the investor's election at any time after one
year based on a per share price equal to the lesser of 70% of the market price
of the Company's Common Stock at the time of conversion or $2.50. The
convertible debentures are payable one year after issuance or, if the Company
elects, two years after issuance. If the term is extended for the extra one
year, the Company must issue to the investor at the time of extension,
additional warrants to purchase 375,000 shares of Common Stock on the same term
as the other warrants. Interest on the convertible debentures is payable at 8%
quarterly in cash or, at the investor's option, Common Stock at its then current
fair market value. Repayment of the Convertible Debentures is secured by a first
security interest in all of the Company's assets. Additionally, warrants to
purchase 337,500 shares of Common Stock were issued to the Company's placement
agent in this offering. The warrants have a term of five years and are
exercisable at an exercise price equal to the lesser of 70% of the market price
of the Common Stock at the time of the exercise or $1.00.
The convertible debentures beneficial conversion feature is valued at $336,400
and the warrants to purchase 1,875,000 shares of common stock are valued at
$715,100. In accordance with SEC reporting requirements for such transactions,
the Company recorded the value of the beneficial conversion feature and warrants
(a total of $1,051,500) as additional paid in capital. The corresponding amount
of $1,051,500 was recorded as a discount on convertible debentures and is
amortized over 1 year using the interest rate method.
F-28
YOU SHOULD RELY ONLY ON INFORMATION CONTAINED IN THIS PROSPECTUS. WE
HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION DIFFERENT FROM THAT
CONTAINED IN THIS PROSPECTUS. THE SELLING STOCKHOLDERS LISTED IN THIS PROSPECTUS
ARE OFFERING TO SELL, AND SEEKING OFFERS TO BUY, SHARES OF COMMON STOCK ONLY IN
JURISDICTIONS WHERE OFFERS AND SALES ARE PERMITTED. THE INFORMATION CONTAINED IN
THIS PROSPECTUS IS ACCURATE ONLY AS OF THE DATE OF THIS PROSPECTUS, REGARDLESS
OF THE TIME OF DELIVERY OF THIS PROSPECTUS OR OF ANY SALE OF OUR COMMON STOCK.
NO ACTION IS BEING TAKEN IN ANY JURISDICTION OUTSIDE THE UNITED STATES
TO PERMIT A PUBLIC OFFERING OF THE COMMON STOCK OR POSSESSION OR DISTRIBUTION OF
THIS PROSPECTUS IN ANY SUCH JURISDICTION. PERSONS WHO COME INTO POSSESSION OF
THIS PROSPECTUS IN JURISDICTIONS OUTSIDE THE UNITED STATES ARE REQUIRED TO
INFORM THEMSELVES ABOUT AND TO OBSERVE ANY RESTRICTIONS AS TO THIS OFFERING AND
THE DISTRIBUTION OF THIS PROSPECTUS APPLICABLE TO THAT JURISDICTION.
THE FEMALE HEALTH COMPANY
4,929,175 SHARES OF COMMON STOCK
--------------------------------
PROSPECTUS
-------------------------------
__________, 1999
44
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 24. Indemnification of Directors and Officers.
Pursuant to sections 180.0850 to 180.0859 of the Wisconsin
Business Corporation Law, directors and officers of the Company are entitled to
mandatory indemnification from the Company against certain liabilities and
expenses (i) to the extent such officers or directors are successful in the
defense of a proceeding and (ii) in proceedings in which the director or officer
is not successful in the defense thereof, unless (in the latter case only) it is
determined that the director or officer breached or failed to perform his duties
to the Company and such breach or failure constitute: (a) willful failure to
deal fairly with the Company or its shareholders in connection with a matter in
which the director or officer had a material conflict of interest; (b) a
violation of the criminal law unless the director or officer had reasonable
cause to believe his or her conduct was lawful or had no reasonable cause to
believe his or her conduct was unlawful; (c) a transaction from which the
director or officer derived an improper personal profit; or (d) willful
misconduct. It should be noted that section 180.0859 of the Wisconsin Business
Corporation Law specifically states that it is the public policy of Wisconsin to
require or permit indemnification in connection with a proceeding involving
securities regulation, as described therein, to the extent required or permitted
under sections 180.0850 to 180.0858 as described above. Additionally, under the
Wisconsin Business Corporation Law, directors of the Company are not subject to
personal liability to the Company, its shareholders or any person asserting
rights on behalf thereof for certain breaches or failures to perform any duty
resulting solely from their status as such directors, except in circumstances
paralleling those in subparagraphs (a) through (d) outlined above.
Consistent with sections 180.0850 to 180.0859 of the Wisconsin
Business Corporation Law, Article VIII of the Company's Amended and Restated
By-Laws provides that the Company shall indemnify any person in connection with
legal proceedings threatened or brought against him by reason of his present or
past status as an officer or director of the Company in the circumstances
described above. Article VIII of the Amended and Restated By-Laws also provides
that the directors of the Company are not subject to personal liability to the
Company, its shareholders or persons asserting rights on behalf thereof, as
provided in the Wisconsin Business Corporation Law. The Amended and Restated
By-Laws also contain a nonexclusivity clause which provides in substance that
the indemnification rights under the Amended and Restated By-Laws shall not be
deemed exclusive of any other rights to which those seeking indemnification may
be entitled under any agreement with the Company, any Amended and Restated
By-Law or otherwise.
The indemnification provided as set forth above is not
exclusive of any other rights to which a director or an officer of the Company
may be entitled.
The general effect of the foregoing provisions is to reduce
the circumstances in which an officer or director may be required to bear the
economic burdens of the foregoing liabilities and expenses.
45
Item 25. Other Expenses of Issuance and Distribution.
The expenses in connection with the offering are as follows:
[Enlarge/Download Table]
Item Amount*
---- ------
Registration fee.................................................................... $ 1,370
Printing expenses................................................................... $ 5,000
Legal fees and expenses............................................................. $ 25,000
Accounting fees and expenses........................................................ $ 10,000
Miscellaneous expenses.............................................................. $ 5,000
--------
Total................................................................. $ 46,370
========
----------
* All amounts estimated except the registration fee.
Item 26. Recent Sales of Unregistered Securities.
On September 12, 1996, the Company completed a Regulation S offering to
five offshore institutional investors selling to such investors 8% cumulative
convertible debentures for an aggregate principal amount of $2 million. The
debentures are convertible into the Company's common stock. In addition, the
debenture holders received warrants to purchase 40,201 shares of the Company's
common stock at an exercise price of $5.72 per share.
On February 20, 1997, the Company sold $2,020,000 of 8% convertible
debentures and related warrants to eight foreign investors pursuant to the
exemption from the securities registration requirement provided by Regulation S
promulgated under the Securities Act of 1933, as amended. The convertible
debentures mature on January 31, 2000 and bear interest at 8% per annum, payable
semiannually. The convertible debentures are convertible at the election of the
holders into shares of common stock in accordance with their terms. As required
by Regulation S, the Company offered and sold the convertible debentures and
warrants in an offshore transaction only to non-U.S. persons. The Company did
not use the services of an underwriter in this offering but, rather, European
American Services, Inc. acted as a distributor for the offering. For its
services as the distributor, European American Services, Inc. received a
placement fee of 7% of the principal amount of the debentures sold. In
connection with this Regulation S offering, the investors also received warrants
to purchase a total of 67,333 shares of the Company's common stock at an
exercise price of $5.00 per share. The warrants expire on October 30, 1999.
The Company believes the above transactions were exempt from the
securities registration requirement pursuant to Regulation S promulgated under
the Securities Act because such sales were made to nonresidents of the United
States in an offshore transaction without any directed selling efforts made in
the United States by the Company, any distributor or any of their respective
affiliates or any persons acting on behalf of any of such parties. In addition,
the Company believes it implemented all offering restrictions and complied with
all of the terms and conditions of Regulation S which were imposed on the issuer
of the securities as of the date of each offering.
On each of March 25, 1997, March 25, 1998 and March 25, 1999 the
Company refinanced its $1 million borrowing from Mr. Dearholt by extending the
one-year note payable to him for an additional year. Accordingly, the note is
now payable in full on March 25, 2000. As part of these transactions, on the
date of each extension, the Company issued to Mr. Dearholt warrants to purchase
200,000 shares of the Company's common stock at exercise prices of $1.848, $2.25
and $1.16 per share, respectively. These exercise prices represented 80% of the
average trading price of the Company's common stock for the five trading days
immediately prior to each of the refinancings. The warrants expire on the
earlier of their exercise or five years after the date of their issuance.
46
The Company believes that the sales described above were exempt from
registration under section 4(2) of the Securities Act and/or Regulation D
promulgated under the Securities Act because such sales were made to one person
who is an accredited investor and a director of the Company. Mr. Dearholt also
represented to the Company that he was purchasing for investment without a view
to further distribution. Restrictive legends were placed on all instruments
evidencing the securities described above.
On July 29, 1997, the Company completed a private placement of 680,000
shares of Class A Convertible Preferred Stock--Series 1 (the "Series 1 Preferred
Stock") to a group of accredited investors. Each share of the Series 1 Preferred
Stock was sold for $2.50. In connection with this private placement, the Company
issued to the placement agents in the offering warrants exercisable for a total
of 52,000 shares of common stock at an exercise price of $2.50 per share. The
Company also paid the placement agents a cash commission equal to 7% of the
proceeds received by the Company from sales made by the placement agents. The
Company raised approximately $1.6 million of proceeds, net of issuance costs of
$96,252. The Company believes that it has satisfied the exemption from the
securities registration requirement provided by section 4(2) of the Securities
Act and Regulation D promulgated thereunder in this offering in that the
securities were sold in a private placement to only accredited investors, most
of whom had a pre-existing personal or business relationship with the Company or
its officers or directors and each of whom provided representations which the
Company deemed necessary to satisfy itself that they were accredited investors
and were purchasing for investment and not with a view to resale in connection
with a public offering.
On December 31, 1997, the Company sold 729,927 shares of Class A
Convertible Preferred Stock--Series 2 ("Series 2 Preferred Stock") and warrants
to purchase 240,000 shares of the Company's common stock to three institutional
accredited investors pursuant to section 4(2) of the Securities Act and
Regulation D promulgated thereunder. Each share of Series 2 Preferred Stock was
sold for $2.74. This private placement netted the Company $1.82 million, after
deduction for expenses and commissions. in connection with this private
placement, the Company issued to its placement agent in the offering warrants to
purchase 4,000 shares of the Company's common stock at an exercise price of
$4.11 per share. The Company also paid the placement agent a commission equal to
7% of the gross proceeds raised by the Company in this offering. The warrants
issued to the investors are exercisable at an exercise price per share equal to
the lesser of (a) $3.25 or (b) the average of the three closing bid prices per
share of the Company's common stock for any three consecutive trading days
selected by the holder in the 30 consecutive trading day period ending on the
trading day immediately prior to the date of exercise. Both the warrants issued
to the investors and the warrants issued to the Company's placement agent in
this offering expire on December 31, 2001. The Company believes that it has
satisfied the exemption from the securities registration requirement provided by
section 4(2) of the Securities Act and Regulation D promulgated thereunder in
this offering in that the securities were sold in a private placement to only
sophisticated, institutional, accredited investors, each of whom provided
representations which the Company deemed necessary to satisfy itself that they
were accredited investors and were purchasing for investment and not with a view
to resale in connection with a public offering.
On May 19, 1999 and June 3, 1999, the Company issued an aggregate of
$1,500,000 of convertible debentures and warrants to purchase 1,875,000 shares
of the Company's common stock to five accredited investors. The convertible
debentures bear interest at 8% per annum and have a one-year term; provided,
however, that the Company may extend the repayment term for an additional one
year if, upon such extension, it issues to the investors warrants to purchase
375,000 shares of the Company's common stock having the same terms and
conditions as the warrants issued to the investors in the private placement. The
investors may convert the convertible debentures into common stock at any time
after one year from the date they were issued as follows: (a) the first 50% of
the original principal balance of the convertible debentures, plus any accrued
but unpaid interest thereon, is convertible into common stock based on a per
share price equal to the lesser of (i) 70% of the market price of the common
stock at the time of conversion or (ii) $1.25; and (b) the second 50% of the
original principal balance plus any accrued but unpaid interest thereon is
convertible into common stock based on the per share price equal to the lesser
of (i) 70% of the market price of the common stock at the time of conversion or
(ii) $2.50. As part of this offering, the Company also issued to the investors
warrants to purchase 1,875,000 shares of the Company's common stock. The
warrants are exercisable by the investors at any time within five years after
their date of issuance at an exercise price per share equal to the lesser of (a)
70% of the market price of the Company's common stock from the date of exercise
or (b) $1.00. As part
47
of the consideration that the Company paid R.J. Steichen & Company, the
Company's placement agent in the private placement of the convertible debentures
and warrants, the Company issued to R.J. Steichen warrants to purchase a total
of 337,500 shares of the Company's common stock. The warrants issued to R.J.
Steichen are exercisable at any time commencing one year after the date of the
private placement and for a period of four years thereafter at an exercise price
of $1.00 per share.
The Company believes it has satisfied the exemption from the securities
registration requirement provided by section 4(2) of the Securities Act and
Regulation D promulgated thereunder in this offering since the securities were
sold in a private placement to only sophisticated, accredited investors, each of
whom provided representations which the Company deemed necessary to satisfy
itself that they were accredited investors and were purchasing for investment
and not with a view to resale in connection with a public offering.
On September 24, 1999, the Company completed a private placement of
666,671 shares of its common stock to nine investors. Each share of common stock
was sold for a purchase price of $0.75, representing a discount of 12% from the
market price on the date that the shares were sold. In connection with this
private placement, the Company agreed to register the investors' resale of these
shares pursuant to this registration statement. The Company raised approximately
$500,000 of proceeds, net of issuance cost of $0 in connection with this private
placement. The Company believes that it has satisfied the exemption from the
securities registration requirement provided by section 4(2) of the Securities
Act and Regulation D promulgated thereunder in this offering since the
securities were sold in a private placement to only accredited investors, most
of whom had a preexisting personal or business relationship with the Company or
its officers or directors and each of whom provided representations which the
Company deemed necessary to satisfy itself that they were accredited investors
and were purchasing for investment and not with a view to resale in connection
with a public offering. In addition, the common stock issued to these investors
contained restrictive legends indicating that the shares had not been registered
and, therefore, cannot be resold unless the resale was registered under the
Securities Act or an exemption from such registration requirement was available.
On February 18, 1999, the Company extended for an additional one-year term its
one-year, $50,000 promissory note payable to O.B. Parrish, the Company's
Chairman and Chief Executive Officer. The extension was completed through the
execution of a promissory note and Note Purchase and Warrant Agreement and Stock
Issuance Agreement. Pursuant to this transaction, Mr. Parrish was granted
warrants to purchase 10,000 shares of common stock at an exercise price of $1.35
per share. The warrants expire upon the earlier of their exercise or five years
after the date of their issuance. Under the Stock Issuance Agreement, if we fail
to pay the $50,000 promissory note when due, we must issue 10,000 shares of our
common stock to Mr. Parrish. The issuance will not, however, alleviate our
liability under the note. We also granted Mr. Parrish securities registration
rights with respect to any common stock he receives from us under these warrants
or the Stock Issuance Agreement.
On February 12, 1999, we borrowed $250,000 from Mr. Dearholt. The
borrowing was effectuated in the form of a $250,000, one-year promissory note
payable by us to Mr. Dearholt. As part of this transaction, the Company entered
into a Note Purchase and Warrant Agreement and a Stock Issuance Agreement.
Pursuant to the Note Purchase and Warrant Agreement, Mr. Dearholt received a
warrant to purchase [50,000] shares of our common stock at an exercise price of
$1.25 per share. The warrants expire upon the earlier of their exercise or five
years after the date of their issuance. Under the Stock Issuance Agreement, if
we fail to pay the $250,000 under the note when due, we must issue [50,000]
shares of our common stock to Mr. Dearholt. This issuance will not, however,
alleviate our
48
liability under the note. We also granted Mr. Dearholt securities registration
rights with respect to any common stock he receives from us under these warrants
or the Stock Issuance Agreement.
Item 27. Exhibits. The following exhibits are filed as part of this
Registration Statement.
[Enlarge/Download Table]
Exhibit No. Description
----------- -----------
3.1 Amended and Restated Articles of Incorporation of the Company.
3.2 Amended and Restated By-Laws of the Company.(1)
4.1 Amended and Restated Articles of Incorporation (same as Exhibit 3.1).
4.2 Articles II, VII and XI of the Amended and Restated By-Laws of the Company (included in Exhibit 3.2).(1)
4.3 Private Equity Line of Credit Agreement between the Company and Kingsbridge Capital Limited dated
November 19, 1998.(2)
4.4 Registration Rights Agreement between the Company and Kingsbridge Capital Limited dated as of
November 19, 1998.(2)
4.5 Warrant to Purchase up to 200,000 shares of common stock of the Company issued to Kingsbridge Capital
Limited as of November 19, 1998.(2)
4.6 Warrant to Purchase up to 100,000 shares of common stock of the Company issued to Kingsbridge Capital
Limited as of February 12, 1999.(2)
5 Legal Opinion of Reinhart, Boerner, Van Deuren, Norris & Rieselbach, s.c. regarding legality of
securities being issued.
10.1 Employment Agreement between John Wundrock and the Company dated October 1, 1989.(3)
10.2 Wisconsin Pharmacal Company, Inc. (k/n/a The Female Health Company) 1990 Stock Option Plan.(4)
10.3 Commercial Building Lease dated May 1, 1992 covering the Jackson, Wisconsin, office and manufacturing
facility.(5)
10.4 Reality Female Condom Clinical Trial Data Agreement between the Company and Family Health International
dated September 24, 1992.(6)
10.5 Trademark License Agreement for Reality Trademark.(7)
10.6 Office space lease between the Company and John Hancock Mutual Life Insurance Company dated
June 1, 1994.(8)
10.7 Employment Agreement dated September 10, 1994 between the Company and Dr. Mary Ann Leeper.(9)
10.8 1994 Stock Option Plan.(10)
49
[Enlarge/Download Table]
10.9 Investor relations and development services Consulting Agreement between the Company and C.C.R.I.
Corporation dated March 13, 1995.(11)
10.10 Consultant Warrant Agreement dated March 13, 1995 between the Company and C.C.R.I. Corporation, as
amended on April 22, 1996.(12)
10.11 Company Promissory Note payable to Stephen M. Dearholt for $1 million dated March 25, 1996 and related
Note Purchase and Warrant Agreement, warrants and Stock Issuance Agreement.(13)
10.12 Outside Director Stock Option Plan.(12)
10.13 Exclusive Distribution Agreement between Chartex International Plc and Taiho Pharmaceutical Co., Ltd.
dated October 18, 1994.(14)
10.14 Supply Agreement between Chartex International Plc and Deerfield Urethane, Inc. dated August 17, 1994.
(14)
10.15 Employment Letter dated February 28, 1990 from Chartex Resources Ltd. to Michael Pope and Board
amendments thereto.(14)
10.16 Grant Letter dated March 7, 1996 from the Government Office for London of the Secretary of State of
Trade and Industry regarding economic development grant to the Company.(14)
10.17 Letter Amendment to Asset Sale Agreement dated April 29, 1996 between the Company and Dowty Seals
Limited and Chartex International Plc.(14)
10.18 Form of 8% Convertible Debenture due August 31, 1999 issued by the Company to certain foreign investors
on September 12, 1996.(15)
10.19 Form of Warrant issued by the Company to certain foreign investors as of September 12, 1996.(15)
10.20 Fund Raising Agreement dated May 1, 1998 by and between Hartinvest-Medical Ventures and the Company.
10.21 Change of Control Agreement dated January 27, 1999, between The Female Health Company and Michael Pope.
(16)
10.22 Agreement between Kingsbridge Capital Limited and the Company dated February 12, 1999.(2)
10.23 Consulting Agreement between the Company and Kingsbridge Capital Limited dated February 12, 1999.(2)
10.24 Company Promissory Note to Stephen M. Dearholt for $250,000 dated February 1, 1999 and related Note
Purchase And Warrant Agreement, warrants and Stock issuance Agreement.(16)
10.25 Company Promissory Note to O.B. Parrish for $50,000 dated February 1, 1999 and related Note Purchase And
Warrant Agreement, warrants and Stock issuance Agreement.(16)
50
[Enlarge/Download Table]
10.26 Company Promissory Note to Stephen M. Dearholt for $1 million dated March 25, 1999 and related Note
Purchase and Warrant Agreement, Warrant and Stock Issuance Agreement.(16)
10.27 Form of Registration Rights Agreement between the Company and certain private placement investors dated
as of June 1, 1999.(17)
10.28 Amendment to Registration Rights Agreement between the Company and Private Placement Investors dated as
of June 1, 1999.(17)
10.29 $1 million Convertible Debenture issued by the Company to Gary Benson dated May 19, 1999.(17)
10.30 $100,000 Convertible Debenture issued by the Company to Daniel Bishop dated June 2, 1999.(17)
10.31 $100,000 Convertible Debenture issued by the Company to Robert Johander dated June 3, 1999.(17)
10.32 $100,000 Convertible Debenture issued by the Company to Michael Snow dated June 3, 1999.(17)
10.33 $100,000 Convertible Debenture issued by the Company to W.G. Securities Limited Partnership dated
June 3, 1999.(17)
10.34 Warrant to purchase 1,250,000 shares of the Company's common stock issued to Gary Benson on
May 19, 1999.(17)
10.35 Warrant to purchase 125,000 shares of the Company's common stock issued to Daniel Bishop on
June 3, 1999.(17)
10.36 Warrant to purchase 125,000 shares of the Company's common stock issued to Robert Johander on
June 3, 1999.(17)
10.37 Warrant to purchase 250,000 shares of the Company's common stock issued to Michael Snow on
June 3, 1999.(17)
10.38 Warrant to purchase 125,000 shares of the Company's common stock issued to W.G. Securities Limited
Partnership on June 3, 1999.(17)
10.39 Form of Common Stock Purchase Warrant to acquire 337,500 shares issued to R.J. Steichen as placement
agent.(17)
10.40 Form of Change of Control Agreement between the Company and each of O. B. Parrish and Mary Ann Leeper.
21 Subsidiaries of Registrant.
23.1 Consent of McGladrey & Pullen, LLP
23.2 Consent of Reinhart, Boerner, Van Deuren, Norris & Rieselbach, s.c. (included in Exhibit 5).
51
-----------------------
(1) Incorporated herein by reference to the Company's 1995 Form 10-KSB.
(2) Incorporated herein by reference to the Company's Form SB-2 Registration
Statement filed December 8, 1998.
(3) Incorporated herein by reference to the Company's Registration
Statement on Form S-18, Registration No. 33-35096, as filed with the
Securities and Exchange Commission on May 25, 1990.
(4) Incorporated herein by reference to the Company's December 31, 1990
Form 10-Q.
(5) Incorporated herein by reference to the Company's June 30, 1992 Form
10-Q.
(6) Incorporated herein by reference to Pre-Effective Amendment No. 1 to
the Company's Registration Statement on Form S-1, Registration No.
33-51586, as filed with the Securities and Exchange Commission on
September 28, 1992.
(7) Incorporated herein by reference to the Company's 1992 Form 10-KSB.
(8) Incorporated herein by reference to the Company's June 30, 1994 Form
10-Q.
(9) Incorporated herein by reference to the Company's Registration
Statement on Form S-2, Registration No. 33-84524, as filed with the
Securities and Exchange Commission on September 28, 1994.
(10) Incorporated herein by reference to the Company's 1994 Form 10-KSB.
(11) Incorporated herein by reference to the Company's March 31, 1995 Form
10-Q.
(12) Incorporated herein by reference to the Company's Form S-1 Registration
Statement filed with the Securities and Exchange Commission on April
23, 1996.
(13) Incorporated herein by reference to the Company's June 30, 1995 Form
10-Q.
(14) Incorporated herein by reference to Pre-Effective Amendment No. 1 to
the Company's Form S-1 Registration Statement filed with the Securities
and Exchange Commission on June 5, 1996.
(15) Incorporated herein by reference to the Company's 1996 Form 10-K.
(16) Incorporated herein by reference to the Company's March 31, 1999 Form
10-QSB.
(17) Incorporated herein by reference to the Company's June 30, 1999 Form
10-QSB.
Item 28. Undertakings.
The small business issuer hereby undertakes as follows:
(a) Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the small business issuer pursuant
52
to the foregoing provisions, or otherwise, the small business issuer has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the small business issuer of
expenses incurred or paid by a director, officer or controlling person of the
small business issuer in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the small business issuer will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
(b) File, during any period in which offers and sales of
securities may be made pursuant to this registration, a post-effective amendment
to this registration statement to:
(i) include any prospectus required by section 10(a)
(3) of the Securities Act;
(ii) reflect in the prospectus any facts or events
which, individually or together, represent a fundamental change in the
information in the registration statement; and
(iii) include any additional or changed material
information on the plan of distribution.
(c) For determining liability under the Securities Act, treat
each post-effective amendment as a new registration statement of the securities
offered, and the offering of the securities at that time to be the initial bona
fide offering.
(d) File a post-effective amendment to remove from
registration any of the securities that remain unsold at the end of the
offering.
53
SIGNATURES
In accordance with the requirements of the Securities Act of
1933, the registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form SB-2 and authorized this
Registration Statement to be signed on its behalf by the undersigned, in the
City of Chicago, State of Illinois, on the 19th day of October, 1999.
THE FEMALE HEALTH COMPANY
BY /s/ O.B. Parrish
----------------------------------------
Its Chairman and Chief Executive Officer
-------------------------------------
Pursuant to the requirements of the Securities Act of 1933,
this registration statement has been signed below by the following persons in
the capacities and on the dates indicated:
[Enlarge/Download Table]
Signature Title Date
--------- ----- ----
/s/ O.B. Parrish Chairman of the Board, Chief October 19, 1999
------------------------------ Executive Officer and Director ----------
O.B. Parrish
------------------------------ President and Chief Operating , 1999
Mary Ann Leeper, Ph.D. Officer and Director ----------
/s/ Robert R. Zic Chief Financial Officer October 19, 1999
------------------------------ ----------
Robert R. Zic
/s/ William R. Gargiulo, Jr. Secretary and Director October 19, 1999
------------------------------- ----------
William R. Gargiulo, Jr.
Director , 1999
------------------------------- ----------
David R. Bethune
/s/ Stephen M. Dearholt Director October 19, 1999
------------------------------- ----------
Stephen M. Dearholt
/s/ James R. Kerber Director October 19, 1999
-------------------------------- ----------
James R. Kerber
Director , 1999
-------------------------------- ----------
Michael R. Walton
54
EXHIBIT INDEX
[Enlarge/Download Table]
Page
Exhibit Number Description Number
-------------- ----------- ------
3.1 Amended and Restated Articles of Incorporation of the Company.
5 Legal Opinion of Reinhart, Boerner, Van Deuren, Norris &
Rieselbach, s.c. regarding legality of securities offered
10.40 Form of Change of Control Agreement between the Company and each of
O. B. Parrish and Mary Ann Leeper
23 Consent of McGladrey & Pullen, LLP
55
Dates Referenced Herein and Documents Incorporated by Reference
22 Subsequent Filings that Reference this Filing
↑Top
Filing Submission 0000950124-99-005508 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Sun., Apr. 28, 12:27:00.3pm ET 
